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Background: People with aphasia may improve their communication with speech and language therapy
many months/years after stroke. However, NHS speech and language therapy reduces in availability
over time post stroke.
Objective: This trial evaluated the clinical effectiveness and cost-effectiveness of self-managed
computerised speech and language therapy to provide additional therapy.
Design: A pragmatic, superiority, single-blind, parallel-group, individually randomised (stratified block
randomisation, stratified by word-finding severity and site) adjunct trial.
Setting: Twenty-one UK NHS speech and language therapy departments.
Participants: People with post-stroke aphasia (diagnosed by a speech and language therapist) with
long-standing (> 4 months) word-finding difficulties.
Interventions: The groups were (1) usual care; (2) daily self-managed computerised word-finding
therapy tailored by speech and language therapists and supported by volunteers/speech and language
therapy assistants for 6 months plus usual care (computerised speech and language therapy); and
(3) activity/attention control (completion of puzzles and receipt of telephone calls from a researcher
for 6 months) plus usual care.
Main outcome measures: Co-primary outcomes – change in ability to find treated words of personal
relevance in a bespoke naming test (impairment) and change in functional communication in conversation
rated on the activity scale of the Therapy Outcome Measures (activity) 6 months after randomisation.
A key secondary outcome was participant-rated perception of communication and quality of life using the
Communication Outcomes After Stroke questionnaire at 6 months. Outcomes were assessed by speech
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ABSTRACT
and language therapists using standardised procedures. Cost-effectiveness was estimated using treatment 
costs and an accessible EuroQol-5 Dimensions, five-level version, measuring quality-adjusted life-years.
Results: A total of 818 patients were assessed for eligibility and 278 participants were randomised 
between October 2014 and August 2016. A total of 240 participants (86 usual care, 83 computerised 
speech and language therapy, 71 attention control) contributed to modified intention-to-treat analysis at 
6 months. The mean improvements in word-finding were 1.1% (standard deviation 11.2%) for usual care, 
16.4% (standard deviation 15.3%) for computerised speech and language therapy and 2.4% (standard 
deviation 8.8%) for attention control. Computerised speech and language therapy improved word-finding 
16.2% more than usual care did (95% confidence interval 12.7% to 19.6%; p < 0.0001) and 14.4% more 
than attention control did (95% confidence interval 10.8% to 18.1%). Most of this effect was maintained 
at 12 months (n = 219); the mean differences in change in word-finding score were 12.7%
(95% confidence interval 8.7% to 16.7%) higher in the computerised speech and language therapy group 
(n = 74) than in the usual-care group (n = 84) and 9.3% (95% confidence interval 4.8% to 13.7%) higher in 
the computerised speech and language therapy group than in the attention control group (n = 61). 
Computerised speech and language therapy did not show significant improvements on the Therapy 
Outcome Measures or Communication Outcomes After Stroke scale compared with usual care or 
attention control. Primary cost-effectiveness analysis estimated an incremental cost per participant of 
£732.73 (95% credible interval £674.23 to £798.05). The incremental quality-adjusted life-year gain was 
0.017 for computerised speech and language therapy compared with usual care, but its direction was 
uncertain (95% credible interval –0.05 to 0.10), resulting in an incremental cost-effectiveness ratio of
£42,686 per quality-adjusted life-year gained. For mild and moderate word-finding difficulty subgroups, 
incremental cost-effectiveness ratios were £22,371 and £28,898 per quality-adjusted life-year gained, 
respectively, for computerised speech and language therapy compared with usual care.
Limitations: This trial excluded non-English-language speakers, the accessible EuroQol-5 Dimensions, 
five-level version, was not validated and the measurement of attention control fidelity was limited.
Conclusions: Computerised speech and language therapy enabled additional self-managed speech
and language therapy, contributing to significant improvement in finding personally relevant words
(as specifically targeted by computerised speech and language therapy) long term post stroke. Gains 
did not lead to improvements in conversation or quality of life. Cost-effectiveness is uncertain owing 
to uncertainty around the quality-adjusted life-year gain, but computerised speech and language 
therapy may be more cost-effective for participants with mild and moderate word-finding difficulties. 
Exploring ways of helping people with aphasia to use new words in functional communication contexts 
is a priority.
Trial registration: Current Controlled Trials ISRCTN68798818.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology 
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 19.
See the NIHR Journals Library website for further project information. The Tavistock Trust for Aphasia 
provided additional support to enable people in the control groups to experience the intervention after 
the trial had ended.
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language therapy
CTRU Clinical Trials Research Unit
DMEC Data Monitoring and Ethics
Committee
EQ-5D-3L EuroQol-5 Dimensions,
three-level version
EQ-5D-5L EuroQol-5 Dimensions,
five-level version
EVPI expected value of perfect
information
HRQoL health-related quality of life
ICER incremental cost-effectiveness
ratio
ICF International Classification of
Functioning, Disability and Health
IQR interquartile range
IR incidence rate
IRR incidence rate ratio
ITT intention to treat
MDC mean difference in change
MI multiple imputation
mITT modified intention to treat
NICE National Institute for Health
and Care Excellence
OR odds ratio
PC personal computer
PCPI patient, carer and public
involvement
PhD Doctor of Philosophy
PPI patient and public involvement
PSS Personal Social Services
PSSRU Personal Social Services
Research Unit
QALY quality-adjusted life-year
RCT randomised controlled trial
RELEASE Rehabilitation and recovery of
people with aphasia after stroke
SAE serious adverse event
SAP statistical analysis plan
SD standard deviation
SLT speech and language therapist
SLTA speech and language therapy
assistant
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Plain English summary
Aphasia is a communication disorder that can be caused by a stroke. It affects a person’sunderstanding of spoken words and their talking, reading and writing abilities. Communication
may improve months, or years, after a stroke with speech and language therapy. Many patients want
more speech and language therapy than the NHS can provide.
The Big CACTUS (clinical and cost-effectiveness of aphasia computer treatment versus usual stimulation
or attention control long term post-stroke) trial evaluated the use of speech and language therapy software
for people with aphasia to practise finding words independently at home on their own computer or one
loaned by the NHS.
People with aphasia who had had a stroke at least 4 months previously were randomly allocated to
one of three groups:
1. usual speech and language therapy care
2. daily use of computerised speech and language therapy for 6 months, tailored by a speech and
language therapist and supported by a volunteer or speech and language therapy assistant
3. daily completion of puzzles and supportive telephone calls from a researcher to mimic the activity/
attention the computerised speech and language therapy group received.
All groups received usual speech and language therapy.
A total of 278 people with aphasia took part in this trial, from 21 UK NHS speech and language therapy
departments. They had their strokes between 4 months and 36 years previously. Computerised speech
and language therapy enabled more practice (28 hours on average) than usual speech and language
therapy (3.8 hours). The computerised speech and language therapy group significantly improved their
ability to say words they chose to practise compared with those in the usual speech and language
therapy or puzzle book groups.
Although computerised speech and language therapy can help people with aphasia to learn new
words for years after stroke, no improvements in conversation or quality of life were seen. The
cost-effectiveness for the NHS is still uncertain. However, our best estimate is that it is unlikely
to be cost-effective for everyone with aphasia, but it may be cost-effective for people with mild and
moderate word-finding difficulties. Next steps will focus on how to encourage use of new words in
conversation to have an impact on quality of life.
DOI: 10.3310/hta24190 Health Technology Assessment 2020 Vol. 24 No. 19
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Palmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
xxi

Scientific summary
Background
More than one-third of stroke survivors acquire aphasia. This language disorder affects a person’s ability
to understand spoken language, talk, read and write, leading to frustration, isolation, low mood and
difficulty carrying out roles at work, in the family and in the wider community. People with aphasia often
want more speech and language therapy than they have access to from NHS services in the long term
post stroke despite evidence that improvements can continue for years with speech and language therapy.
Self-managed use of specialist aphasia computer software provides a potentially low-cost option to enable
more language practice without increasing demands on limited speech and language therapy resources.
Computer software can provide the opportunity for repetitive practice of meaningful language material
and feedback on success to the person with aphasia (adhering to principles of experience-dependent
neuroplasticity) in their homes without a speech and language therapist present. The pilot study suggested
feasibility, acceptability and potential clinical effectiveness and cost-effectiveness of an approach to
self-managed computerised word-finding therapy. Big CACTUS (Clinical and cost-effectiveness of aphasia
computer treatment versus usual stimulation or attention control long term post-stroke) was the first trial
to evaluate the clinical effectiveness and cost-effectiveness of such an approach to providing long-term
aphasia therapy in a full randomised controlled trial.
Objectives
The aim was to provide definitive evidence of whether or not self-managed computerised speech
and language therapy for word-finding for persisting post-stroke aphasia in addition to usual care
was clinically effective and cost-effective, when compared with usual care alone or attention control.
The main research objectives were to establish whether or not:
1. self-managed computerised speech and language therapy for word-finding (computerised speech
and language therapy) increases the ability of people with aphasia to retrieve vocabulary of
personal importance
2. computerised speech and language therapy improves functional communication ability in conversation
3. patients receiving computerised speech and language therapy perceive greater changes in social
participation in daily activities and quality of life
4. computerised speech and language therapy is cost-effective for persistent aphasia post stroke
5. any effects of computerised speech and language therapy are evident 12 months after therapy has begun.
This trial also sought to investigate:
6. functional use of treated words in conversation
7. generalisation to retrieval of untreated words
8. carer perception of communication effectiveness and the impact on carers’ quality of life
9. negative effects of computerised speech and language therapy.
Methods
Design
Big CACTUS was a pragmatic, superiority, individually randomised, single-blind (blinded outcome
assessors), parallel-group randomised controlled adjunct trial.
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Setting
The trial was conducted in 21 NHS speech and language therapy departments across the UK.
Participants were treated by speech and language therapists working in routine clinical practice.
Participants (eligibility and recruitment)
Participants were eligible if they were aged > 18 years and had aphasia subsequent to stroke(s)
at least 4 months prior to randomisation. Participants were required to have word-finding difficulties
(demonstrated by a score of 5–43 out of 48 on the Naming Objects test of the Comprehensive Aphasia
Test) and to have sufficient cognitive and visual ability to use the computer software. They were
excluded if they had a premorbid speech and language disorder caused by a neurological deficit other
than stroke, required treatment in a language other than English or were currently using a computer
program aimed at improving word-finding.
Eligible participants were identified from current and past speech and language therapy caseloads and
from voluntary sector support groups. Speech and language therapists used a consent support tool to
identify the support required for each individual to provide informed consent. This also identified those
who were unable to provide consent with support and required a carer declaration of belief that they
wished to take part (or a relative to provide consent in Scotland).
Interventions
Participants were randomised to one of three groups. All groups received usual care.
Usual care
This was the usual speech and language therapy being provided to each individual (for some, this entailed
no speech and language therapy input). Therapy was provided by qualified speech and language therapists
or speech and language therapy assistants face to face in either one-to-one or group sessions.
Computerised speech and language therapy
The computerised speech and language therapy intervention focused on the treatment of word-finding,
a difficulty experienced by most people with aphasia. The approach evaluated had four key components:
1. Specialist aphasia software – StepByStep© version 5.0 (Steps Consulting Ltd, Acton Turville, UK)
was chosen as it allowed for tailoring and selection of personally relevant words, and provided
feedback on whether or not words produced were correct, adhering to principles of experience-
dependent neuroplasticity.
2. A speech and language therapist assessed the participant and selected and tailored the software
exercises and word-finding cues according to the language profile on the baseline language
assessment. The speech and language therapist supported the participant to select 100 words of
personal relevance for practice and trained and supported a volunteer/speech and language therapy
assistant to provide support to the participant.
3. Self-managed, independent practice of the therapy exercises at home by the participant was
recommended for 20–30 minutes per day over a 6-month period.
4. A volunteer/speech and language therapy assistant provided monthly support including encouraging
practice, moving on to harder exercises, practice using the new words in functional contexts and
adding new words if needed.
The speech and language therapists attended 1 day of training on how to use and tailor the software.
They were given an intervention manual.
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Attention control
This group aimed to control for the additional activity and attention received in the computerised
speech and language therapy group. Puzzle books were provided each month according to level of
difficulty needed and participant interests. Participants were encouraged to complete one puzzle
per day for the 6-month period. A member of the research team telephoned the participant for a
supportive chat once a month.
Randomisation
Participants were randomised to one of the three groups using a fixed 1 : 1 : 1 allocation ratio by
a centralised web-based randomisation system. The randomisation schedule was generated using
stratified block randomisation stratified by centre and severity of word-finding difficulty at baseline.
Outcomes
The trial had co-primary outcomes looking for change in both impairment and activity. Impairment was
defined as the ability to use vocabulary of personal importance, measured by naming pictures of 100
words chosen for use in therapy. Activity was defined as functional communication ability in conversation
measured by 10-minute videos of conversations structured around topics of personal importance, rated
using the activity scale of the Therapy Outcome Measures. A key secondary outcome was change in
participants’ own perception of communication-related social participation and quality of life using the
Communication Outcomes After Stroke patient-reported outcome measure. All outcome measures were
undertaken at baseline prior to randomisation, 6 months post randomisation (end of treatment – primary
time point) and at 9 and 12 months post randomisation. Further secondary outcomes included health-
related quality of life and resource use to estimate the cost-effectiveness of computerised speech and
language therapy compared with usual care and activity/attention control. An unofficial accessible variant
of the EuroQol-5 Dimensions, five-level version, was developed for this trial so that participants were
able to rate their own quality of life for quality-adjusted life-year estimation. The standard EuroQol-5
Dimensions, five-level version, was also completed by proxy by carers.
Additional outcomes included the use of treated words in the videoed conversations; generalisation
of the therapy to untreated words using the Object Naming test of the Comprehensive Aphasia Test;
and carer perception of communication effectiveness and impact on their own quality of life using
the Carer Communication Outcomes After Stroke. Negative effects of the computerised speech and
language therapy were recorded using a questionnaire for computerised speech and language therapy
participants, and through collection of adverse events and serious adverse events for all groups.
Blinding
The trial was single blind as participants knew their allocated treatment group. However, all outcome
measures at all time points were conducted by speech and language therapy assessors who were blind
to the treatment group.
Sample size
The trial aimed to recruit 285 participants (95 per group) to address both co-primary objectives with
90% power for a 5% two-sided test adjusted for a 15% drop-out rate. A 10% mean difference in
change in word-finding and a Therapy Outcome Measures effect size of 0.45 were assumed to be
minimal clinically important differences to detect. This sample size had 83% power to address the key
secondary objective on change in Communication Outcomes After Stroke for a 5% two-sided test
assuming a 7.2% mean difference in change as clinically worthwhile.
Analysis
The analysis of the primary outcome measures was based on a modified intention-to-treat principle
detailed in the full report. A multiple linear regression model adjusted for stratification factors was used.
A sensitivity analysis was conducted exploring the impact of missing data and heterogeneity of treatment
effect across predefined subgroups (word-finding severity, time post stroke and comprehension ability).
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The primary health economic analysis was a model-based cost–utility analysis adopting a lifetime time
horizon and an NHS payer perspective. Cost-effectiveness is expressed in terms of the incremental
cost-effectiveness ratio, that is cost per quality-adjusted life-year gained. Secondary analyses included
within-trial analysis, a broader perspective (including volunteer costs) and analysis of subgroups.
Results
A total of 995 potential participants were screened, of whom 288 (29%) consented and 278 (28%)
were randomised, slightly lower than the target of 285 but sufficient to address the co-primary
and key secondary research questions with intended statistical power owing to the drop-out rate
(9%) being lower than anticipated (15%). A total of 240 participants were included in the modified
intention-to-treat analysis: usual care, n = 86; attention control, n = 71; and computerised speech and
language therapy, n = 83.
The mean age of participants was 65.4 years (range 23–92 years) and 61% of participants were male.
Forty-four per cent of participants had mild word-finding difficulties (Comprehensive Aphasia Test
Naming Objects score of 31–43), 30% had moderate difficulties (score of 18–30) and 26% had severe
difficulties (score of 5–17). Participants were 2 years (median) post stroke (range 4 months to 36 years).
The characteristics of groups were broadly similar at baseline.
Computerised speech and language therapy participants practised computer exercises for 28 hours
(mean). The quality of delivery of computerised speech and language therapy in terms of tailoring the
software and provision of support to the participants was good. However, 85% of participants were
assisted to practise using their new words in functional contexts for only 45 minutes (median) in total
over 6 months. Similar mean amounts of usual care were received by all groups across the 6-month
intervention period (computerised speech and language therapy, 3.2 hours; usual care, 3.8 hours; and
attention control, 3.2 hours).
The mean improvement in word-finding at 6 months was 1.1% (standard deviation 11.2%), 2.4% (standard
deviation 8.8%) and 16.4% (standard deviation 15.3%) based on 86, 71 and 83 participants in the usual
care, attention control and computerised speech and language therapy groups, respectively. On average,
computerised speech and language therapy improved word-finding by 16.2% more than usual care (95%
confidence interval 12.7% to 19.6%; p< 0.0001) and by 14.4% more than attention control (95% confidence
interval 10.8% to 18.1%), indicating that the effect was not attributable only to activity/attention. Most of
this effect was maintained at 9 and 12 months. Computerised speech and language therapy improvement in
word-finding was broadly consistent regardless of time post stroke.
However, improvements in functional communication were negligible and very similar across groups. The
mean difference in change between the computerised speech and language therapy group and the usual-
care group was –0.03 (95% confidence interval –0.21 to 0.14; p = 0.709) and between the computerised
speech and language therapy group and attention control group was –0.01 (95% confidence interval
–0.20 to 0.18). Similarly, there was insufficient evidence to suggest that computerised speech and language
therapy improved participants’ perceptions of their communication ability and participation or its impact
on their life. The computerised speech and language therapy group mean improvement in Communication
Outcomes After Stroke was only 0.5% (95% confidence interval –3.1% to 4.1%) and 3.8% (95% confidence
interval –0.0% to 7.5%) compared with usual care and attention control, respectively.
On average, there was no improvement in treated words used in conversation across groups. However,
close to 1 out of 10 participants in the usual-care and attention control groups used at least five more
treated words in conversation at 6 months than at baseline, compared with approximately 3 out of
10 participants in the computerised speech and language therapy group. In addition, there was insufficient
evidence to suggest that improved word-finding of treated words generalises to untreated words.
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Subgroup analyses indicated that the effect of computerised speech and language therapy on word-
finding was slightly higher for participants with mild word-finding difficulties and for those with verbal
comprehension within normal limits.
Small differences were seen in carers’ perception of communication effectiveness: 4.6% in favour of
computerised speech and language therapy compared with usual care (95% confidence interval 0.3% to
9.0%) at 6 months, and 5.1% in favour of computerised speech and language therapy compared with
attention control (95% confidence interval 0.5% to 9.7%). The differences were not maintained at 9 and
12 months. Improvement in carers’ quality of life in the computerised speech and language therapy group
compared with the usual-care group was 5.3% (95% confidence interval –1.1% to 11.7%), but only 0.3%
(95% confidence interval –6.4% to 6.9%) compared with the attention control group at 6 months.
Negative effects of computerised speech and language therapy were low: 27% of participants in the
computerised speech and language therapy group reported fatigue or anxiety at some point, which
translates to one event per person per year. Differences in the incidences of adverse events and
serious adverse events were similar between groups.
The computerised speech and language therapy was a low-cost intervention, at £733 per person. The
cost of delivering the same average amount (28 hours) of therapy face to face would be £1400.
The primary cost-effectiveness analysis estimated an incremental cost per participant of £732.73
(95% credible interval £674.23 to £798.05) and an incremental quality-adjusted life-year gain of 0.017
(95% credible interval –0.05 to 0.10) for computerised speech and language therapy compared with
usual care, resulting in an incremental cost-effectiveness ratio of £42,686 per quality-adjusted life-year
gained. For computerised speech and language therapy compared with attention control, the incremental
cost-effectiveness ratio was £40,164 per quality-adjusted life-year gained. Subgroup analyses resulted
in incremental cost-effectiveness ratios of £22,371 and £28,819 per quality-adjusted life-year gained for
computerised speech and language therapy compared with usual care in participants with mild or moderate
word-finding difficulty, respectively. Using EuroQol-5 Dimensions, five-level version, quality-of-life
scores reported by carers on behalf of patients instead of scores derived from the unofficial accessible
version of the EuroQol-5 Dimensions, five-level version, resulted in an incremental cost-effectiveness
ratio of £28,819 for computerised speech and language therapy compared with usual care.
Conclusions
The computerised speech and language therapy intervention provided additional hours of speech
and language therapy to people with persistent aphasia at a low cost. Computerised speech and
language therapy led to significant improvements in word-finding ability that were maintained
irrespective of time post stroke. Word-finding improvements did not generalise to conversation or
participant perceptions of communication participation and quality of life. Cost-effectiveness results
suggest that computerised speech and language therapy is unlikely to be considered cost-effective
for the whole population investigated, given typical current National Institute for Health and Care
Excellence cost-effectiveness thresholds. Subgroup analyses are prone to increased uncertainty;
however, the intervention may be more cost-effective for people with mild and moderate
word-finding difficulties.
The computerised speech and language therapy intervention can be offered as part of speech and
language therapy provision to achieve repetitive word-finding practice and improve the ability to find
new words. This research suggests that it is important to use words of personal relevance in therapy
owing to limited generalisation to untreated words, and that there needs to be a focus on supporting
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the generalisation of new words into functional use. Further research recommendations in order of
priority include:
1. investigating ways to assist with generalisation of newly learned vocabulary into use in conversation
and other functional communication contexts
2. identification of what was practised, and whether or not all of the exercises set up by the speech
and language therapist were used
3. exploration of further cost and time efficiencies
4. exploration of who to target the intervention towards
5. implementation of an optimised computerised speech and language therapy approach as part of
NHS speech and language therapy provision
6. validation of the accessible variant of the EuroQol-5 Dimensions, five-level version.
Trial registration
This trial is registered as ISRCTN68798818.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 19.
See the NIHR Journals Library website for further project information. The Tavistock Trust for Aphasia
provided additional support to enable people in the control groups to experience the intervention after
the trial had ended.
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Chapter 1 Introduction
Post-stroke aphasia
Aphasia is the most common language disorder acquired post stroke, affecting a person’s ability to
speak, read, write or understand language. One-third of stroke survivors are affected by aphasia and
30–43% of them will remain significantly affected in the long term.1 Aphasia has an impact on everyday
activity including the ability to have conversations, make telephone calls, listen to the radio, write
letters, e-mails and text messages and read for pleasure, information or work. It therefore restricts
the ability to carry out pre-stroke roles at work, in the family and in the community, often leading
to withdrawal from participation in usual activities and reduced social networks. These changes
affect the wellbeing of both the person with aphasia and their family/carer, with increased frustration,
misunderstandings and breakdown of/strain on relationships. Consequently, people with aphasia are
highly susceptible to depression.2
Evidence for speech and language therapy
Speech and language therapy is provided for people with aphasia. It aims to improve the language
impairment and the ability to communicate and participate in daily activities. Neuroplasticity is the
process by which the brain can form new connections and pathways to enable a person to relearn
a skill, such as language, previously controlled by an area of the brain now affected by the stroke.
Impairment-focused speech and language therapy aims to promote experience-dependent neuroplasticity
for language. Key principles of experience-dependent neuroplasticity underpinning therapy according
to Kleim and Jones3 include ‘use it or lose it’, ‘use it and improve it’, specificity matters (the nature of
the therapy dictates the nature of the plasticity, i.e. you get better at doing what you practice doing),
salience matters (therapy must be meaningful to induce plasticity) and repetition matters (induction of
plasticity requires sufficient repetition).
In a Cochrane review of aphasia therapy for people with aphasia post stroke, Brady et al.4 showed
that speech and language therapy was more effective than no treatment, resulting in clinically and
statistically significant benefits to patients’ functional communication, reading, writing and expressive
language. They found no evidence of one type of therapy being superior to another and there is no
current evidence of long-term effects of therapy.4 Medical instability, fatigue and confusion may reduce
full engagement with language therapy in the early weeks post stroke, reducing the opportunity for
some people to engage in therapy; however, some stroke survivors may tolerate speech and language
therapy later post stroke.
Traditionally, it was thought that language recovery can reach a ‘plateau’ after 6 months or more,
leading to speech and language therapy services being delivered predominantly in the first few months
after stroke. However, in a systematic review of 21 randomised controlled trials (RCTs), Allen et al.5
found evidence to support the provision of speech and language therapy for more than 6 months
after the onset of post-stroke aphasia. In a recently published RCT of speech and language therapy
for aphasia in the chronic stage post stroke (> 6 months), Breitenstein et al.6 randomised 156 patients
with aphasia to either speech and language therapy or waiting list control in 18 rehabilitation centres
in Germany and showed significant statistical and clinical functional language (activity) benefit of speech
and language therapy. The therapy was delivered in clinical settings for ≥ 10 hours per week for at least
3 weeks (minimum dose of 30 hours) and combined one-to-one speech and language therapy, group
therapy with a speech and language therapist (SLT) and self-managed computer therapy or pencil-and-
paper linguistic exercises prescribed by a SLT.6
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Delivery of therapy for persistent aphasia: the clinical problem
Despite evidence of benefit, treatment of aphasia that persists beyond the first few months after
stroke is often not available through NHS services,7 as ongoing therapy is costly through face-to-face
speech and language therapy and places greater demands on already-limited resources, which are
predominantly targeted in the earlier months following stroke. If people with aphasia are to be able to
reach their recovery potential, lower-cost options for the support of repetitive practice in the longer
term are urgently needed to enable access to therapy at a time that is best for each individual, and for
as long as the individual is able to benefit.
Potential solutions to increasing the amount of tailored therapy delivered
for persistent aphasia without increasing demand on speech and language
therapy resources
There is evidence that non-speech and language therapy professionals can be employed successfully
to support therapy activity and the Cochrane review found little indication of a difference in the
effectiveness of therapy facilitated by volunteers trained by a SLT and the effectiveness of therapy
delivered by a SLT directly.4,8,9 Computer technology can also provide the potential for supporting
treatment in the long term. Computer programs developed for the treatment of aphasia have been
reported to be useful in the provision of targeted language practice and provide opportunities for
independent home practice as part of a self-managed approach to maximise repetitive practice,10–12
improving outcomes for reading, spelling, word-finding and expressive language.11,13–15 Computer-based
tasks can be tailored to the individual’s needs, accounting for personal context and language ability
levels, potentially helping to motivate independent practice. Self-managed practice schedules can
also account for personal needs, such as fatigue, ability to travel and fitting practice around other
commitments. Bespoke software and applications (apps) are available for self-managed aphasia therapy
practice. In addition to personal computers (PCs), Stark and Warburton16 showed the feasibility of
using iPads (Apple Inc., Cupertino, CA, USA) to deliver app-based aphasia therapy. In a systematic
review of computer therapy for aphasia, Zheng et al.17 concluded that therapy delivered using a
computer is more effective than no therapy, and potentially as effective as therapy delivered
by a SLT. The meta-analysis carried out in the Cochrane review4 similarly concluded that there was
no evidence of a difference between therapy delivered on a computer and one-to-one therapy from a
SLT. Both studies acknowledge the low quality of this evidence, with only five small RCTs (the largest
having 55 participants) reported to date (2016). Only one of these five studies considered impact
on functional communication, indicating that the majority of the evidence is for impairment-based
outcomes rather than functional or activity-based outcomes. No a priori sample size calculations were
reported. Computer-based services for long-term management of aphasia therapy have the potential
to provide a low-cost therapy option. However, the actual cost-effectiveness has not been investigated
until recently in the Clinical and cost-effectiveness of aphasia computer treatment versus usual
stimulation or attention control long term post-stroke (CACTUS) pilot study.18 There is therefore
a pressing need for fully powered, well-designed RCTs of both the clinical effectiveness and the
cost-effectiveness of self-managed computer aphasia therapy approaches for aphasia.
Intervention aimed at addressing delivery of long-term speech and language
therapy for persistent aphasia investigated in the Big CACTUS trial:
self-managed, computer aphasia therapy approach for persistent aphasia
The computerised approach to long-term aphasia therapy used in the Big CACTUS project [see
Chapter 2, Self-managed computerised therapy intervention for word-finding (computerised speech and
language therapy)] combines current theory and evidence underpinning language therapy with practical
considerations for treatment delivery. As word-finding is a common difficulty for people with aphasia,
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this intervention focuses on the treatment of word-finding specifically. The approach has four
main components:
1. Access to specialist speech and language therapy software.
2. Skills of a qualified SLT used to select individually targeted therapy exercises (specificity) to practice
retrieval of words of personal relevance to each individual with aphasia (salience).
3. Regular self-managed practice of the therapy exercises (20–30 minutes per day over 6 months is
recommended as shown to be manageable in the pilot study).18
4. Volunteers/speech and language therapy assistants (SLTAs) support use of the computer exercises
and generalisation of the newly acquired vocabulary in conversation.19
The intervention was predominantly focused on improving the word-finding impairment, with support
from volunteers or SLTAs designed to assist with generalisation of words learned to functional use.
The computer software package used within this trial is called StepByStep© version 5.0 (Steps Consulting
Ltd, Acton Turville, UK),20 and is marketed by Steps Consulting Ltd at a cost of £250 for an individual
lifetime licence to be purchased for a patient to put on their own computer, or £550 for a clinician
licence owned by the NHS and installed on an NHS computer. The Stroke Association funded the initial
development of the first version of StepByStep in the early 2000s. Since that time, it has been iteratively
developed and marketed by Steps Consulting Ltd. Version 5 was used in the Big CACTUS trial. The
approach described above is based on a similar approach used in therapy by Steps Consulting Ltd as an
independent therapy provider. The software is intended to be tailored by SLTs with practice supported
by a non-SLT specialist, often a carer or relative. The approach has been adapted for use in the NHS,
particularly recognising that not everyone who accesses NHS services has a carer/relative able to provide
support and therefore a training programme for volunteers and SLTAs was developed. Steps Consulting
Ltd was not a collaborator on the project and therefore was not involved in project design, delivery or
analysis. It did, however, support therapists on the trial with software use as it would for any therapist
who purchased the software independently of the trial. For rationale for the choice of StepByStep,
see Chapter 2, Self-managed computerised therapy intervention for word-finding (computerised speech and
language therapy).
We carried out a pilot study evaluating the approach described above with 34 people with persistent
aphasia.21 They were randomly assigned to using the computer therapy approach or usual long-term
care (most frequently this was social support). On average, people with aphasia practised their speech
exercises on the computer independently for 25 hours over 5 months. The therapy significantly improved
people’s ability to use spoken words when compared with usual care (UC). The mean improvement in
word-finding was 19.8% [95% confidence interval (CI) 4.4% to 35.2%; p = 0.014]. The results indicated
that self-managed computer therapy supported by volunteers (total of 4 hours’ support over 5 months
on average) could help people with chronic aphasia to continue to practise, improving their vocabulary
and confidence when speaking.21 Patients and carers found it an acceptable alternative to face-to-face
therapy.22 The pilot study also showed, through qualitative interviews, that self-managed computer
therapy could potentially improve the quality of life of people with persistent aphasia,22 at a relatively
low cost to the NHS and society, but that a full economic evaluation with a larger sample was still
required to reduce uncertainty in estimates of cost-effectiveness.18
Research rationale and objectives
The literature shows that people with persistent aphasia can improve their communication with
sufficient amounts of speech and language therapy. This can be difficult to provide face to face with
limited resources. Consequently, the use of specialist computer software for self-managed repetitive
practice with volunteer support has been explored as a potential option for the provision of effective
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speech and language therapy to people with persistent aphasia, providing the opportunity for people
with aphasia to receive greater quantities of therapy over a longer period than would be possible face
to face. The aim of the Big CACTUS trial was to provide definitive evidence of whether or not targeted,
speech and language impairment based therapy intervention for word-finding through self-managed
computer exercises for persisting post-stroke aphasia in addition to currently available face-to-face
speech and language therapy was clinically effective and cost-effective, when compared with currently
available speech and language therapy alone. This built on the successful 3-year Research for Patient
Benefit-funded pilot RCT conducted by this team, which informed possible effects, measures, feasibility,
recruitment rates, compliance, cost-effectiveness analysis and a power calculation. Results demonstrating
feasibility were published by Palmer et al.21
The World Health Organization recommends use of the International Classification of Functioning, Disability
and Health (ICF)23 to describe and evaluate the impact of health problems on a person’s life. As the
intervention in Big CACTUS predominantly targeted word-finding impairment anticipating carry-over
to functional activity, both impairment and activity were relevant to evaluate, along with participation.
The first three research objectives therefore sought to identify the effect of the Big CACTUS approach
to self-managed computer treatment for persisting aphasia supplementing UC (for a definition of UC in
this trial, see Chapter 2, Usual-care control group), compared with UC alone or activity/attention control
(AC) plus UC on the ICF dimensions of impairment, activity and participation:
The main research objectives were to:
1. establish whether or not self-managed computerised speech and language therapy (CSLT) for
word-finding increases the ability of people with aphasia to retrieve vocabulary of personal
importance (impairment)
2. establish whether or not self-managed CSLT for word-finding improves functional communication
ability in conversation (activity)
3. investigate whether or not patients receiving self-managed CSLT perceive greater changes in social
participation in daily activities and quality of life (participation)
4. establish whether or not self-managed CSLT is cost-effective for persistent aphasia post stroke
5. identify whether or not any effects of the intervention are evident 12 months after therapy
has begun.
Additional research objectives include investigating the generalisation of treatment to retrieval of
untreated words (impairment); the generalisation of treated words to functional use in conversation;
carers’ perception of communication effectiveness (participation) and the impact on carers’ quality
of life; and identification of any possible negative effects. Consistent with our objectives, we selected
assessments to measure impairment, activity and participation (see Chapter 2 for details). Since our
trial was designed, the international aphasia research community has developed a consensus statement
about the importance of measuring these ICF dimensions and has identified recommended measures.24
Patient, carer and public involvement
The CACTUS pilot study had a strong patient, carer and public involvement (PCPI) group, which
acted as an independent advisory group made up of people with aphasia and carers. This group was
refreshed at the beginning of the Big CACTUS trial, with four members (two people with aphasia and
two carers) providing continuity from the pilot study and three new members (two people with aphasia
and one carer) joining the group to provide a fresh perspective. Members were recruited via a stroke
patient and public involvement (PPI) database held by the University of Sheffield. The work of the group
has been reported throughout this report using the Guidance for Reporting Involvement of Patients
and the Public 2 (GRIPP2).
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
4
The aims of the group were to:
l facilitate the recruitment and inclusion of people with aphasia in the trial
l ensure that trial materials and processes were accessible to people with aphasia
l ensure that the interventions and trial procedures were appropriate and manageable for people
with aphasia
l ensure that dissemination of trial results reached a broad audience in accessible formats.
The group met with members of the research team and was predominantly facilitated by the chief
investigator, Rebecca Palmer, who is a qualified SLT. Involving people with language difficulties
presents additional challenges for PCPI collaboration. Standard supportive techniques used included
having an aphasia-friendly agenda at each meeting (see study documentation at www.journalslibrary.
nihr.ac.uk/programmes/hta/122101/#/), using practical activities with pictures and keywords to support
discussions, and, for key decisions, members of the research team worked with each member with
aphasia independently to facilitate inclusion of their perspectives. The clinically trained members of
the research team worked with those members with the most limited language ability. The group
members met when their advice or help with decision-making or production of materials was required
and therefore the frequency of meetings varied. Fifteen meetings took place during the project.
The level of involvement was collaborative. Activities included development of the plain English
summary for the original application; assisting with style and content of information sheets for people
with different severities of aphasia; assisting with the design and evaluation of the consent support
tool used in recruitment; advising on recruitment; informing the design of an aphasia-friendly adapted
EuroQol-5 Dimensions, five-level version (EQ-5D-5L); making decisions about the materials used in
the AC group; identifying key facts from the results that need to be particularly highlighted for people
with aphasia; driving the dissemination plans; and stimulating and co-producing a film and accessible
booklet of the trial results. The contribution of the PCPI group has been further detailed in Chapter 2.
The impact of the PCPI activity has been considered in the discussion section (see Chapter 6). The group
was awarded a PCPI prize at the UK Stroke Forum 2016 in recognition of their contribution to the
Big CACTUS project.
In addition, a person with aphasia and his wife were members of the Trial Steering Committee (TSC).
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Chapter 2 Methods
This report is concordant with the Consolidated Standards of Reporting Trials (CONSORT) guidelinesfor individually randomised parallel-group trials25 (including non-pharmacological treatments,26
pragmatic27 and harms28 extensions) and the Template for Intervention Description and Replication
(TIDieR) checklist.29
Trial design
The trial used a pragmatic, superiority, individually randomised, single-blind (blinded outcome assessors),
parallel-group, randomised controlled adjunct trial design. All participants received UC, and outcomes
were compared for people with persistent aphasia 4 months or more post stroke who were randomly
allocated to one of the following groups:
l UC
l self-managed CSLT in addition to UC
l AC in addition to UC.
Participants were randomised to one of the three groups using a 1 : 1 : 1 allocation ratio. Randomisation
was stratified by the NHS speech and language therapy department (site) providing the interventions
and severity of the patient’s word-finding difficulty.
Important changes to methods after trial commencement
The planned sample size was 285 participants. We extended the recruitment period by 1 month to
increase recruitment as it was slightly short of the target owing to the recruitment rate slowing down
towards the end of the recruitment period. The reduction in recruitment rate is likely to be caused by
the fact that recruitment was from current and past patient lists and by the end of recruitment past
patient lists had been exhausted. After an extra month of recruitment, the trial team, in discussion
with the Trial Steering Committee and the trial statistician, made a decision to stop recruitment at
278 participants, seven participants short of the planned target, as the withdrawal rate was lower (9%)
than that estimated in the sample size calculation (15%) and therefore sufficient numbers had been
recruited to address research objectives with the intended statistical power.
The original funded trial did not include measurement of fidelity, beyond that of participant adherence
to the interventions. Fidelity measurement of additional components of CSLT (i.e. delivery by SLTs and
support from volunteers or SLTAs) was later funded by the Stroke Association as part of a postgraduate
research [Doctor of Philosophy (PhD)] fellowship awarded to one of the Big CACTUS research associates,
Madeleine Harrison, who was supervised by two of the Big CACTUS collaborators, Rebecca Palmer and
Cindy Cooper. The methods for the fidelity assessment were added to the Big CACTUS protocol version
4.0, dated 17 July 2015, 8 months after recruitment commenced.
Important protocol changes since version 1.0
In the original protocol, the co-primary outcome ‘conversation’ was measured using two assessments.
These were the Therapy Outcome Measures (TOMs) and the number of target words used in conversation.
The trial was originally powered on only the TOMs and the other co-primary outcome, ‘word-finding ability’.
It was not possible to power the trial also on ‘number of words used in conversation’ as there was no prior
information to inform a sample size calculation. Prior to the trial starting and publication of the protocol,
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it was recognised that there was not adequate information to combine the two measures of the co-primary
outcome of ‘conversation’ into one outcome. Therefore the validated, published measure, TOMs, was kept
as the co-primary outcome and number of words used in conversation was moved to be a secondary
outcome before recruitment began.
An additional ‘per-protocol’ definition for intervention use was added for clarity during the recruitment
period but before data lock and analysis: ‘across at least a 4 month period will be considered per
protocol’.
An inter-rater and intrarater reliability testing protocol for raters of the practice videos in the primary
outcome measure was added prior to evaluation of the videoed conversations.
Details of key subgroup analyses were added during development of the statistical analysis plan
(SAP) prior to data lock: severity of word-finding difficulty, length of time post stroke and baseline
comprehension ability.
Participants and eligibility criteria
Participants were included if:
1. They were aged ≥ 18 years.
2. They were diagnosed with stroke(s). Studies often limit inclusion to first stroke. As this is a pragmatic
trial, and patients with multiple strokes are typically treated, inclusion was not limited to patients with
a first stroke.
3. Their onset of stroke was at least 4 months prior to randomisation (to ensure that aphasia
was persistent).
4. They had been diagnosed with aphasia, subsequent to stroke, confirmed by a trained SLT.
5. They scored 5–43 out of 48 on the Comprehensive Aphasia Test (CAT) Naming Objects30 (mild is
31–43, moderate is 18–30 and severe is 5–17; participants scoring < 5 were excluded as the pilot
study showed no benefit for participants who were able to retrieve < 10% of words).
6. They were able to perform a simple matching task in StepByStep with at least 50% accuracy (score
of at least 5/10; this was a pragmatic method that may be used clinically to confirm sufficient visual
and cognitive ability to use the computer exercises).
7. They were able to repeat at least 50% of words in a simple word-repetition task in the StepByStep
program (score of at least 5/10). Significant difficulty with repeating words is an indication of apraxia
of speech, which would require a different intervention.
Participants were excluded from the trial if they:
1. Had another premorbid speech and language disorder caused by a neurological deficit other than
stroke. A formal diagnosis could be reported by the participant or relatives and confirmed by the
recruiting SLT.
2. Required treatment for a language other than English (as the software is currently only available
in English).
3. Were currently using the StepByStep computer program or other computer speech therapy aimed
at word retrieval/naming to avoid similarity between groups.
Eligibility of providers
NHS speech and language therapy departments were eligible to participate if they routinely provided
community services for people with aphasia post stroke. Treating clinicians were eligible if they were
METHODS
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qualified SLTs with experience of treating post-stroke aphasia. Speech and language therapy or generic
rehabilitation assistants were eligible if they routinely carried out work under the supervision of a
qualified SLT. Services were invited to use volunteers to provide the same support as assistants if they
routinely used volunteers to support speech and language therapy work.
Settings and locations where the data were collected
Participant identification
Participants were recruited from 21 speech and language therapy departments in 20 NHS trusts (see
Appendix 1) across the UK, from both current and past patient records, speech and language therapy
colleagues and contacts with longer-term voluntary support groups. Identification from past patient
records and voluntary support groups was aimed at including participants who may have finished
their speech and language therapy intervention based on currently available services. However, these
potential participants would be eligible for additional/extended therapy if the Big CACTUS approach
to providing more therapy through self-managed computer exercise was to be implemented in the
future if found to be clinically effective and cost-effective. Speech and language therapy departments
agreeing to participate in the project were asked to identify potential participants. Potential participants
unknown to speech and language therapy departments and voluntary groups, who found the trial on
the website, were able to self-present by contacting the central trial team who put them in touch with
their nearest local NHS speech and language therapy departments in the trial where possible. Potential
participants (those identified as having had a stroke, and a diagnosis of aphasia, at least 4 months post
stroke, aged ≥ 18 years) were contacted by the research SLT in each participating NHS trust. This person
was a member of the local clinical team who was appointed to take responsibility for the running of the
trial and the trial intervention in their NHS trust. The participant was sent project summary information
and followed up by a telephone call 1 to 2 weeks later to establish whether or not they were interested in
the trial. If they were, the research SLT made an appointment to visit them at home. All trial procedures,
including recruitment, intervention and outcome measures, were conducted in the participants’ own homes.
A screening log was completed by the therapist who identified potentially eligible patients from patient
records, speech and language therapy colleagues or voluntary groups. Data recorded and sent back to
the clinical trials research unit (CTRU) included unidentifiable information including initials, gender and
age. The reason, if given, for not arranging an appointment was recorded.
Screening for eligibility
At the first visit to the potential participant, before providing detailed trial information, the research
SLT determined whether or not the person was eligible. They requested verbal consent to undertake
the naming test of the CAT,30 which is used in routine practice and can establish the severity of a
person’s word-finding deficit. If the word-finding score was < 5 (10%) or > 43 (90%) (out of 48), an
explanation was given to the patient that this type of computer therapy was not suitable for them.
If they were still interested in computer-based therapies, they were directed to the aphasia software
finder (www.aphasiasoftwarefinder.org; accessed 20 June 2018) developed to help patients with
aphasia to identify software that would be most suitable for them. If the potential participant had
eligible word-finding scores, the research SLT asked them to attempt a simple matching task on the
computer to confirm ability to see the screen and perform simple tasks.
Recruitment
The level of support required to enable a person with aphasia to provide informed consent is dependent on
the severity and profile of the aphasia. Considerable attention was given to the recruitment of participants
with aphasia to ensure informed consent. In order to provide information in a format consistent with
each individual’s language ability, the Consent Support Tool was used.31 The research SLT at each site
requested verbal consent from the potential participant to carry out part A of the Consent Support Tool
(language screening test of 5–10 minutes). The result indicated which style of information would best
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support their understanding of the trial. Three different styles of information sheet were available
to enable as many participants as possible to make their own decision regarding whether or not to
consent to participation in this trial. The consent support tool, carer information sheets and consent
forms can be accessed online (see www.journalslibrary.nihr.ac.uk/programmes/hta/122101/#/related-
articles), as can aphasia-friendly/accessible information sheets and videos (see www.sheffield.ac.uk/
scharr/sections/dts/ctru/bigcactus). Patient information sheet 1 was in large font with keywords
emboldened for those who could understand written paragraphs. Patient information sheet 2 was for
those who could read simple sentences but not full paragraphs. It followed standard aphasia-friendly
principles with one idea presented per page in short simple sentences of large font. Keywords were
emboldened and each idea was represented by a picture. Patient information sheet 3 was for those
who could understand with significant support. Each idea/sentence was presented on a Microsoft
PowerPoint® (Microsoft Corporation, Redmond, WA, USA) slide with simple text, keywords emboldened
and picture support. Research SLTs were instructed to present each point in turn, read aloud to the
potential participant and support with gestures, objects and drawings. The next sentence was then
presented. All participants were given sufficient time to consider their participation before informed
consent was taken by the research SLT. Participants providing their own informed consent were asked
to sign an aphasia-friendly consent form.
The Consent Support Tool also identified individuals who did not have the mental capacity to consent
for themselves owing to the severity of their language difficulty (those with severe aphasia who find
it difficult to understand information, even with the support of adapted/pictorial information formats).
These individuals receive speech and language therapy treatment in practice and may benefit from the
trial intervention; therefore, it was important to include them. These potential participants were shown
a short video clip of the computer program being used and of someone being assessed to show what
was involved. If potential participants with severe aphasia who lacked capacity to consent indicated
an interest, a relative (in Scotland, the person’s legal representative or nearest relative) was asked to
read the full information sheet and a covering letter detailing their responsibility, and to sign a carer
declaration that they believed that their relative wished to take part (in Scotland, they were asked to
sign a consent form). At the request of the PCPI group, all patients were given a copy of either the
standard information sheet or the aphasia-friendly information booklet and a picture summary on one
side of A4 paper.
For those participants with a carer, the carer was asked if they were willing to complete outcome
measures related to their own quality of life and perception of their relative’s communication ability.
They were provided with the carer information sheet and were asked to sign a consent form.
Interventions
Following the TIDieR checklist,29 the three trial interventions are described below.
Usual-care control group
Usual care for people with long-standing aphasia following stroke varies across the country in terms
of type, frequency and length of provision, and is dependent on available resources in each locality.
To accurately describe UC provided to people with aphasia > 4 months post stroke, patients, carers and
therapists were asked what therapy they had received in the 3 months before they were randomised.
Therapy notes were then consulted to record the dates of therapy sessions, therapy goals, length of
sessions, personnel providing therapy and the mode of therapy delivery. The UC received prior to
randomisation is reported here based on the 244 participants who were at least 4 months post stroke
at the start of the observation period. These data can be considered as a trial result. However, as
describing UC was not a research objective, and as the data describe one of the trial interventions,
the information has been reported in this section.
METHODS
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What?
Of the people with aphasia at least 4 months post stroke in the 3 months prior to randomisation,
40% were in receipt of speech and language therapy and 60% were not. People with aphasia were
more likely to receive therapy than not if they were < 12 months post stroke, but they were less
likely to receive therapy if they were > 12 months post stroke. A lower proportion of people with
mild word-finding difficulties (32%) received therapy than those with moderate (52%) and severe (40%)
word-finding difficulties. Forty-eight per cent of the participants attended voluntary or social support
groups. Twenty-three per cent of participants were in receipt of therapy but did not attend voluntary
or social support groups, 32% attended support groups but did not receive therapy, 29% had neither
and 16% had both.
Therapy aims or goals recorded for each therapy session in speech and language therapy notes were
analysed using a quantitative content analysis by two SLTs (RP and HW). The goal categories, descriptions
and examples in Table 1 show the range of speech and language therapy activity forming UC. Approximately
50% of therapy goals in UC focused on rehabilitation of the language impairment. Twenty-three per cent of
goals focused on enabling the person to communicate, often with compensatory strategies. Time was
also spent on providing support, in addition to assessment and reviewing progress. More than 5 years
after stroke, enabling goals were more prevalent than rehabilitation goals.
TABLE 1 Goals of therapy in UC
Goal category (level 1) and goal
description (level 2)
Example (as described in the patient notes
from which data were collected)
Number
of goals
Percentage
of goals
Assessment Assess higher level language functions 44 4.8
Review Review progress made in therapy 49 5.2
Rehabilitation (improving impairment) 4628 49.8
Comprehension Improve auditory comprehension 21 2.3
Expressive language To produce longer/more complete
verbal sentences
87 9.4
Intelligibility Clearer speech 15 1.6
Money skills Money handling skills 14 1.5
Number skills Number recognition 10 1.1
Phonological skills Phonological therapy 32 3.5
Reading Identify functional written words 81 8.8
Semantic skills Semantic categorisation of concrete items 44 4.7
Word-finding To be able to find words in conversation with
more ease
107 11.5
Writing To be able to write short clear emails 51 5.5
Enabling 211 22.7
Augmentative and alternative
communication
Functional communication using low tech AAC 29 3.1
Conversation support Supported conversation using technology 82 8.8
Participation in social conversation/
activities
Speak more fluently with golf friends 18 1.9
Total communication strategies Alternative ways to get message across 19 2.1
Using everyday technology Use of spell check 40 4.3
Word-finding/self-cueing strategies Functional and compensatory strategies for
word-finding
23 2.5
continued
DOI: 10.3310/hta24190 Health Technology Assessment 2020 Vol. 24 No. 19
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Palmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
11
Who?
Usual speech and language therapy was predominantly provided by qualified SLTs at Agenda for Change
bands 6 and 7. Some therapy sessions were provided by SLTAs on Agenda for Change bands 2 and 3.
How?
Usual speech and language therapy was predominantly provided face to face, with 87% of sessions
delivered one to one and 12% of sessions delivered to a group of patients. Overall, five telephone
calls were recorded as being used to provide therapeutic intervention and one instance of the use of
telehealth was recorded.
TABLE 1 Goals of therapy in UC (continued )
Goal category (level 1) and goal
description (level 2)
Example (as described in the patient notes
from which data were collected)
Number
of goals
Percentage
of goals
Supportive 36 3.9
Emotional support Exploring loss and gain 8 0.9
Improve mood To improve mood 1 0.1
Increase confidence in
communicating
To improve confidence in talking in group setting 6 0.7
Managing frustration Frustration levels 1 0.1
Providing information To advise patient and family about impact and
recovery from aphasia
13 1.4
Support communication with other
professionals/form completion
Form filling support 3 0.3
Support for family Communication support for family 1 0.1
Vocational support Attend ‘fit for work’ interview 3 0.3
Activity to support therapy 39 4.2
Discussing discharge Discharge planning 5 0.5
Expert patient training Expert patient training 2 0.2
Goal-setting To set goals for occupational therapy and
speech therapy
16 1.7
Handover Handover to new SLT 4 0.4
Liaison with other staff/family Liaison with social worker
To demonstrate laptop comprehension tasks
to family
4 0.4
Preparing/monitoring homework Set up home exercises 2 0.2
Therapy planning Establish motivation for therapy 6 0.7
Insufficient information 86 9.3
Goal not sufficiently described Activity practice
To achieve 90% on tasks
74 8.0
No goal recorded 12 1.3
Not communication therapy 1 0.1
Total 928 100.0
AAC, augmentative and alternative communication.
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Where?
Therapy was predominantly provided in patients’ own homes when one to one, and in outpatient/
community health-care settings when provided in a group.
When and how?
The median therapy time received was 5 hours and 20 minutes, delivered in 1-hour sessions once
every 2 weeks (median averages). The total time and number of sessions reduced with length of time
post stroke, from 8 hours delivered in 1-hour sessions 0.67 times per week for people between 4 and
6 months post stroke to only 2 hours and 45 minutes delivered in 45-minute sessions once per month
for people > 5 years post stroke (median averages).
Tailoring
Usual-care goals were tailored depending on a participant’s interests and clinical decisions regarding
their needs.
Modifications
As this was a pragmatic trial, UC varied between sites and participants according to usual practices. No
attempt was made to standardise the UC received. Consequently, there were no planned modifications
to UC during the trial.
Fidelity/measurement of how well usual care was delivered
Amounts of therapy time were recorded for UC throughout the trial to assess whether or not this stayed
constant between trial groups. Fidelity to UC is reported in the trial results [see Chapter 4, Usual-care
speech and language therapy offered (fidelity/adherence to provision of usual care)].
Self-managed computerised therapy intervention for word-finding (computerised speech
and language therapy)
Why?
The intervention targeted word retrieval as it is one of the challenges most frequently experienced by
people with aphasia, restricting their communication. The intervention was designed by SLTs specialising
in aphasia and use of computer software for its treatment. The components of the intervention were
designed to incorporate key factors that neuroplasticity principles and research suggest positively
influence aphasia therapy outcomes combined with practical considerations: exercises tailored to the
difficulty experienced by the individual with aphasia (specificity); content of therapy tailored to personal
interests (salience); use of computer software to enable independent practice and therefore increased
amounts of practice for a duration longer than that achievable through face-to-face therapy alone; and
practical support and motivation for use of the software.
The four key components of the intervention are summarised below:
1. StepByStep software (version 5) – specialist aphasia software designed by SLTs and commercially
available.
2. Qualified SLT assessment of the participant’s language profile to tailor computer exercises using
StepByStep so that they target the specific language deficit identified. Creation of exercises using
target words of personal relevance to the participant.
3. Daily independent word-finding practice with the tailored computer exercises by the participant for
6 months.
4. Volunteer/SLTA support to enhance adherence to the computer exercises and to encourage transfer
of new words into functional daily situations.
The TIDieR items ‘what?’, ‘who?’, ‘how?’, ‘where?’, ‘when?’, ‘how much?’ and ‘tailoring’ are described
within each of the four components of the intervention in the following sections.
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StepByStep software
What?
StepByStep software was chosen as it focuses on word-finding, allows for exercises to be tailored
to individual need, enables personalisation through the addition of photographs (e.g. their spouse’s)
and provides feedback to the person with aphasia on practice frequency and duration and progress
to aid motivation for repetitive practice. All of these features support the principles of experience-
dependent neuroplasticity. The software was purchased by each NHS trust and provided to participants
randomised to the computer therapy group of the trial. If participants had their own laptop/desktop
or tablet computer, a home licence was installed by the SLT (for additional information on devices
and microphone recommendations, refer to the Therapy manual: Big CACTUS StepByStep computer
therapy approach at www.sheffield.ac.uk/scharr/sections/dts/ctru/bigcactus). If the participant did not
own their own device, or their device could not run the software, a laptop or tablet computer owned
by the NHS trust was loaned with a clinician licence of the software installed (for more than one user)
for a period of 6 months. Participants with a home licence installed on their own computer kept this
after the 6-month period. The combination of loaning devices for set periods of time and provision of
home-user licences enabled equity of intervention provision, and reflected pragmatic decisions
required for delivery of such interventions in clinical practice.
Qualified speech and language therapist assessment, tailoring of exercises
and monitoring
Who?
A qualified SLT (one at each site) with experience of treating aphasia post stroke as part of the clinical
team at that site.
What and tailoring
The SLT-tailored computer exercises to the individual using 100 words of personal relevance chosen by
the participant. The word sets were standardised to 100 for each participant to allow sufficient words to
maintain interest and motivation to practice for the long intervention period (up to 6 months). A meta-
analysis of numbers of words used in word-finding therapy and outcome showed that people with all
severities of aphasia could manage large word sets.32 There is a large bank of photographs within the
StepByStep computer program from which to select personally relevant vocabulary and if something
extra was required (e.g. a picture of a grandchild or favourite football team) it was photographed digitally
and added by the SLT. The computer software20 enabled the SLT to select exercises using these words;
the exercises follow steps in the therapy process that the therapist would take if delivering word-finding
therapy face to face. The SLTs based the selection of exercises on language skills demonstrated in the
initial language assessments and therefore ensured that word-finding cues were useful and exercises
were set at a level of difficulty with which the participant could experience success before moving on
to more challenging exercises (see Therapy manual: Big CACTUS StepByStep computer therapy
approach for the NHS, for instructions on how to modify exercises according to assessment results, at
www.sheffield.ac.uk/scharr/sections/dts/ctru/bigcactus). The SLT provided an initial demonstration of
the software exercises and spent time checking that the individual was able to use the software and
monitoring the appropriateness of the tailored exercises. The SLT also reviewed the need for additional
pieces of hardware, such as tracker balls, in order to make it physically possible for participants to use
the computer.
Where?
The SLT carried out both assessment of and introduction to the computer exercises in the participants’
own homes.
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Regular self-managed practice
How, where, when and how much?
The participant was then asked to work through the exercises on the computer, with the aim that they
would practise each day for 20–30 minutes. Participants were given a 6-month period to work through
the therapy material on the computer at home and to practise using the new vocabulary in their daily
lives. Practice with the computer for a minimum of 20 minutes three times per week at home on
average across at least a 4-month period was considered per protocol. This accounted for periods
of illness and holiday expected to occur in a 6-month period. The amount of practice was captured
automatically by the computer program. Those participants who had the software installed on their
own computers were not prevented from continuing to practise if they wished (with no prescribed
support) following the 6-month supported intervention time. If computers were loaned, they were
taken back after 6 months or when a new participant needed to borrow a computer (as permanent
loan of equipment would be unusual in practice).
Volunteer or speech and language therapy assistant support with treatment
adherence and carry-over into daily activity
Who?
To support use of the computer exercises, the SLT provided training to local volunteers who already
had a working relationship with the speech and language therapy department (based in NHS trusts,
local voluntary organisations or student SLTs) or SLTAs based in their department. This variation aimed
to allow for consistency with the current mechanisms for providing therapy support in each NHS trust.
What, when, where, and how much?
The training programme and instruction book developed and evaluated during the pilot study was
used (see Big CACTUS volunteer/assistant handbook at www.sheffield.ac.uk/scharr/sections/dts/ctru/
bigcactus). The volunteer was asked to visit the participant at home for a minimum of 4 hours (once
a month for 1 hour, or every 2 weeks for half an hour to suit the participant), carrying out the
following tasks:
l provide technical assistance
l observe and encourage use of computer exercises
l check results and discuss difficulties
l assist the participant to move on to harder tasks in the therapy process pre-programmed by the SLT
l encourage the use of new words in everyday situations through conversation and discussions with
family about how to encourage use
l set up new vocabulary sets if all 100 words had been completed.
Further advice provided to the volunteers/assistants on how to support the participant is detailed in the
volunteer handbook (see www.sheffield.ac.uk/scharr/sections/dts/ctru/bigcactus). The participants were
able to contact the volunteer/SLTA by telephone for technical advice on computer use between planned
visits if necessary. The volunteer/assistant was introduced to the participant by the SLT on a joint home
visit, and the volunteer was shown the exercises that had been set up. After each planned visit to the
participant, the volunteer/assistant completed a feedback form for the SLT on what they did in the
session and any issues/questions. The volunteer could contact the SLT by e-mail or telephone between
support sessions to report any concerns/difficulties.
The computer intervention was delivered in addition to UC (see Usual-care control group).
Modifications
In response to feedback from the first four therapists providing the intervention to their first participants,
the handbook was modified to explain that not all available cues needed to be tailored, only those assessed
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as being useful for the individual. Provision was also made for therapists to provide the words to the
participant over more than one session, to add cues for a subset of words and to review the usefulness of
the cue before adding to all 100 words.
Fidelity/measurement of how well the intervention was delivered
The aim was to measure the effectiveness of the intervention as it would be delivered in clinical
practice. The SLTs delivering the intervention attended 1 day of training on how to use the StepByStep
software; training was provided by SLTs in the central Big CACTUS team based on training available
to SLTs from Steps Consulting Ltd. They received a therapy manual (see www.sheffield.ac.uk/scharr/
sections/dts/ctru/bigcactus).
The volunteers/assistants and SLTs were to support participants’ adherence to computer practice as
part of the intervention. However, no additional strategies were used to maintain or improve fidelity
that could not be used in routine clinical practice.
Fidelity measures of the four key components of the intervention are outlined in the following sections.
StepByStep software
The proportion of participants allocated to the computer therapy group who had access to the
StepByStep therapy software (the coverage of the intervention) was indicated by the completion of
forms by the SLT to confirm that access had been given.
Assessment and tailoring of software by the speech and language therapist
Following training on how to set up the software and deliver the intervention, quality of delivery of the
intervention was evaluated using a quiz of SLT knowledge about the intervention and a therapy planning
form that SLTs completed each time they tailored the StepByStep software that captured their reasoning
for the prompts and cues selected. SLTs delivering the intervention completed the quiz 5, 10 and
15 months after randomising their first participant. In addition, SLTs delivering the intervention were
asked to complete therapy planning forms for an independent SLT to judge the extent to which exercises
chosen were consistent with the language assessment results. For each SLT delivering the intervention,
one therapy planning form was appraised by a StepByStep approach expert (RP, the Big CACTUS chief
investigator, author of the therapy manual and a SLT experienced in delivering the StepByStep approach
in clinical practice). Scores of 2 (reasonable rationale for tailored steps), 1 (partial rationale) or 0 (no or
inexplicable rationale) were used. The time spent on each of the activities involved in delivering the
intervention described in the manual was recorded by the SLTs delivering the intervention.
Practice of exercises by the participant
Adherence to exercise practice on the computer was captured automatically by the software and the
total practice time was reported over the 6-month intervention period and compared with predefined
per-protocol definitions (see Chapter 3, Per-protocol sets).
Volunteer/assistant support
The volunteers/SLTAs kept logs of the amount of time spent with each participant, including the
number of sessions, duration of each session and session content.
The original Big CACTUS protocol funded by the Health Technology Assessment programme did not
incorporate fidelity assessment. Measurement of fidelity to all components of the intervention was
managed by a Big CACTUS research associate (MH) under the supervision of the chief investigator (RP)
and co-investigator (CC) as part of a PhD funded by the Stroke Association. The results of the fidelity
assessment described above are reported in the clinical results section of this report (see Chapter 4,
Fidelity to computerised speech and language therapy: adherence to practice and quality of intervention delivery).
A more-detailed evaluation of the fidelity to the intervention described within this trial will be available
on completion of the PhD.
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Attention control group
Why?
To control for the potential impact of elements of the computer intervention, which, of themselves,
do not provide or require specific speech and language intervention.
What?
Participants were provided with generalised activities to carry out and general attention in addition to
UC. On allocation to this group, the SLT conducting baseline assessments provided books of standard
puzzles that could be purchased from most supermarkets or from high-street shops. Each book contained
enough activities for one to be carried out each day for at least 1 month. Examples of puzzles include
‘spot the difference’, noughts and crosses, and word searches. The PCPI group advised on types of puzzle
book that may be of interest and practical factors, such as size of the text.
Who?
The SLT provided age-appropriate puzzle books that matched the participant’s linguistic and cognitive
ability as indicated by the baseline assessments. Puzzle books were colour coded into levels of easy,
medium and hard by the clinicians on the research team centrally with support from the PCPI group
and a leaflet was provided to give SLTs guidance on skills required for each level.
Who, how, where, when and how much?
A member of the research team contacted the participant or their carer by telephone or e-mail (whichever
was preferred by the participant) once a month for the duration of the 6-month intervention period to
mimic the attention provided by volunteers in the intervention group. Participants were asked if they
were enjoying the activities, how many they managed to do at home, whether or not they would like a
new puzzle book sent to them for the coming month and whether or not it needed to be the same level
of difficulty, or easier or harder. The participants also had access to contact details of the research team
to enable them to ask for easier or harder books at any time if necessary, mimicking the access to the
volunteers/SLTAs and type of attention available in CSLT.
Modifications
No modifications were made to AC during the course of the trial.
Fidelity/measurement of how well the intervention was delivered
The number of puzzle books sent out and the number of contacts made by the research team were
used as a proxy measure of adherence to AC. A puzzle book was sent out if a participant or carer
reported completing the previous one. A minimum of six puzzle books and four contacts was used
as a measure of adherence to the intervention.
Outcomes
Primary outcome measures
Research objective 1: to establish whether or not self-managed computerised
speech and language therapy for word-finding increases the ability of people with
aphasia to use vocabulary of personal importance (impairment)
The change in word-finding ability, between baseline and 6 months, of words personally relevant to the
participant was measured by a picture-naming task (100 words with a maximum of 2 points each).
The word-finding score was expressed as a percentage of the total score, and change in the percentage
6 months from baseline was calculated. This is a measure of the change in the impairment and was
considered to be of interest to SLTs as it indicates whether or not word-finding treatment for persistent
aphasia (i.e. beyond the acute and subacute phase) is effective for improving retrieval of words.
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The pictures were presented within an assessment module of the StepByStep programme by the
research SLT at baseline at the NHS trust from which the participant was recruited.
The research SLTwas trained on how to score the word-finding test and was provided with written
instructions in the outcome measure therapists’ handbook (see www.sheffield.ac.uk/scharr/sections/dts/
ctru/bigcactus). The research SLTwas given two videos of people with aphasia carrying out word-finding
tests for practice and this was reviewed by a speech and language therapy trainer from the central
project team who provided feedback to the research therapist. The same test was performed 6 months
after randomisation by an outcome measure therapist (a qualified SLT). This therapist was trained to
score the test through webinar training from the central trial team. The scores derived from the two
practice videos were compared with the scores of the research SLT in the same NHS trust to check for
inter-rater reliability between raters within each trust. When there was a discrepancy, the research SLT
and outcome measure therapist were encouraged to discuss differences and rate a third video.
Research objective 2: to establish whether or not self-managed computerised
speech and language therapy for word-finding improves functional communication
ability in conversation (activity)
Change in functional communication between baseline and 6 months was measured by blinded ratings of
10-minute video-recorded conversations between a SLT (research SLT at baseline and outcome measures
SLT at outcome) and participants, using the activity scale of the TOMs.33 Conversations were structured
around topics of personal relevance to the participants by the SLT performing baseline measures, based
on the 100 words they selected. The same conversation topic guide was followed by SLTs performing
outcome measures. Independent SLTs blinded to treatment allocation and measurement time point rated
the videoed conversations at the project co-ordinating centre. This measure of functional communication
ability was used to indicate whether or not the word-finding intervention had any impact on the ability
to communicate in conversation. TOMs were chosen as a primary outcome measure of this ability as they
have been standardised, shown to be reliable and have been used to rate videoed conversations in a
previous RCT of aphasia intervention [Assessing Communication Therapy in the North West (ACT NoW)8]
with good reliability.
A benchmarking session using the TOMs was conducted with potential raters to get consensus on
the application of the TOMs in this project, followed by inter-rater and intrarater reliability tests at
least 6 weeks apart using 10 practice videos. Scoring instructions were provided following consensus
during the benchmarking session (see Appendix 2). The consensus was that pairs of videos were easier
to rate for each individual rather than isolated videos for each participant. The 14 raters selected for
final rating of all participant videos had intrarater reliability of at least 70% (7/10) of practice videos
rated within 0.5 between rating at time 1 and time 2, and inter-rater reliability of at least 70% (14/20)
of videos rated within 0.5 of the median scores from all raters at both time points. In total, 86% (240) of
the 20 ratings made by each of the 14 reviewers (total 280 ratings) were within 0.5 of the median score,
and 88% (123/140 ratings) were within 0.5 between time 1 and time 2. A slight upwards trend was
noted in scoring between time 1 and time 2; therefore, the pairs were presented in random order. For
further detail of the process for selection of TOMs raters and the scoring procedure, see Appendix 2.
Key secondary outcome measure
Research objective 3: to investigate whether or not patients receiving self-managed
computerised speech and language therapy perceive greater changes in social
participation in daily activities and quality of life (participation)
Improvement in patient perception of communication between baseline and 6 months was measured
using the Communication Outcome after Stroke (COAST) scale, a patient-reported measure of
communication, participation and quality of life validated for evaluating speech and language therapy
interventions in the Health Technology Assessment ACT NoW project.8 This measure was used to
provide SLTs with quantitative information on participant perceptions of the effects of the intervention
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on their life to complement the qualitative information collected through patient interviews in the pilot
study. The COAST was administered face to face by the research SLT at each participating NHS trust at
baseline and by outcome measures therapists at 6 months.
Secondary outcome measures
Research objective 4: to establish whether or not self-managed computerised
speech and language therapy is cost-effective for persistent aphasia post stroke
A cost–utility analysis was undertaken from a NHS and Personal Social Services (PSS) perspective.
The cost-effectiveness outcome was the incremental cost-effectiveness ratio (ICER), where effectiveness
was measured in quality-adjusted life-years (QALYs). The incremental analysis included all three of the
trial groups. Resource costs were estimated for patients, including intervention software and hardware,
and SLT and assistant input time, combined with standard costing sources. Volunteer time was also
recorded and costed for inclusion in a supplementary analysis taking a broader perspective. SLTs
were asked to complete therapy activity forms for each contact with each participant, detailing their
Agenda for Change pay band, time spent setting up the computer therapy or in face-to-face support,
or support/training of the volunteer/assistant, and travel mileage. Assistants and volunteers were also
asked to complete activity forms with information on their Agenda for Change pay grade if applicable,
time spent face to face or indirectly with the participant, activity conducted with the participant
and mileage.
The EQ-5D-5L questionnaire was administered at all time points and combined with standard valuation
sources to measure QALYs gained in each treatment group. An accessible version of the EQ-5D-5L
designed by the PCPI group for people with aphasia was completed by participants. An accessible
version of the EuroQol-5 Dimensions, three-level version (EQ-5D-3L), had been tested in the pilot
study.18 The carers (if available) completed the standard version by proxy. Carers also completed the
EQ-5D-5L for themselves. For more detail about the use of EQ-5D-5L in this trial, see Chapter 5,
Health-related quality of life.
Information on cost-effectiveness was important to inform commissioners of speech and language
therapy services as well as providers to assist with decisions regarding funding such an intervention.
Research objective 5: to identify whether or not any effects of the intervention are
evident 12 months after therapy has begun
Evidence of treatment effect was measured by repeating all outcome measures at 9 and 12 months
from baseline in addition to the primary end point of 6 months. The 9-month time point was included
as an interim measure as withdrawal from the trial was found to increase over time in the pilot study.
Follow-up measurements were important to provide information to SLTs, commissioners and providers
about the long-term impact of the intervention.
Additional secondary outcome measures
The first primary outcome measure identified improvement in the ability to retrieve words practised
in therapy and the second primary outcome measure identified any improvement in conversation using
the standard descriptors provided by the activity scale of the TOMs33 to try to detect generalisation
of any impairment level improvement to the level of activity. As an intermediate and potentially more
sensitive measure of generalisation, use of words practised in therapy in the context of conversation was
measured by two research members of the central trial team who watched each videoed conversation
and identified how many words practised in therapy were used during the structured conversation
on related topics. The researchers ticked the word on a checklist if it was heard and scored the total
number of practice words heard. Intrarater and inter-rater reliability was established for the researchers.
They both rated the same set of 10 videos twice, a minimum of 6 weeks apart. Inter-rater reliability was
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80% (8/10) at both time 1 and time 2. Intrarater reliability was 100% (10/10) for rater Kathryn McKellar
and 90% (9/10) for rater Ellen Bradley. The researchers were blind to the time point at which each video
was made.
Generalisation of treatment to retrieval of untreated words was measured using the object naming test
from the CAT.30 This measure was used to show whether or not generalisation occurs from treated to
untreated words. This is important to SLTs so they know whether or not careful selection of vocabulary
for their treatment of word-finding is important.
Carer perception of communication effectiveness was measured using the Carer COAST (CaCOAST).34
The last five items of the CaCOAST and responses to the Care-related Quality of Life instrument
(CarerQol) were collected to indicate any impact of the intervention on the carers’ quality of life.
As self-managed computer use for speech and language therapy is relatively new and, by nature,
unsupervised, any negative effects specifically felt to be related to computer use were collected
using a negative effects questionnaire (see www.journalslibrary.nihr.ac.uk/programmes/hta/122101/
#/related-articles) that was sent to the participants in the CSLT group every month. This asked
participants whether the computer practice made them feel overtired, affected their eyes, gave them
headaches or made them feel anxious or worried. They were also asked to list any other problems
experienced as a consequence of using the computer therapy. In addition, adverse events (AEs) and
serious adverse events (SAEs) were reported by the research therapists on discovery or following a
telephone call to the participant or carer at 6, 9 and 12 months (see Appendix 3 for definitions of AEs
and SAEs for the population in this trial).
For the method for calculating scores for all of the above outcome measures, see Chapter 3,
Computation of summary outcome scores for analysis.
Staff training for delivery of outcome measures
All research SLTs attended a 1-day training course delivered by the central research team to ensure
understanding of the protocol and trial procedures including how and when to administer outcome
measures. It was understood that some participants may need more than one visit to complete the
assessments. The flow of participants through the trial was the responsibility of the research SLTs
(principal investigators) at each participating NHS trust. A flow diagram of activity was provided to
assist with this (see Appendix 4).
Therapists responsible for carrying out assessments at all follow-up time points (6, 9 and 12 months)
were trained in their responsibilities, the importance of blinding and how to administer outcome
measures. Training was in small groups via a webinar delivered by the trial manager and the central
team speech and language therapy researcher. It was recommended that they conduct each outcome
measure visit within 1 month of each time point to ensure that outcome measure visits were spaced
sufficiently to avoid presenting a burden to participants.
Collection of demographic data
Initial assessment was undertaken by the research SLT at each participating NHS trust. The initial
assessment visit included collection of demographic data: aphasia type, age, gender, time post onset of
stroke, and type and location of stroke (if known).
Recording of usual care
The research SLT at each NHS trust was asked to record UC provided to each participant throughout
the trial to provide a description of UC and also to ensure that UC did not change once participants
were randomised to the trial. UC included care provided by both the NHS and the voluntary sector.
In addition, the research SLTs were asked to record UC provided in the 3 months prior to
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randomisation from participant and carer reports and from SLT notes. For each session, they were
asked to report the therapy goal, length of session, mode of delivery of session, Agenda for Change
band of staff delivering the session and distance travelled. This information was sought every 3 months
via telephone calls with the participants and carers and from inspection of participant notes if they
were made aware that therapy had been received.
Sample size
The trial aimed to recruit a maximum of 285 participants (95 per group) across 20–24 speech and
language therapy sites to preserve 90% power for a 5% two-sided test to address both co-primary
objectives relating to word-finding of personally selected words and functional communication outcomes.
We adjusted for a 15% drop-out rate observed in an external pilot trial.21 For the change in word-finding,
based on consensus of the therapists on the trial team and the aphasia PPI group, we assumed a 10%
mean difference as clinically worthwhile to detect and a standard deviation (SD) of 17.38% estimated
from an external pilot trial21 based on an analysis-of-covariance model.
We inflated the sample sizes by 1.14 to account for the fact that the variance was estimated from a
pilot trial.35,36 For the change in functional communication (TOMs activity scale), we sought an effect
size of 0.45 of the SD as clinically worthwhile and a 0.5 correlation between baseline and outcome
observed in the ACT NoW study (Professor Andy Vail, University of Manchester, 2013, personal
communication).
For the change in COAST, a key secondary outcome measure, we sought a 7.2% clinically worthwhile
effect to detect and a SD of 18% based on externally supplied data and we assumed a 0.5 correlation
between baseline and outcome. For a sample size of 285 (95 per group), the trial had 83% power for
the COAST. The observed overall drop-out rate was about 9%, versus the planned 15%; as a result,
further recruitment was terminated at 278 participants because the trial had the desired statistical
power to address co-primary and key secondary outcomes.
Interim analyses and stopping guidelines
The initial phase of the trial was conducted as an internal pilot trial and included clear criteria to
inform decisions about progression and the feasibility of the full trial only. No interim analysis for
efficacy, futility or stopping early for safety was planned. Data from the internal pilot are included in
the final analysis.
The internal pilot trial was limited to six sites (> 25% of the total). However, during this phase we
recruited and commenced set-up processes for all of the intended sites to avoid a delay in the event
that the trial continued. In accordance with the guidance on progression rules for Health Technology
Assessment internal pilot trials, the lag phase expected before recruitment reached the target rate
was excluded. For the substantive study, the lag phase included the period for obtaining approvals,
site recruitment and staff training. The progression criteria were reviewed 8 months from site set-up
of the sixth site.
Based on recruitment rates from the previously published pilot study,21 we aimed to recruit participants
at an average rate of one participant per site per month. At the end of the internal pilot trial phase, the
six pilot trial sites had been recruiting for a minimum of 8 months. The progression of the trial was
based on achieving the following criteria.
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Numbers recruited
The overall target for the six sites was 36 participants. The overall progression target for numbers
recruited from the six sites was 30. This was equivalent to the number recruited in total in our previous
pilot study and enabled comparison with previous recruitment rates to confirm whether or not our
projections for the substantive study were accurate. There was also information available from other
sites that had completed set-up and started to recruit; therefore, we expected at least 40 participants
to have been recruited by the end of the internal pilot phase in total.
Recruitment as a percentage of the full-study recruitment targets
At the end of the internal pilot trial, progression depended on having recruited 30 participants (i.e.
10% of the total population recruited from 25% of the sites; this was midway through the recruitment
phase for these sites). If we achieved this number, we would be on track to recruit only 80% of the
sample size within the study period. We would then have to bring in the additional four contingency
sites included in the costs to raise the recruitment to the sample size. If we did not meet this number,
it would indicate that the larger study was unlikely to be feasible.
Retention to first outcome measure time point at 6 months (primary outcome)
The sample size calculation was based on an attrition rate of 15% at 90% power for the co-primary
outcomes. The progression criterion for retention was set to ensure a minimum power of 80%.
This would be achievable with a retention rate of 65%, which would still ensure that the results
were generalisable.
Identification and retention of volunteers
Sites could provide support to patients in the intervention group of the trial from paid SLTAs or
volunteers. Use of volunteers was reviewed at the end of the internal pilot phase. Progression
criteria for continued use of volunteer support were set at 80% of participants having been offered
a volunteer and 70% of participants continuing to be supported by the same volunteer for their
6-month treatment period. If these progression criteria were not achieved, continuation of the study
would be with paid assistant support only.
Summary
In summary, 8 months after set-up of the sixth site, our progression criteria indicating feasibility of the
full trial were:
l recruitment of no fewer than 30 participants (10% of the target for the full trial)
l a minimum retention rate of 65%.
Randomisation and concealment
We used a centralised web-based randomisation system hosted by the Sheffield CTRU to randomise
participants to one of the three treatment groups using a fixed 1 : 1 : 1 allocation ratio. The randomisation
schedule was generated using stratified block randomisation with randomly ordered blocks of sizes three
and six, stratified by centre and the severity of word-finding at baseline based on scores of the naming
test of the CAT (mild, 31–43; moderate, 18–30; and severe, 5–17). Only the randomisation statistician
knew about the block sizes and they were disclosed after the trial had finished. A Sheffield CTRU
statistician independent of the trial conduct logged on to the randomisation system to specify the
randomisation details and generated the randomisation schedule, which was retained within the system.
The system offers restricted access such that research team members are granted access to particular
functionalities depending on their roles in the trial.
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The SLTs randomised participants in their homes, following baseline assessments, using the Sheffield
CTRU web-based online randomisation system and disclosed the allocation to the participant. If no
internet connection was available, the SLT would telephone the research team at the Sheffield CTRU,
who randomised online and gave the allocation immediately over the telephone to the SLT to disclose
to the participant.
Blinding
This was a single-blind trial recognising that participants and lead research SLTs at each participating
NHS trust could not be blinded to participants’ treatment allocation as participants would be provided
with software personalised by the research SLT, or provided with puzzle books, or neither, depending
on their allocation. However, all baseline and outcome measures were conducted blind to treatment
allocation. The research SLTs conducting baseline assessments did this prior to randomisation. After
randomisation, the research SLTs were unblinded to treatment allocation to be able to provide the
correct intervention. Therefore, separate outcome measure SLTs were trained at each participating
NHS trust to ensure that 6-, 9- and 12-month follow-up assessments were conducted by assessors
who were blind to treatment allocation. The outcome assessors were SLTs with no previous involvement
in the conduct of the trial. They were trained, via a webinar session run by the central team, on the
importance of remaining unaware of the treatment allocation of the participants they would be
assessing. Research SLTs were asked not to disclose baseline case report forms, not to openly discuss
participants with colleagues in open-plan offices and to remind their participants not to discuss their
activities on the trial with any other SLTs they may come into contact with as it was ‘a secret’. When
outcome assessors contacted participants and conducted their assessments, they were advised to remind
participants that their activity on the trial was ‘a secret’. It was possible that during a conversation with
the participant or carer, outcome assessors could become unblinded by the participant or their carer.
If this happened on the telephone, before the assessment took place, then the assessment was carried
out by a different, blinded, outcome measure SLT. If unblinding happened at the end of the visit, when
the assessment was complete, this was not classed as an unblinded assessment, as the actual assessment
was carried out when the assessor was still blinded. However, in the event of unblinding of the SLT
during an assessment, the next assessment was carried out by a different blinded assessor. All sites had
a minimum of two trained speech and language therapy assessors who were blinded to the allocation to
allow for unblinding issues.
If the treatment group allocation was disclosed during an assessment, then the outcome assessor
would continue with the assessment but subsequently alert the research SLT (principal investigator)
and complete an unblinding form. The unblinding form asked the assessor to record what they believed
the participant’s treatment allocation to be (‘the suspected allocation’). In some instances, the assessor
would guess the treatment allocation incorrectly, so the central team would report this as ‘suspected
unblinding’ only. Descriptive summaries of circumstances surrounding the unblinding of SLTs’ cases
were recorded and instances of unblinding are reported in Chapter 4, Reported cases of unblinding of
outcome assessments, to indicate the relative success of blinding procedures.
Video recordings of conversations at baseline and 6, 9 and 12 months were rated for the primary
outcome measure by SLTs, using TOMs, who were independent of the trial team at the central trial
site. Two researchers from the trial team rated the videos for the secondary outcome measure of
number of treated words used in conversation. In addition to blinding to treatment allocation, blinding
to time point was also maintained for the raters by presenting the videos to be rated in random order.
The trial statistician did not have access to any information that could reveal participants’ treatment
allocations during the trial and the randomisation statistician was not the same individual as the trial
statistician who performed the analysis.
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Methods of analysis are described in the chapters that follow: statistical analysis in Chapter 3 and
health economic analysis in Chapter 5.
The full trial protocol version 5.0 is available online (see www.journalslibrary.nihr.ac.uk/programmes/
hta/122101/#).
Ethics approval was obtained from Leeds West NHS Research Ethics Committee (reference number
13/YH/0377) and Scotland A Research Ethics Committee (reference number 14/SS/0023).
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Chapter 3 Statistical analysis methods
This chapter describes the statistical methods and principles used to analyse the trial to address theclinical effectiveness objectives [all main and additional research objectives except the objective
referring to cost-effectiveness (number 4); see Chapter 1, Research rationale and objectives]. The SAP
version 1.2 was written to conform to the International Conference on Harmonisation topic E9,37
applicable standard operating procedures from the Sheffield CTRU and the trial protocol. The SAP
was signed off before blinded or unblinded review of the data and is accessible online (see www.
journalslibrary.nihr.ac.uk/programmes/hta/122101/#). Post hoc analyses are explained with rationale.
All analyses were undertaken using Stata® 15.1 (StataCorp LP, College Station, TX, USA).38
Analysis populations
Modified intention-to-treat set
The modified intention-to-treat (mITT) population includes all participants for whom consent was
obtained, for whom treatment was allocated as per the randomised list regardless of circumstances
after randomisation and who had primary outcome data at the 6-month assessment. This was the
primary analysis set; other sets described below are for sensitivity analysis.
Complete-case set
This includes participants with outcome data at a particular assessment. The set was used for
subsidiary analysis of co-primary and key secondary outcomes at 9 and 12 months, and other
secondary outcomes at different assessments, and for plotting mean profile response of participants
over time across interventions.
Per-protocol sets
The goal here was to explore the effectiveness of the intervention among participants who adhered to
key components of the intervention. Therefore, the per-protocol sets include participants for whom key
components of the intervention were adhered to, including achieving the minimum amount of practice
recommended (20–30 minutes per day) and having access to support up to and including at their 6-month
assessment. Per-protocol classification relating to adherence to the intervention was undertaken for only
the CSLT and AC groups.
Per-protocol definitions were developed using the following rationale.
The recommended practice time was 20–30 minutes per day over 6 months. It was calculated that
26 hours provided an indication of high levels of adherence to this recommendation for the CSLT group
based on a minimum of 20 minutes three times per week for at least 4 months, accounting for periods
of holiday, illness and other commitments. A lower total practice time of 10 hours was also considered
to identify engagement with the computer intervention even if at a lower practice amount than
recommended. Participants in the AC group were recommended to complete one puzzle each day.
We estimated that, on average, there were enough puzzles in a book to last for 1 month so we used
six puzzle books requested/sent as a proxy for adherence to carrying out regular puzzle book activities.
The intervention descriptions recommend that support should be provided once per month in both the
CSLT group and the AC group. Accepting that this is not always possible, four contacts was used as an
indicator that support was being provided.
For all intervention groups, participants were excluded from the per-protocol analysis if outcome
measures were assessed 14 days before or 31 days after the expected 6-month assessment or if they
were randomised but failed to meet at least one inclusion criterion.
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The four per-protocol sets in the CSLT and AC groups were matched as follows:
1. high levels of adherence to recommended practice – practised computer therapy for a minimum total
of 26 hours (CSLT) or were sent at least six puzzle books (AC) within 6 months of randomisation
(referred to as PP1 CSLT26 AC6)
2. adherence to practice – practised computer therapy for a minimum total of 10 hours (CSLT) or were
sent at least six puzzle books (AC) within 6 months of randomisation (PP2 CSLT10 AC6)
3. high levels of adherence to recommended practice and provided with recommended support –
practised computer therapy for a minimum total of 26 hours (CSLT) or were sent at least six puzzle
books (AC) and contacted at least four times (if they wished) (in both the AC group and the CSLT
group) within 6 months of randomisation (PP3 CSLT26 AC6_4)
4. adherence to practice and provided with recommended support – practised computer therapy for
a minimum total of 10 hours (CSLT) or were sent at least six puzzle books (AC) and contacted at
least four times (if they wished) (in both the AC group and the CSLT group) within 6 months of
randomisation (PP4 CSLT10 AC6_4).
On 7 March 2018, the Trial Management Group discussed the final trial results in detail. It was noted
that only a small proportion of participants in the AC group met the predefined per-protocol inclusion
criteria. It was agreed that the predefined per-protocol proxy of being sent six puzzle books in 6 months
was overambitious and inconsistent with expectations of per protocol for CSLT. To align the puzzle book
per-protocol classification in the AC group with the CSLT group, the Trial Management Group requested
post hoc per-protocol classification based on being sent at least four puzzle books. This will only change
the per-protocol results for comparisons involving the AC group.We therefore modified the per-protocol
classifications presented above for sensitivity analysis as follows:
1. high levels of adherence to recommended practice – practised computer therapy for a minimum total
of 26 hours (CSLT) or were sent at least four puzzle books (AC) within 6 months of randomisation
(PP1 CSLT26 AC)
2. adherence to practice – practised computer therapy for a minimum total of 10 hours (CSLT) and
were sent at least four puzzle books (AC) within 6 months of randomisation (PP2 CSLT10 AC 4)
3. high levels of adherence to recommended practice and provided with recommended support –
practised computer therapy for a minimum total of 26 hours (CSLT) or were sent at least four
puzzle books (AC) and contacted at least four times (if they wished) (in both the AC group and the
CSLT group) within 6 months of randomisation (PP3 CSLT26 AC4_4)
4. adherence to practice and provided with recommended support – practised computer therapy for
a minimum total of 10 hours (CSLT) or were sent at least four puzzle books (AC) and contacted at
least four times (if they wished) (in both the AC group and the CSLT group) within 6 months of
randomisation (PP4 CSLT10 AC4_4).
Multiple imputation set
This includes all randomised participants excluding those who died prior to 6 months; it is for sensitivity
analysis. Multiple imputation (MI) was conducted for only the co-primary outcomes (word-finding and
functional communication) and key secondary outcome (COAST). The mean value of participants with
available baseline data was used to impute missing baseline data during analysis for a few participants
with follow-up outcome data but who had missing related baseline data for some reason. We adopted
a strategy to inform the MI statistical model for imputing missing data:
1. Potential predictors of outcomes independent of the intervention were clinically prespecified in the
SAP (see www.journalslibrary.nihr.ac.uk/programmes/hta/122101/#).
2. The characteristics of completers (those meeting the mITT inclusion criteria) and all randomised
participants (excluding those who died) were descriptively compared to explore predictors of
missing data.
3. We graphically explored the association between baseline characteristics and outcomes of interest.
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Based on these exploratory results, the intervention group appeared to be a mild predictor of missing
data. Therefore, it was implausible to assume that the data were missing completely at random. Other
measured predictors of missing data were unclear. As a result, we adopted the following strategy to
impute missing data:
l Intervention group (UC, AC or CSLT), age, gender (male or female), the presence of a carer (yes or
no), severity of word-finding (total score), severity of comprehension ability (total score) and baseline
outcome measure under consideration were mandatory covariates in all MI statistical models.
l Co-primary and key secondary outcomes at baseline (covariates) and 6, 9 and 12 months were
included in all MI statistical models.
l The longitudinal nature of the outcome data under consideration was accounted for in the MI
statistical models using chained equations39,40 implemented via the Stata 15.1 mi command.
The multiple imputation using chained equations analysis was conducted and reported in accordance
with the guidance provided by White et al.41 We chose the number of imputations (n = 20) based on
the observed proportion of missing data.41
Linear interpolation set
For additional sensitivity analysis on the impact of missing data on the trial results, we used a linear
interpolation model as a deterministic imputation approach. Where data were missing at an assessment
(ti) but valid data are available at previous (ti –1) and future (ti+1) assessments, the missing value was
linearly interpolated by the formula:
ymissing = yi−1 + (yi+1 − yi−1)
ti − ti−1
ti+1 − ti−1
. (1)
Safety set
Safety analysis relates to the evaluation of the intervention effect on AEs and SAEs, and negative
effects of the computer therapy. This includes all randomised participants with informed consent and
treatment allocation for analysis used the actual intervention received (treatment as received principle)
based on available evidence, such as the number of books sent and computer therapy practice time.
We also used treatment allocation as randomised for sensitivity analysis.
Statistical considerations
Approach to dealing with deaths after randomisation
We expected some deaths in this trial population during the trial. The research team discussed implications
of deaths and approaches to handle them during analysis. The influence of the trial interventions on
increasing risk of mortality was unanimously viewed to be very unlikely. In addition, the interpretation
of imputed missing data, such as word-finding and functional communication for participants who died,
was clinically challenging. As a result, the research team agreed not to impute data that were missing
because of participant deaths. Therefore, deaths that happened prior to the 6-month assessment
were excluded in any clinical effectiveness analysis but included in the safety analysis. This approach is
consistent with related recommendations.42 We performed sensitivity analysis to explore the impact of
data that were missing for other reasons, unrelated to death, on the bias of the results using the MI,
linear interpolation and complete-case sets.
Hochberg multiple testing procedure
We used the Hochberg procedure to interpret the co-primary (word-finding and functional communication)
and key secondary (COAST) outcome results at 6 months in order to control the chances of falsely declaring
statistically significant results (at 5% nominal level).43 There are two sources of multiple hypothesis testing at
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6 months: multiple outcome measures (co-primary measures and a key secondary measure) and key
multiple treatment comparisons (CSLT vs. UC and CSLT vs. AC). Figure 1 displays the interpretation strategy
of the results in order to claim statistical significance and superiority of the intervention.
Computation of summary outcome scores for analysis
This section details the generation of outcome scores from measurement instruments and how related
missing data were handled.
Primary outcomes at
6 months
Comparison: CSLT vs.
UC
YES
NO
Is one end point
statistically significant
at p < 0.025?
IF YES, declare
significance for
that end point
IF YES, declare
significance for
that end point
Is one end point
statistically significant
at p < 0.025?
NO
NO
NO
NO
STOP
STOP
STOP
YES
YES
Comparison: CSLT vs.
UC
Primary outcomes at
6 months
Secondary outcomes
at 6 months
Comparison: CSLT vs.
AC
Secondary outcomes
at 6 months
Comparison: CSLT vs.
AC
Change in word-finding
of personally selected
words
Change in functional
communication:
conversation (TOMs)
Change in word-finding
of personally selected
words
Change in functional
communication:
conversation (TOMs)
Improvement in patient perception of communication
effectiveness and impact on quality of life: change in
COAST (%)
Declare statistical significance if p < 0.05f
Improvement in patient perception of communication
effectiveness and impact on quality of life: change in 
COAST (%)
Is p < 0.05e?
Are both primary end points statistically significant
at 5% level: p < 0.05c AND p < 0.05d?
Are both primary end points statistically significant
at 5% level: p < 0.05a AND p < 0.05b?
FIGURE 1 Interpretation of the Hochberg hierarchical sequential hypotheses testing strategy. Superscript letters
correspond to footnotes in Table 8.
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Classification of the severity of word-finding difficulty and comprehension ability
We categorised the severity of word-finding difficulty at baseline based on total scores from the
CAT Naming Objects using a severity rating of mild (31–43), moderate (18–30) and severe (5–17).
In addition, we generated a categorical comprehension ability variable at baseline based on the total
scores from the CAT Comprehension of Spoken Sentences as follows:
l severe (0–8) – inconsistently understanding at the two information-carrying words level
l moderate (9–17) – consistently understanding at the two/three information-carrying words
level/simple sentence structures but not complex sentence structures
l mild (18–26) – some understanding of complex sentence structures but not consistent
l within normal limits (27–32) based on CAT cut-off score for normal/aphasic.
Word-finding of personally selected words for treatment
As highlighted in Chapter 2, Primary outcome measures, we used the personal vocabulary naming test to
assess word-finding ability based on 100 personally selected words for treatment. For each personally
selected word, word-finding ability was assessed using the following scoring system: 0 for an incorrect
or no response; 1 for a word named correctly after a delay of at least 5 seconds and/or for a self-
correction; and 2 for a correct prompt answer within 5 seconds. This method was consistent with the
scoring method used in the CAT Naming Objects. This scoring system yields a potential maximum score
of 200. Although all participants were expected to be assessed based on 100 personally selected words,
it was possible that some participants could have been assessed based on fewer than 100 words for
some reason, such as fatigue. At least 70 words should have been assessed for an assessment to be
considered valid. If fewer than 100 words but more than 70 words were assessed, the word-finding
ability for the participant, k (Yk), expressed as a percentage, was calculated based on the total score
relative to the potential maximum score as:
Yk =
∑Xi=1itemi
2X
× 100, (2)
where i = {1, 2, . . ., X} is the picture item on the personal vocabulary naming test and X is the total
number of personally selected words assessed.
Functional communication in conversation
The activity dimension of the TOMs instrument was used to assess functional communication in
conversation. The rating is measured on a 6-point ordinal scale ranging from 0 (unable to communicate
in any way) to 5 (communicates effectively in all situations), which allows scoring between ordinal
descriptors such as 0.5, 1.5, 2.5, 3.5 and 4.5. Thus, the rating scale has 11 ordinal possibilities that can
be treated as a continuous scale. There is a ceiling effect for participants who are able to communicate
effectively in all situations at baseline with a TOMs rating of 5. We report the numbers and proportions
of these participants across interventions.
Social participation and quality of life
The COAST patient-reported measure was used to assess self-perceived communication/social participation
and impact on quality of life.34 The measure has 20 items and each item is assessed on a rating scale of
0 to 4. Other responses (‘not applicable’, ‘unclear’ or ‘no responses’) are permitted. A procedure is then
applied to compute a percentage score under a number of scenarios: all applicable and answered items,
the existence of ‘not applicable’ items, the existence of ‘unclear’ or ‘no response’ items. We computed
the overall percentage score using a validated algorithm as described by Bowen et al.44
DOI: 10.3310/hta24190 Health Technology Assessment 2020 Vol. 24 No. 19
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Palmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
29
Carers’ perception of patient communication effectiveness and of their own
quality of life
The CaCOAST assesses carer perception of patients’ communication effectiveness and impact on their
quality of life.45 The measure has 20 items; each item is assessed on a scale of 0 to 4, and a percentage
summary measure is calculated. The CaCOAST was administered by the research therapists as one
questionnaire. The first 15 items assess carer perception of patients’ communication and the last
five items assess the impact of the patients’ communication difficulties on the carers’ quality of life.
Although the original validated scoring algorithm is based on all 20 items, we considered the first
15 items (CaCOAST 15) and the last five items (CaCOAST 5) separately to assess different questions.
We therefore modified the scoring algorithm consistent with the validated scoring system using all
20 items44 to compute the CaCOAST 15 (%) and CaCOAST 5 (%), based on the first 15 and last five
items, respectively. These use the same scoring algorithm as described for the COAST but account for
missing data as other aspects are uninformative (‘not applicable’ and ‘unclear’).
Generalisation of treatment to untreated words
The CAT Naming Objects consists of 24 pictures of words to assess word-finding. We used this to
measure generalisation to untreated words. For each picture to be named, the following scoring system
applies depending on a participant’s response: 0 for an incorrect response, 1 for an accurate response
after a delay of more than 5 seconds and 2 for an accurate and prompt answer. A total score ranging
from 0 to 48 is then generated to assess word-finding of untreated words. Missing information (item
level or all items) was possible owing to tiredness or being unable to complete the tests. For missing
items, summary scores from the CAT Naming Objects were calculated assuming a conservative worst-
case scenario: a 0 for a missing item score. No summary score was calculated if all items were missing.
Use of treated words in conversation
The use of treated vocabulary in the context of the conversation was assessed using a checklist of
target words during ratings of videoed conversations at 6 months. Out of the 100 treated words,
personally selected for treatment, the number of words retrieved during videoed conversations
was counted (total score ranging from 0 to 100). A correct word retrieved was counted only once
regardless of the number of times it was retrieved during the conversation.
EuroQol-5 Dimensions, five-level version utility and visual analogue scale
The approach described here applies to the carer, patient proxy and patient aphasia-friendly versions
of the EQ-5D-5L. The EQ-5D-5L was used to assess health status and produces a single index value for
health status for use in the calculation of QALYs to inform health economics evaluation of investigative
interventions.46 The instrument consists of a EQ-5D-5L descriptive system and a EQ-5D-5L visual
analogue scale (VAS). The descriptive system has five dimensions assessing mobility, self-care, usual
activity, pain/discomfort and anxiety. Each of these dimensions has five levels of severity, which
participants were asked to select one of to best describe their health status ‘today’: no problems,
slight problems, moderate problems, severe problems and extreme problems. Based on participants’
responses from these five dimensions, a single index value was calculated. The index values are on a
scale of 1 (full health) to 0 (state equivalent to dead) and health states considered to be worse than
dead attain negative values (< 0). For the analysis of clinical effectiveness, the index values were
estimated directly from the EQ-5D-5L data, as detailed by Devlin et al.47 For the base-case economic
analysis, index values were estimated using the approach currently recommended by the National
Institute for Health and Care Excellence (NICE),48 by converting EQ-5D-5L responses to utility scores
using the UK cross-walk mapping algorithm developed by van Hout et al. in 2012.49 The economic
analysis tested the sensitivity of the cost-effectiveness results to the various techniques of estimating
utility scores from EQ-5D-5L data, as described in Chapter 5, Health-related quality of life. As for the
EQ-5D-5L VAS, participants were asked to rate how good or bad their health is ‘today’ on a scale of
0 (the worst health imaginable) to 100 (best health imaginable). The scores from this continuous scale
assess change in overall self-rated health status.
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Statistical analysis methods
Clinical effectiveness
For the co-primary and key secondary outcomes at 6 months, we used a multiple linear regression
model adjusted for associated baseline outcome measures and fixed stratification factors: centre and
the severity of word-finding (mild, moderate or severe). We expressed the maximum likelihood estimate
of the intervention effect as the adjusted mean difference in change (MDC) between the CSLT and UC
groups, and the CSLT and AC groups, with associated 95% CIs and p-values. The intervention effect
between the AC and UC groups obtained via contrasts was for exploratory purposes only. We used a
Hochberg procedure, as described in Hochberg multiple testing procedure, to control for the false-positive
error rate for claiming the evidence of clinical effectiveness.
For sensitivity analysis, we used a multiple linear regression model adjusted for associated baseline
outcome measures, fixed stratification factors (centre and the severity of word-finding), the length of
time post stroke (continuous) and the location of stroke (yes or no) (middle cerebral artery, frontal
lobe, parietal lobe and temporal lobe).
The long-term intervention effect at 9 and 12 months on the co-primary and key secondary outcomes,
and other secondary continuous outcomes (at 6, 9 and 12 months), such as CaCOAST domains, word-
finding of untreated words and word-finding of treated words used in conversation, was evaluated
using a multiple linear regression model adjusted for associated baseline outcome measures and fixed
stratification factors: centre and the severity of word-finding (mild, moderate and severe).
We used a multiple logistic regression model adjusted for fixed stratification factors (centre and the
severity of word-finding) to explore the intervention effect on the proportion of participants achieving
predefined clinical improvements of 5% and 10% in word-finding of both treated words (from personal
vocabulary naming test) and untreated words (from CAT Naming Objects). The numbers and proportion
of participants meeting each clinical improvement criterion are reported by intervention together with
the odds ratio (OR) and associated 95% CIs and p-values. This was performed under two scenarios by
considering (1) only participants with complete data and (2) all randomised participants, but assuming
that those with missing data failed to achieve clinical improvement (worst-case scenario). Related results
are presented in the statistical report version 1.0, which is available online as a supplementary appendix to
Palmer et al.50
Functional impact
For post hoc analysis at the request of the chief investigator following the disclosure of the results
(as per predefined SAP), we explored the intervention effect on the proportion of participants who did
and did not use treated words in conversation based on a 5% or 10% improvement in naming treated
words (from personal vocabulary naming test) and functionally used at least 5 or 10 treated words
(retrieved during videoed conversation). This analysis was requested to identify if any patients were able
to retrieve newly learned words in functional contexts so that further investigation of characteristics of
those who do and do not automatically use new words in context can be explored in further research
to inform how others might be assisted to use new words functionally. We calculated the proportion
of participants meeting each clinical improvement criterion by intervention group. The difference in
proportions of participants achieving a ‘clinical improvement’ criterion between interventions was
calculated, with associated 95% CIs estimated using the normal approximation to the binomial
distribution without significance testing.
An additional post hoc analysis explored the proportion of participants who do or do not generalise
word-finding to untreated words. A multiple logistic regression model adjusted for fixed stratification
factors (centre and the severity of word-finding) and baseline measures were used to explore the
intervention effect on the proportion of participants achieving clinical improvement of 5% and 10%
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in the generalisation of word-finding to untreated words (from CAT Naming Objects) without
significance testing.
Subgroup evaluation
We prespecified the following subgroups to explore potential heterogeneity in the intervention effect
on the co-primary and key secondary outcomes at 6 months (SAP version 1.2; see www.journalslibrary.
nihr.ac.uk/programmes/hta/122101/#):
l the severity of word-finding difficulty – mild (31–43), moderate (18–30) and severe (5–17)
l comprehension ability – within normal limits (27–32), mild (18–26), moderate (9–17) and severe (0–8)
l the length of time post stroke – categorisation was quantile based because there was no existing
literature to guide the clinical classification.
We performed subgroup analysis based on the mITT set. The number of participants and mean change
in outcomes are reported stratified by the intervention received and subgroup category. We assessed
effect modification between the intervention and subgroup using a multiple linear regression model
that included an interaction term between the intervention and the subgroup of interest adjusted for
baseline outcome measures and fixed stratification factors: centre and the severity of word-finding
difficulty (mild, moderate and severe). We report the overall p-values from the interaction tests
to explore the strength of evidence for heterogeneity of the intervention effect across subgroups.
We use forest plots to present results and aid visual interpretation, showing the maximum likelihood
estimate of the intervention effect (CSLT vs. UC and CSLT vs. AC), with associated 95% CIs stratified
by subgroup category.
Safety evaluation
The primary analysis of safety outcomes was based on the safety set. We also performed sensitivity
analysis on the safety outcomes using the treatment as randomised, as described in Safety set.
Negative effects of computer use in computerised speech and
language therapy
The number and proportion of participants who experienced any perceived negative effects are
summarised stratified by negative effect category: tiredness (fatigue), vision, headaches and anxiousness
or worrisome. We calculated the total number of repeated events experienced by a participant per
negative effect category and exposure (follow-up contributing to the 6-month data). We used a negative
binomial regression model accounting for overdispersion and the exposure without significance testing
to estimate the incidence rate (IR) with 95% CI.
Adverse events and serious adverse events
We calculated the number and proportion of participants who experienced any AEs or SAEs by
intervention. For each participant, we calculated the exposure (trial follow-up) and the number of
repeated AEs and SAEs. We used a negative binomial regression model to estimate the IR in each
intervention and incidence rate ratio (IRR), with associated 95% CI accounting for overdispersion
and the exposure without statistical significance testing.
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Chapter 4 Clinical effectiveness results
Introduction
This chapter reports the results to address the clinical effectiveness research questions in conformity
with the CONSORT guidelines for individually randomised parallel-group trials (2010)25 (including
non-pharmacological treatments,26 pragmatic trials27 and harms28 extensions). The statistical analysis
methods used and related trial outcomes are detailed in Chapter 3 and the SAP is accessible online
(www.journalslibrary.nihr.ac.uk/programmes/hta/122101/#). Chapter 6 discusses these results in detail
together with other findings.
Statistical results
Screening and flow of trial participants
Between September 2014 and August 2016, 995 participants were screened and 818 were found to
be appropriate for further assessment of eligibility across 20 NHS trusts in the UK (21 randomisation
centres/speech and language therapy departments), predominantly via patient records (including word
of mouth from speech and language therapy colleagues) and voluntary support groups. Figure 2 shows
the flow of participants from screening to randomisation including trial follow-up at 6, 9 and 12 months
from randomisation. Of the 995 patients screened, 288 (28.9%) eligible participants were consented and
278 (27.9%) were randomised: UC, n = 101; AC, n = 80; and CSLT, n = 97.
Of the 278 patients randomised, eight (2.9%) died before their 6-month assessments: UC, n = 4;
AC, n = 1; and CSLT, n = 3. For the remaining 270, 240 (88.9%) completed their 6-month assessments:
86, 71 and 83 in the UC, AC and CSLT groups, respectively. The proportions of participants who
completed 6- and 9-month outcome assessments were very similar across interventions. However, the
discontinuation rate at 12 months was slightly higher in the AC (23.8%) and the CSLT (23.7%) groups
than in the UC (16.8%) group. Attrition reasons are stated in Figure 2 and detailed in Table 2. The most
common reasons were personal or family issues and being unhappy with the allocated trial intervention.
In total, 240 randomised participants were eligible for inclusion in the primary mITT analysis: 86 in
the UC group, 71 in the AC group and 83 in the CSLT group. As for the secondary MI analysis, 270
randomised participants were eligible for inclusion: 97 in the UC group, 79 in the AC group and 94 in
the CSLT group.
Characteristics of participating speech and language therapy departments in NHS trusts
The 21 speech and language therapy departments participating in the trial served a mixture of urban
and rural populations. Ten sites were described by local principal investigators as predominantly rural,
four as predominantly urban and seven as mixed rural and urban. Twenty-six eligible SLTs were trained
to deliver the CSLT intervention in total. Sixteen sites chose to use only SLTAs to provide the support
component of the intervention, three sites used only volunteers and two sites used both SLTAs and
volunteers.
Baseline demographics and characteristics of randomised participants
Tables 3 and 4 show the demographics and characteristics of randomised participants stratified by
intervention; 270 met the MI inclusion criteria and 240 met the mITT inclusion criteria (‘completers’).
Baseline characteristics of the eight participants who died before the 6-month outcome assessment
are not reported as they were not included in the analysis because the association between the
interventions and increased risk of mortality was viewed as extremely unlikely.
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Baseline UC(n = 101)
AC
(n = 80)
CSLT
(n = 97)
Alive
(n = 97)
Assessed
(n = 83)
Failed visit
(n = 1)
Assessed
(n = 83)
Failed visit
(n = 3)
Assessed
(n = 77)
Failed visit
(n = 3)
Assessed
(n = 64)
Failed visit
(n = 1)
Alive
(n = 79)
Assessed
(n = 61)
Assessed
(n = 84)
Assessed
(n = 74)
MI (n =  270): 97 + 79 + 94; mITT (n = 240): 86 + 71 + 83
Alive
(n = 94)
Died
(n = 4)
Died
(n = 1)
Died
(n = 3)
Withdrew consent
(n = 7)
Lost to follow-up
(n = 1)
Investigator decision
(n = 1)
Withdrew consent
(n = 1)
Lost to follow-up
(n = 1)
Withdrew consent
(n = 2)
Withdrew consent
(n = 8)
Withdrew consent
(n = 1)
Lost to follow-up
(n = 1)
Investigator decision
(n = 2)
Withdrew consent
(n = 4)
Lost to follow-up
(n = 2)
Withdrew consent
(n = 10)
Withdrew consent
(n = 3)
Investigator decision
(n = 3)
Withdrew consent
(n = 4)
Randomised
(n = 278; 27.9%)
Consented
(n = 288; 28.9%)
Eligibility screening consent
(n = 511; 51.4%)
Visit conducted
(n = 522; 52.5%)
Visit arranged 
(n = 541; 54.4%)
Contact established
(n = 818; 82.2%)
Sent project summary
(n = 985; 99.0%)
Not sent project summary
(n = 10; 1.0%)
Not established contact
(n = 167; 16.8%)
• Not interested, n = 204
• Illness, n = 29
• Lack of time, n = 19
• Deceased, n = 1
• Unable, n = 5
• Ineligible, n = 17
• Other, n = 1
• Not stated, n = 1
• Not screened, n = 2
• Refused consent, n = 9
• Patient records, n = 894 (89.8%)
• Support group, n = 97 (9.7%)
• Other, n = 4 (0.4%)
Identified for screening
(n = 995)
• Not interested, n = 9
• Illness, n = 5
• Lack of time, n = 1
• Unable, n = 3
• Ineligible, n = 1
• Withdrew due to social/family
    issues, n = 1
• Withdrew consent (unwell), n = 2
• Withdrew consent due to other
    reasons, n = 6
• Suffered another stroke, n = 1
6 months
9 months
12 months
Assessed
(n = 86)
Failed visit
(n = 2)
Assessed
(n = 71)
Reasons for visit not arranged
(n = 277; 27.8%)
No
(n = 11; 1.1%)
• Not eligible, n = 169
• Did not want to use computers, n = 5
• Did not want to be video recorded, n = 1
• Not interested in further SLT, n = 1
• Not interested in participating in
    research, n = 10
• Carer consent required but unavailable, n = 1
• Felt too ill, n = 6
• Felt too busy, n = 9
• Felt study lasts too long, n = 1
• Other, n = 15
• No reason given, n = 5
Reasons for not consenting
(n = 223; 22.4%)
Reasons for visit not conducted
(n = 19; 1.9%)
Reasons for not randomised
(n = 10; 1.0%)
FIGURE 2 Trial participant flow chart. Adapted from Palmer et al.50 This is an Open Access article distributed in accordance
with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt
and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/
licenses/by/4.0/.
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TABLE 2 Reasons for attrition
Discontinuation type Reason for withdrawal
Number of participants
UC (n= 17) AC (n= 19) CSLT (n= 23) Total (n= 59)
Death N/A 4 1 3 8
Investigator decision Personal/family issue 1 2 3 6
Lost to follow-up N/A 2 3 0 5
Participant withdrew
consent
Personal/family issue 5 4 6 15
Unhappy with allocated
trial group
4 3 4 11
Unwilling to complete
outcome measures
1 3 2 6
Prefers not to say 0 1 1 2
Moving out of the area 0 0 1 1
Other (lost motivation and
feeling unwell)
0 1 0 1
Other (time commitment) 0 0 1 1
Other 0 1a 2b 3
N/A, not applicable.
a In the AC group, one participant wanted to spend their time doing other activities that they enjoy more and feel are
more beneficial.
b In the CSLT group, one participant struggled with voice recognition not working consistently, difficulties with the
computer and frustration. One reported that they found it upsetting it does not do well (‘It’s not doing me any good’)
despite explaining that it is just the monitoring now to help with the study and she has done all the hard work’.
TABLE 3 Baseline demographic characteristics of randomised participants
Variable
MI population (N= 270) mITT population (N= 240)
UC (n= 97) AC (n= 79) CSLT (n= 94) UC (n= 86) AC (n= 71) CSLT (n= 83)
Site, n (%)
Ayr 3 (3.1) 2 (2.5) 4 (4.3) 3 (3.5) 2 (2.8) 4 (4.8)
Belfast 5 (5.2) 3 (3.8) 3 (3.2) 5 (5.8) 3 (4.2) 3 (3.6)
Cambridgeshire 5 (5.2) 3 (3.8) 5 (5.3) 5 (5.8) 3 (4.2) 4 (4.8)
Cwm Taf 3 (3.1) 1 (1.3) 5 (5.3) 2 (2.3) 1 (1.4) 4 (4.8)
Derbyshire 6 (6.2) 5 (6.3) 5 (5.3) 6 (7.0) 5 (7.0) 5 (6.0)
Dorset 4 (4.1) 3 (3.8) 5 (5.3) 4 (4.7) 3 (4.2) 5 (6.0)
Glasgow 8 (8.2) 6 (7.6) 8 (8.5) 8 (9.3) 5 (7.0) 7 (8.4)
Hull 6 (6.2) 4 (5.1) 5 (5.3) 5 (5.8) 4 (5.6) 4 (4.8)
Newcastle 6 (6.2) 5 (6.3) 4 (4.3) 6 (7.0) 4 (5.6) 4 (4.8)
Norfolk 3 (3.1) 5 (6.3) 2 (2.1) 2 (2.3) 4 (5.6) 2 (2.4)
North Bedforda 3 (3.1) 3 (3.8) 4 (4.3) 3 (3.5) 3 (4.2) 4 (4.8)
North Lincolnshire 4 (4.1) 5 (6.3) 2 (2.1) 3 (3.5) 3 (4.2) 2 (2.4)
Northampton 5 (5.2) 4 (5.1) 6 (6.4) 5 (5.8) 4 (5.6) 6 (7.2)
Northern 5 (5.2) 4 (5.1) 3 (3.2) 5 (5.8) 4 (5.6) 3 (3.6)
Nottinghamshire 6 (6.2) 6 (7.6) 7 (7.4) 5 (5.8) 6 (8.5) 7 (8.4)
continued
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TABLE 3 Baseline demographic characteristics of randomised participants (continued )
Variable
MI population (N= 270) mITT population (N= 240)
UC (n= 97) AC (n= 79) CSLT (n= 94) UC (n= 86) AC (n= 71) CSLT (n= 83)
Plymouth 3 (3.1) 1 (1.3) 3 (3.2) 3 (3.5) 1 (1.4) 2 (2.4)
Sheffield 5 (5.2) 4 (5.1) 6 (6.4) 5 (5.8) 4 (5.6) 6 (7.2)
Somerset 4 (4.1) 5 (6.3) 5 (5.3) 1 (1.2) 4 (5.6) 3 (3.6)
South Bedfordb 6 (6.2) 5 (6.3) 4 (4.3) 5 (5.8) 4 (5.6) 2 (2.4)
Sunderland 3 (3.1) 2 (2.5) 5 (5.3) 2 (2.3) 2 (2.8) 4 (4.8)
Swansea 4 (4.1) 3 (3.8) 3 (3.2) 3 (3.5) 2 (2.8) 2 (2.4)
Gender, n (%)
Male 60 (61.9) 49 (62.0) 55 (58.5) 54 (62.8) 44 (62.0) 47 (56.6)
Female 37 (38.1) 30 (38.0) 39 (41.5) 32 (37.2) 27 (38.0) 36 (43.4)
Age at consent (years) n = 97 n = 79 n = 94 n = 86 n = 71 n = 83
Mean (SD) 65.6 (13.1) 64.8 (13.1) 65.6 (12.7) 64.9 (13.0) 63.8 (13.1) 64.9 (13.0)
Median (IQR) 66.6
(55.8–74.7)
66.2
(54.6–74.9)
66.1
(55.5–75.5)
66.5
(55.1–74.3)
65.1
(53.0–73.4)
64.7
(54.5–74.7)
Min., max. 23.1, 91.8 30.4, 88.7 34.1, 89.2 23.1, 89.6 30.4, 88.7 34.1, 89.2
CAT comprehension scorea n = 97 n = 79 n = 94 n = 86 n = 71 n = 83
Mean (SD) 21.0 (6.0) 19.5 (7.2) 20.0 (7.0) 21.0 (5.9) 19.8 (7.0) 20.1 (7.3)
Median (IQR) 22.0
(17.0–26.0)
21.0
(14.0–25.0)
21.5
(15.0–26.0)
22.0
(17.0–26.0)
21.0
(14.0–26.0)
22.0
(14.0–26.0)
Min., max. 0.0, 30.0 1.0, 30.0 0.0, 32.0 0.0, 30.0 1.0, 30.0 0.0, 32.0
CAT comprehension severity,a n (%)
Severe 3 (3.1) 6 (7.6) 5 (5.3) 3 (3.5) 3 (4.2) 5 (6.0)
Moderate 24 (24.7) 24 (30.4) 29 (30.9) 20 (23.3) 24 (33.8) 26 (31.3)
Mild 50 (51.5) 36 (45.6) 43 (45.7) 46 (53.5) 31 (43.7) 35 (42.2)
Within normal limits 20 (20.6) 13 (16.5) 17 (18.1) 17 (19.8) 13 (18.3) 17 (20.5)
Severity of word-finding difficulty,c n (%)
Mild 40 (41.2) 38 (48.1) 41 (43.6) 35 (40.7) 35 (49.3) 36 (43.4)
Moderate 33 (34.0) 19 (24.1) 28 (29.8) 29 (33.7) 17 (23.9) 26 (31.3)
Severe 24 (24.7) 22 (27.8) 25 (26.6) 22 (25.6) 19 (26.8) 21 (25.3)
Type of aphasia, n (%)
Anomic 39 (40.2) 22 (27.8) 35 (37.2) 33 (38.4) 19 (26.8) 33 (39.8)
Non-fluent (e.g. Broca’s) 40 (41.2) 29 (36.7) 38 (40.4) 36 (41.9) 27 (38.0) 34 (41.0)
Mixed non-fluent 13 (13.4) 21 (26.6) 15 (16.0) 13 (15.1) 20 (28.2) 11 (13.3)
Fluent (e.g. Wernicke’s) 5 (5.2) 7 (8.9) 6 (6.4) 4 (4.7) 5 (7.0) 5 (6.0)
Evidence of apraxia of speech, n (%)
No 64 (66.0) 48 (60.8) 62 (66.0) 55 (64.0) 42 (59.2) 52 (62.7)
Yes 33 (34.0) 31 (39.2) 32 (34.0) 31 (36.0) 29 (40.8) 31 (37.3)
Type of stroke, n (%)
Infarct 79 (81.4) 64 (81.0) 69 (73.4) 69 (80.2) 58 (81.7) 60 (72.3)
Haemorrhage 14 (14.4) 7 (8.9) 14 (14.9) 12 (14.0) 6 (8.5) 13 (15.7)
Not known 9 (9.3) 8 (10.1) 11 (11.7) 9 (10.5) 7 (9.9) 10 (12.0)
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For the 270 randomised participants meeting the MI inclusion criteria, the recruitment across 21 speech
and language therapy centres/departments (20 NHS trusts) ranged from 7 to 22 participants, with
a median of 12 [interquartile range (IQR) 10–15] participants. The majority of participants (n = 164;
60.7%) were male. The overall mean age at consent was 65.4 (SD 12.9) years, ranging from 23.1 to
91.8 years. Most participants (n = 119; 44.1%) had mild word-finding difficulty; 80 participants (29.6%)
had moderate and 71 (26.3%) had severe difficulty. The overall median time post stroke was
approximately 2 years (IQR 1–4 years). Most participants showed no evidence of apraxia of speech
(n = 174; 64.4%) and 212 (78.5%) had suffered an infarction stroke.
In summary, randomised participants and ‘completers’ were very similar on average with respect to
measured characteristics and demographics (see Table 3). Furthermore, on average, the participants
appeared broadly similar across interventions. However, by chance, there were a few exceptions
indicating relatively small differences between interventions, such as with respect to the location of
the stroke, time post stroke, the type of stroke and lateralisation, if not brain stem. There was also
a chance imbalance in the number of participants randomised to AC compared with UC or CSLT.
Table 4 shows the characteristics of the randomised participants and ‘completers’ (with their available
carers) with respect to continuous covariates (outcomes assessed at baseline), which are broadly similar
between the two MI and mITT populations and across interventions. However, the available carers of
TABLE 3 Baseline demographic characteristics of randomised participants (continued )
Variable
MI population (N= 270) mITT population (N= 240)
UC (n= 97) AC (n= 79) CSLT (n= 94) UC (n= 86) AC (n= 71) CSLT (n= 83)
Location of stroke, n (%)
Middle cerebral artery 47 (48.5) 48 (60.8) 43 (45.7) 41 (47.7) 43 (60.6) 37 (44.6)
Frontal lobe 8 (8.2) 5 (6.3) 11 (11.7) 7 (8.1) 5 (7.0) 9 (10.8)
Temporal lobe 13 (13.4) 3 (3.8) 3 (3.2) 12 (14.0) 1 (1.4) 3 (3.6)
Parietal lobe 14 (14.4) 7 (8.9) 11 (11.7) 13 (15.1) 6 (8.5) 9 (10.8)
Occipital lobe 5 (5.2) 0 (0.0) 3 (3.2) 4 (4.7) 0 (0.0) 3 (3.6)
Cerebellum 1 (1.0) 0 (0.0) 0 (0.0) 1 (1.2) 0 (0.0) 0 (0.0)
Not known 25 (25.8) 23 (29.1) 33 (35.1) 22 (25.6) 21 (29.6) 31 (37.3)
Lateralisation (if not brain stem), n (%)
Right side 9 (9.3) 1 (1.3) 5 (5.3) 9 (10.5) 1 (1.4) 5 (6.0)
Left side 79 (81.4) 73 (92.4) 81 (86.2) 69 (80.2) 65 (91.5) 71 (85.5)
Not known 12 (12.4) 5 (6.3) 11 (11.7) 11 (12.8) 5 (7.0) 10 (12.0)
Time post stroke (years) n = 97 n = 79 n = 94 n = 86 n = 71 n = 83
Mean (SD) 2.8 (2.7) 3.4 (4.6) 2.8 (2.9) 2.8 (2.6) 3.6 (4.8) 2.9 (2.9)
Median (IQR) 1.9 (0.9–3.8) 1.9 (1.0–4.3) 1.8 (0.7–3.6) 1.9 (0.9–4.0) 2.1 (1.0–4.5) 1.9 (0.7–3.6)
Min., max. 0.3, 15.7 0.4, 36.1 0.4, 12.7 0.3, 15.7 0.4, 36.1 0.4, 12.7
IQR, interquartile range; max., maximum; min., minimum.
a Based on a CAT Comprehension of Spoken Sentences with possible total scores ranging from 0 to 32.
b Two sites in same NHS trust.
c Based on the CAT Naming Objects with possible total scores ranging from 0 to 48.
Notes
Adapted from Palmer et al.50 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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TABLE 4 Baseline characteristics of randomised participants (outcome covariates)
Variable
MI population (N= 270) mITT population (N= 240)
UC (n= 97) AC (n= 79) CSLT (n= 94) UC (n= 86) AC (n= 71) CSLT (n= 83)
Word-finding ability (%)a n = 97 n = 79 n = 94 n = 86 n = 71 n = 83
Mean (SD) 42.8 (18.1) 41.4 (20.7) 43.2 (19.0) 42.6 (18.1) 41.7 (20.6) 43.7 (19.0)
Median (IQR) 44.0 (30.0–57.0) 37.5 (23.5–59.0) 43.8 (30.0–57.5) 42.3 (30.0–57.0) 37.5 (25.0–59.0) 43.0 (30.0–58.2)
Min., max. 5.0, 85.0 9.0, 82.0 4.5, 86.0 5.0, 85.0 9.5, 82.0 4.5, 86.0
Functional communication
(TOMs)b n = 96 n = 78 n = 93 n = 86 n = 70 n = 82
Mean (SD) 3.1 (1.0) 2.7 (1.0) 2.9 (1.2) 3.1 (1.0) 2.7 (1.1) 2.9 (1.2)
Median (IQR) 3.0 (2.5–4.0) 2.5 (2.0–3.5) 3.0 (2.0–4.0) 3.0 (2.5–4.0) 2.5 (2.0–3.5) 3.0 (2.0–4.0)
Min., max. 0.5, 5.0 1.0, 4.5 0.5, 5.0 0.5, 5.0 1.0, 4.5 0.5, 5.0
COAST (%)c n = 94 n = 79 n = 89 n = 84 n = 71 n = 79
Mean (SD) 59.9 (13.1) 60.0 (13.8) 58.2 (13.6) 59.8 (13.2) 59.5 (14.0) 58.4 (13.6)
Median (IQR) 61.3 (52.5–68.8) 60.0 (48.8–68.8) 57.5 (48.8–68.8) 61.3 (51.9–68.8) 60.0 (48.8–67.5) 57.5 (47.5–68.8)
Min., max. 26.3, 86.3 26.3, 96.3 26.3, 87.5 26.3, 86.3 26.3, 96.3 26.3, 87.5
CaCOAST 15 (%)d n = 58 n = 49 n = 62 n = 53 n = 44 n = 56
Mean (SD) 56.8 (14.9) 53.7 (13.2) 52.8 (15.6) 56.5 (14.7) 54.0 (13.3) 53.6 (14.7)
Median (IQR) 57.5 (46.7–66.7) 51.7 (43.3–66.7) 50.8 (41.7–63.3) 58.3 (46.7–66.7) 52.5 (43.3–66.7) 50.8 (42.5–64.2)
Min., max. 26.7, 81.7 28.3, 78.3 18.3, 81.7 26.7, 81.7 28.3, 78.3 20.0, 81.7
CaCOAST 5 (%)e n = 58 n = 49 n = 62 n = 53 n = 44 n = 56
Mean (SD) 54.7 (19.3) 44.7 (16.4) 48.2 (21.0) 54.1 (18.5) 45.1 (16.7) 48.7 (20.5)
Median (IQR) 55.0 (40.0–70.0) 50.0 (30.0–55.0) 47.5 (30.0–65.0) 55.0 (40.0–65.0) 50.0 (30.0–55.0) 50.0 (32.5–65.0)
Min., max. 20.0, 100.0 10.0, 95.0 5.0, 90.0 20.0, 100.0 10.0, 95.0 5.0, 90.0
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Variable
MI population (N= 270) mITT population (N= 240)
UC (n= 97) AC (n= 79) CSLT (n= 94) UC (n= 86) AC (n= 71) CSLT (n= 83)
Word-finding of untreated
wordsf (CAT score) n = 97 n = 79 n = 94 n = 86 n = 71 n = 83
Mean (SD) 26.4 (11.0) 26.2 (11.5) 26.5 (11.4) 26.2 (11.0) 26.6 (11.3) 26.6 (11.3)
Median (IQR) 28.0 (18.0–36.0) 30.0 (16.0–36.0) 27.5 (17.0–38.0) 27.5 (17.0–35.0) 30.0 (16.0–37.0) 27.0 (17.0–38.0)
Min., max. 5.0, 43.0 6.0, 42.0 5.0, 43.0 5.0, 43.0 6.0, 42.0 5.0, 43.0
EQ-5D-5L VAS score
(patients – aphasia
friendly)g n = 97 n = 79 n = 94 n = 86 n = 71 n = 83
Mean (SD) 69.8 (17.6) 68.9 (20.0) 67.0 (21.1) 70.0 (17.5) 68.7 (20.3) 67.0 (21.5)
Median (IQR) 75.0 (55.0–80.0) 75.0 (55.0–85.0) 70.0 (50.0–85.0) 75.0 (60.0–80.0) 70.0 (55.0–85.0) 70.0 (50.0–85.0)
Min., max. 30.0, 100.0 10.0, 100.0 10.0, 100.0 30.0, 100.0 10.0, 100.0 10.0, 100.0
EQ-5D-5L index (patients –
aphasia friendly)h n = 97 n = 79 n = 93 n = 86 n = 71 n = 83
Mean (SD) 0.72 (0.20) 0.70 (0.22) 0.70 (0.22) 0.75 (0.17) 0.70 (0.22) 0.70 (0.22)
Median (IQR) 0.75 (0.61–0.88) 0.75 (0.57–0.87) 0.75 (0.61–0.87) 0.76 (0.66–0.88) 0.75 (0.57–0.89) 0.75 (0.61–0.87)
Min., max. 0.21, 1.00 0.05, 1.00 0.02, 1.00 0.21, 1.00 0.05, 1.00 0.02, 1.00
EQ-5D-5L index (carer)h n = 59 n = 49 n = 63 n = 53 n = 44 n = 57
Mean (SD) 0.85 (0.18) 0.83 (0.18) 0.82 (0.19) 0.85 (0.18) 0.83 (0.19) 0.82 (0.19)
Median (IQR) 0.90 (0.82–0.95) 0.87 (0.78–0.92) 0.87 (0.75–0.92) 0.90 (0.82–0.95) 0.88 (0.78–0.92) 0.87 (0.75–0.92)
Min., max. 0.21, 1.00 0.19, 1.00 –0.00, 1.00 0.21, 1.00 0.19, 1.00 –0.00, 1.00
EQ-5D-5L VAS score
(carer)g n = 58 n = 49 n = 63 n = 53 n = 44 n = 57
Mean (SD) 79.5 (15.0) 76.6 (19.0) 76.0 (18.8) 79.2 (15.3) 77.7 (17.7) 75.4 (19.2)
Median (IQR) 80.0 (75.0–90.0) 80.0 (65.0–90.0) 80.0 (65.0–90.0) 80.0 (75.0–90.0) 80.0 (70.0–90.0) 80.0 (65.0–90.0)
Min., max. 25.0, 100.0 20.0, 98.0 25.0, 100.0 25.0, 100.0 20.0, 98.0 25.0, 100.0
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TABLE 4 Baseline characteristics of randomised participants (outcome covariates) (continued )
Variable
MI population (N= 270) mITT population (N= 240)
UC (n= 97) AC (n= 79) CSLT (n= 94) UC (n= 86) AC (n= 71) CSLT (n= 83)
EQ-5D-5L VAS score
(proxy)g n = 73 n = 56 n = 65 n = 64 n = 49 n = 59
Mean (SD) 62.5 (18.9) 64.1 (21.9) 62.0 (21.6) 62.6 (18.9) 65.4 (21.1) 62.0 (21.6)
Median (IQR) 65.0 (50.0–80.0) 70.0 (50.0–80.0) 60.0 (45.0–80.0) 65.0 (50.0–80.0) 70.0 (55.0–80.0) 60.0 (45.0–80.0)
Min., max. 15.0, 95.0 4.0, 95.0 10.0, 100.0 15.0, 95.0 4.0, 95.0 10.0, 100.0
EQ-5D-5L index (patient –
proxy)h n = 73 n = 56 n = 64 n = 64 n = 49 n = 58
Mean (SD) 0.63 (0.23) 0.64 (0.21) 0.61 (0.24) 0.64 (0.23) 0.65 (0.22) 0.60 (0.24)
Median (IQR) 0.68 (0.49–0.78) 0.70 (0.51–0.77) 0.65 (0.39–0.79) 0.69 (0.51–0.78) 0.71 (0.51–0.78) 0.63 (0.39–0.79)
Min., max. –0.11, 1.00 –0.06, 1.00 0.04, 1.00 –0.11, 1.00 –0.06, 1.00 0.04, 1.00
IQR, interquartile range; max., maximum; min., minimum.
a Word-finding ability of personally selected words (%) based on the personal vocabulary naming test.
b TOMs rating score ranges from 0 to 5, with higher scores meaning improved functional communication.
c Higher score indicates positive self-perceived communication and impact on patient’s quality of life.
d Based on the first 15 items of the CaCOAST, with higher scores indicating positive carer perception of patient’s communication ability.
e Based on the last five items of the CaCOAST, with higher scores indicating positive carer perception of the impact of the patient’s communication ability on the carer’s quality
of life.
f Based on a CAT Naming Objects, with total scores ranging from 0 to 48; higher scores indicate improved word-finding ability of untreated words.
g Higher score indicates positive perception of health status, with 0 and 100 meaning worst and best health status imaginable.
h Higher values indicate higher health-related quality of life.
Notes
–0.00 means < 0.
Adapted from Palmer et al.50 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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the UC participants who agreed to take part had slightly higher CaCOAST domain scores on average
than their counterparts did. It should also be noted that the participant, not the supporting carer, was
the unit of randomisation.
Reported cases of unblinding of outcome assessments
Table 5 summarises cases of suspected unblinding and when the allocated intervention was guessed
correctly. At the 6-month assessment, 29 (10.7%) cases of suspected unblinding were reported. Of these,
the allocated intervention was incorrectly guessed in only one case. The majority of cases happened
before or during the 6-month assessment, and the proportions of participants were higher in the CSLT
and AC groups than in the UC group. Nevertheless, the reported cases of unblinding are negligible
relative to the number of outcome assessments made during the trial.
Usual-care speech and language therapy offered (fidelity/adherence to provision of usual care)
The objective here was to assess whether or not the overall amounts of UC speech and language therapy
were similar across the intervention groups throughout the trial as it was an adjunct trial aiming to
compare the interventions in addition to UC with UC alone. The descriptive details of what UC speech
and language therapy consisted of are reported in Chapter 2, Usual-care control group. Table 6 shows the
proportion of participants who received UC speech and language therapy 3 months prior to each
assessment time point. The distribution of UC speech and language therapy seems comparable across
interventions; however, slightly fewer participants in the AC group than in the UC and CLST groups
received UC speech and language therapy especially 3 months prior to baseline. In addition, slightly more
participants in the UC group received UC speech and language therapy than their counterparts. Across
interventions, the proportions of participants receiving UC speech and language therapy decreased as
the trial progressed. This was to be expected as participants were further in time post stroke as the trial
progressed and the pre-baseline UC descriptions (see Chapter 2, Usual-care control group) identified the
fact that amounts of speech and language therapy received decreased with length of time post stroke.
The distributions of the average amounts of overall UC speech and language therapy received are
displayed in Figure 3; the averages are calculated based on all participants in the denominator regardless
of whether or not they received UC speech and language therapy. On average, during the 6-month
intervention period (data collection points 3 and 6 months), the UC group received a mean of 3.8 hours
of usual speech and language therapy, the AC group received a mean of 3.2 hours of usual speech and
language therapy and the CSLT group received a mean of 3.2 hours of usual speech and language therapy.
Those in receipt of therapy had a mean of 9.7 hours in UC, 11 hours in AC and 7.8 hours in CSLT. There is
more variation in the average number of hours in receipt of therapy in those who received therapy than
for all participants in each group as the denominator of those in receipt was small, as shown in Table 6.
TABLE 5 Cases of unblinding of outcome assessments
Classification Assessment
Trial group, n (%)
UC (N= 97) AC (N= 79) CSLT (N= 94)
Suspected unblinding 6 months 3 (3.1) 9 (11.3) 17 (18.1)
9 months 2 (2.1) 4 (5.0) 3 (3.2)
12 months 0 (0.0) 1 (1.3) 1 (1.1)
Unblindinga 6 months 2 (2.1) 8 (10.0) 17 (18.1)
9 months 1 (1.0) 4 (5.0) 3 (3.2)
12 months 0 (0.0) 0 (0.0) 1 (1.1)
a Correctly guessed the intervention.
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The mean amounts of overall UC speech and language therapy for only those who received it can be
seen in figure 6 of the full statistical report, which is available online as a supplementary appendix to
Palmer et al.50
Fidelity to computerised speech and language therapy: adherence to practice and quality
of intervention delivery
Time to access computer therapy
All participants randomised to the CSLT group were given access to the computer software (full
intervention coverage was achieved). The median time to access computer therapy since randomisation
among 94 CSLT participants was approximately 26 days (IQR 19–35 days), with a range of 7 to 114 days.
This excludes three deaths prior to the 6-month assessment. Most participants accessed computer therapy
within 1 month from randomisation. There were two outliers who accessed computer therapy after
3.5 months (112 and 114 days) from randomisation. In the first case, there were several reasons for the
delay: there were issues with the participant’s computer and StepByStep software version on the Big
CACTUS laptop, the therapist went on sick leave and then study leave, and the participant was also
hospitalised with cardiac problems. In the second case, the SLT delivering the intervention went on
long-term sick leave and later resigned, so there was no one available to set the computer up for the
participant.
TABLE 6 Receivers of overall UC speech and language therapy
Time point
Trial group, n (%)
UC (N= 96)a AC (N= 79) CSLT (N= 94)
Baseline 43 (44.8) 30 (38.0) 42 (44.7)
3 months 33 (34.4) 22 (27.8) 30 (31.9)
6 months 23 (24.0) 14 (17.7) 21 (22.3)
9 months 17 (17.7) 12 (15.2) 12 (12.8)
12 months 13 (13.5) 10 (12.7) 8 (8.5)
a UC speech and language therapy data were not collected for one participant.
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FIGURE 3 Mean amounts of overall UC speech and language therapy (all participants).
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Computer therapy practice time
Table 7 summarises the distributions of the total computer practice time and the mean computer practice
time (per month and per week) within 6 months from randomisation with the number of computer
therapy sessions contributing to the practice time. The mean total computer practice time per participant
over 6 months was 28 hours and the median was 21.1 hours, with an IQR of 4.9–49.7 hours and a range
of 0–104.5 hours. Appendix 5, Figure 26, shows the patterns of computer practice time per participant
throughout the trial including continued computer use after 6 months. Of the 94 CSLT participants,
57 (60.6%) continued to use the computer therapy beyond the 6 months of randomisation.
Per-protocol adherence to computerised speech and language therapy
Three of the 97 participants randomised to CSLT died prior to the 6-month assessment. Of the remaining
94, 60 (63.8%) and 43 (45.7%) used the computer therapy for at least 10 hours and 26 hours within
6 months of randomisation, respectively. These participants were deemed to have adhered to the
CSLT intervention in terms of practice time. In addition, no computer use at all was recorded for
11 participants (11.7%) within 6 months of randomisation. Six of these participants withdrew from the
intervention owing to illness (n = 2), difficulty using the computer (n = 3) or time commitment of the
intervention (n = 1). In the remaining cases no data were recorded because key files that contain
practice data were corrupted or were not collected from computers. In such cases, it is not known
whether practice was conducted or not. However, average practice times in Table 7 are based on
0 hours for those with no key file data, potentially underestimating the average practice time.
Quality of computerised speech and language therapy intervention delivery
Therapist knowledge about the computerised speech and language therapy intervention
At the 5-month quiz, therapists’ median score was 10 (range 7–13) out of a possible 15, indicating that
therapists generally had a reasonable level of knowledge about the intervention. The level of knowledge
about the intervention increased over time as therapists delivered the intervention to more participants;
the median score was 12 at the 10-month quiz, which was maintained at the 15-month quiz.
Tailoring of the computerised speech and language therapy intervention
Based on the therapy planning form ratings, the StepByStep approach expert had a comprehensive
understanding of why the therapist had tailored the steps as they had (score of 2) for 66% of therapy
planning forms, had some understanding of why the steps had been tailored in this way (score of 1) for
24% and was not clear why the steps had been tailored as they had (score of 0) for 10% of the sample.
This suggests that the majority of SLTs tailored the therapy as intended by the author of the therapy
manual following the speech and language therapy principles for treating a word-finding impairment.
TABLE 7 Summary of the distribution of computer practice time (n= 94)
Computer use classification Mean (SD) Median (IQR) Min., max.
Computer practice time within 6 months
Total (hours) 28.0 (25.6) 21.1 (4.9–49.7) 0.0, 104.5
Average per month (hours) 4.7 (4.3) 3.5 (0.8–8.3) 0.0, 17.4
Average per week (minutes) 64 (59) 49 (11–114) 0, 240
Number of computer sessions
Total 60 (49) 58 (14–100) 0, 177
Average per week 2.3 (1.9) 2.2 (0.5–3.8) 0.0, 6.8
Max., maximum; min., minimum.
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Speech and language therapist activities in delivering the computerised speech and
language therapy intervention
The median amount of time spent setting up and supporting the participant over the intervention period
was 5 hours and 55 minutes (ranging from 30 minutes to 26 hours) over a median of four sessions
(range 1–22 sessions). This can be further broken down into the median amount of time spent interacting
with the participants, including face-to-face, telephone or e-mail contact, of 1 hour and 45 minutes
(range 0 minutes to 11 hours) over three sessions (range 0–19 sessions) and the median amount of time
the therapist spent alone setting up the StepByStep software of 4 hours (range 0 minutes to 18 hours
and 10 minutes) over one session (range 0–11 sessions). Although a greater number of the sessions
were spent interacting with the participant, the therapists generally spent more time alone tailoring the
StepByStep software before providing it to the participants for word-finding practice.
As well as delivering the intervention to the participants, SLTs also trained and supported the volunteer
or SLTA. The median time SLTs spent with each participant’s volunteer or assistant was 1 hour and
40 minutes (range 20 minutes to 8 hours and 35 minutes) across a median of four sessions (range
1–13 sessions). The majority of assistants/volunteers supporting participants were provided with training
(93%) and ongoing support (84%) from the therapists. Training was typically delivered once for 1 hour,
whereas the median number of support sessions was two, lasting a median of 30 minutes. Approximately
half (52%) of the SLTAs or volunteers supporting the participants had their feedback forms monitored
by the SLT. The therapy manual states that the assistant or volunteer should complete a feedback form
and return it to the SLT each time they see the participant and ‘the SLT should use this to monitor the
volunteer/assistant support and the progress of the patient’. This suggests that the two-way communication
between the SLT and the volunteer/assistant was not conducted for half of the participants. For the SLTAs
and volunteers whose feedback forms were monitored, the monitoring took place a median of three times,
taking 20 minutes in total.
Volunteer/speech and language therapy assistant activities in delivering the computerised
speech and language therapy intervention
The volunteer/SLTA activity logs were completed for 86 of the 97 CSLT intervention group participants.
One participant was recorded to have declined all support from a SLTA/volunteer. Either the other
10 participants did not receive support, suggesting partial coverage of this active ingredient of the
intervention, or the activity logs were not completed. Of the 86 participants with completed activity
logs, a median number of five sessions (range 1–12 sessions) took place between the volunteer/assistant
and the participant over a median of 4 hours and 15 minutes (range 20 minutes to 8 hours and
45 minutes). The actual amount of input delivered by the volunteer/assistant was lower than the therapy
manual’s recommendation of 6 hours of input over 6 months, but equal to the minimum amount defined
as per protocol accounting for periods of holiday and illness. The vast majority of participants for whom
an activity log was completed received encouragement and motivation to use the computer therapy
from the volunteer/assistant (99%), which was delivered for a median of 1 hour and 25 minutes across
four sessions. Other activities were carried out with fewer participants. Although this might have been
due to lack of need in the case of setting up or adjusting the computer or microphone (87%) or
assistance with using the software (90%), it is likely that encouraging the use of new words through
practising them in conversation has the potential to be useful for all participants, but it was carried out
with only 85% of participants for a median of 45 minutes (range 5 minutes to 2 hours and 35 minutes).
Per-protocol adherence to the attention control intervention
Only 1 of the 80 participants randomised to the AC intervention died before the 6-month assessment.
Of the remaining 79, only 14 (17.7%) were sent at least six puzzle books and were contacted at least
four times within 6 months. These were deemed to have adhered to the predefined key components of
the AC group as detailed in Chapter 3, Per-protocol sets.
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Using four puzzle books and four contacts as per protocol in the post hoc analysis to be consistent
with the 4 months of computer therapy as per protocol in the CSLT group, 48 out of 79 (60.8%)
participants were deemed to have adhered to the AC intervention. This post hoc approach was used
only for sensitivity analysis (see Chapter 3, Per-protocol sets).
Response profiles of participants
Figure 4 shows the changes in the response of participants with respect to word-finding ability over
time, stratified by intervention. There appear to be marked improvements in the CSLT group compared
with the UC or AC groups. Only 10 CSLT participants failed to improve their word-finding ability at
6 months; three had no computer use recorded, four used computer therapy for < 5 hours in the first
6 months and the remaining three used computer therapy for > 20 hours in the first 6 months.
Figure 5 shows the pattern in functional communication responses, which is unclear but appears to be
similar across interventions. Only five (1.9%) participants had a TOMs rating on the ceiling (score of 5):
3 out of 94 (3.2%) in the CSLT group, 2 out of 97 (2.1%) in the UC group and none in the AC group.
These participants cannot show any further improvements in functional communication during the
trial because they were deemed to communicate effectively in all situations at baseline. It should be
noted that the ability to communicate effectively in all situation does not preclude having word-finding
difficulties as communication can be achieved by other means, such as gesture. No participants were
unable to communicate in any way (with a TOMs score of 0) at baseline.
The COAST response patterns over time, indicating participant perception of social participation and
quality of life, stratified by intervention, are displayed in Figure 6. Participants in the AC group appear
to have deteriorated at the 6-month assessment relative to their baseline. These response profile plots
complement the interpretation of the main and subgroup results presented in Chapter 5, Results.
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FIGURE 4 Changes in word-finding over time stratified by the intervention. (a) UC; (b) AC; and (c) CSLT. Each line,
regardless of colour, indicates a participant’s response profile.
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FIGURE 5 Changes in functional communication in conversation rated by TOMs over time, stratified by intervention.
(a) UC; (b) AC; and (c) CSLT. Each line, regardless of colour, indicates participant’s response profile.
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FIGURE 6 Changes in perception of social participation and quality of life rated by COAST over time, stratified by
intervention. (a) UC; (b) AC; and (c) CSLT. Each line, regardless of colour, indicates a participant’s response profile.
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Effect of the intervention on the co-primary and key secondary outcome measures
The first three primary clinical effectiveness objectives were to establish whether or not self-managed
CSLT intervention increases the ability of people with aphasia to use the vocabulary of personal
importance, improves functional communication ability in conversation and results in perceived greater
changes in social participation in daily activities and quality of life. This section presents results at the
6-month assessment to address these objectives.
Word-finding and functional communication: co-primary outcome measures
Figures 7 and 8 display the unadjusted mean responses to word-finding and functional communication
over time stratified by the intervention.
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FIGURE 7 Mean word-finding ability over time stratified by the intervention. Adapted from Palmer et al.50 This is an
Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work
is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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FIGURE 8 Mean functional communication in conversation over time stratified by the intervention. Adapted from Palmer
et al.50 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution
(CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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For word-finding, 86, 71 and 83 participants in the UC, AC and CSLT groups, respectively, were included
in the mITT analysis. The mean improvement in word-finding of personally selected words was 1.1%
(SD 11.2%) in the UC group, 2.4% (SD 8.8%) in the AC group and 16.4% (SD 15.3%) in the CSLT group.
This indicates an adjusted mean difference in word-finding improvement of 16.2% (95% CI 12.7% to
19.6%; p < 0.0001) in favour of CSLT compared with UC. Detailed results are presented in Table 8.
In Figure 8, the mean functional communication barely changed at 6 months. As shown in Table 8,
the mean change in functional communication in conversation on the TOMs was very similar between
the CSLT and UC groups, translating to an adjusted MDC of –0.03 (95% CI –0.21 to 0.14; p = 0.709)
compared with UC.
In line with the prespecified Hochberg multiple testing strategy, shown in Figure 1, we can only claim
the clinical effectiveness of CSLT compared with UC in improving word-finding of personal choice at a
2.5% significance level. Because both comparisons between CSLT and UC with respect to word-finding
and functional communication in conversation were not statistically significant at a 5% significance
level, further statistical significance testing is prohibited. The mean improvement in word-finding of
personally selected words of 14.4% (95% CI 10.8% to 18.1%) in favour of CSLT compared with AC
supports that the clinical effectiveness in improving word-finding is attributed to CSLT rather than
the attention provided. The mean improvement in word-finding between the AC and UC groups was
similar: 1.8% (95% CI –1.9% to 5.4%). The mean changes in functional communication in conversation
were very similar across interventions. Thus, CSLT did not result in improvement in functional
communication ability in conversation compared with UC or AC.
The effects of CSLT on word-finding and functional communication were very similar after adjusting for
additional prespecified covariates (time post stroke and location of stroke) (Tables 8 and 9).
Patient perception of communication and its impact on their life: key secondary
outcome measure
Figure 9 shows the unadjusted average profile in COAST over time. The effect of the intervention on
the COAST at 6 months is presented in Table 8.
The average improvement in COAST was only 3.3% and 2.7% in the CSLT and UC groups, respectively,
and the AC group COAST decreased slightly, by 0.3%. The adjusted MDC in COAST was only 0.5%
(95% CI –3.1% to 4.1%) in the CSLT group compared with the UC group. The adjusted MDC of 3.8%
(95% CI –0.0% to 7.5%) observed in the CSLT group compared with the AC group was attributable to
the AC group barely changing on average at 6 months, whereas the UC group experienced a small
average improvement that was comparable to that seen in the CSLT group.
In summary, there is insufficient evidence to show that CSLT improves patients’ perceptions of
communication and its impact on their life.
Impact of attrition and adherence on the co-primary and key secondary
outcome measures
As part of the sensitivity analysis, we present the results exploring the influence of attrition and
intervention adherence on the effect of the intervention on word-finding, functional communication
in conversation (TOMs) and participant perception of social participation and quality of life (COAST) at
6 months. The corresponding results for the MI set, four per-protocol sets and linear interpolation set
described in Chapter 3, Analysis populations, are presented in forest plots (Figures 10–12), including the
primary mITT results presented in Table 8 for comparability.
In general, the results are consistent across all analysis sets considered and similar to the primary analysis
set (mITT). The results of per-protocol comparisons that involve the AC group should be interpreted with
caution because of small sample size due to poor adherence to AC of 17.7%, based on the large number
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TABLE 8 Co-primary and key secondary outcomes at 6 months (mITT)
Co-primary and key
secondary outcomes
at 6 months
UC AC CSLT CSLT vs. UCg CSLT vs. ACh AC vs. UCg
n Mean (SD) n Mean (SD) n Mean (SD)
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
Co-primary outcomes
Change in word-finding (%)i 86 1.1 (11.2) 71 2.4 (8.8) 83 16.4 (15.3) 16.2 (12.7 to 19.6)a < 0.0001 14.4 (10.8 to 18.1)c < 0.0001 1.8 (–1.9 to 5.4) 0.338
Change in functional
communicationj
84 0.05 (0.59) 68 0.10 (0.61) 81 0.04 (0.58) –0.03 (–0.21 to 0.14)b 0.709 –0.01 (–0.20 to 0.18)d 0.915 –0.02 (–0.21 to 0.17) 0.812
Key secondary outcome
Change in COAST (%)k 83 2.7 (12.6) 68 –0.3 (12.7) 82 3.3 (11.3) 0.5 (–3.1 to 4.1)e 0.772 3.8 (–0.0 to 7.5)f 0.051 –3.2 (–7.0 to 0.5) 0.089
Superscripts a, b, c, d, e and f are referenced in Figure 1 to aid interpretation of Hochberg sequential and hierarchical hypotheses testing procedure for claiming evidence.
g UC as the reference group.
h AC as the reference group.
i Higher scores indicate improved vocabulary of personal importance.
j Higher scores indicate improved functional communication ability in conversation. Seven participants had missing TOMs data (video not recorded in error, poor video sound
quality, camera technical issues, participant declined to be videoed, recording failed owing to a technical issue, participant was unwell and did not want to complete the assessment
and participant did not want to complete assessment).
k Higher percentage score indicates improved patient perception of communication effectiveness and its impact on their quality of life. Seven participants had invalid COAST records,
with > 10% of applicable items that were unclear or had no response.
Notes
Results are based on a multiple linear regression model adjusted for baseline measures and fixed stratification factors (centre and severity of word-finding difficulty).
The comparisons of interest are CSLT vs. UC and CSLT vs. AC. AC vs. UC is presented for completeness but shaded to indicate that it is not of clinical importance.
Adapted from Palmer et al.50 This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others
to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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TABLE 9 Sensitivity analysis of the co-primary and key secondary outcomes at 6 months (mITT)
Sensitivity analysis:
co-primary and key
secondary outcomes
at 6 months
UC AC CSLT CSLT vs. UCa CSLT vs. ACb AC vs. UCa
n Mean (SD) n Mean (SD) n Mean (SD)
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
Co-primary outcomes
Change in word-finding (%)c 86 1.1 (11.2) 71 2.4 (8.8) 83 16.4 (15.3) 16.3 (12.8 to 19.8) < 0.0001 14.7 (11.0 to 18.4) < 0.0001 1.6 (–2.1 to 5.4) 0.385
Change in functional
communicationd
84 0.05 (0.59) 68 0.10 (0.61) 81 0.04 (0.58) –0.05 (–0.23 to 0.13) 0.596 –0.03 (–0.22 to 0.16) 0.781 –0.02 (–0.22 to 0.17) 0.830
Key secondary outcome
Change in COAST (%)e 83 2.7 (12.6) 68 –0.3 (12.7) 82 3.3 (11.3) 0.9 (–2.8 to 4.5) 0.644 3.6 (–0.2 to 7.5) 0.064 –2.8 (–6.6 to 1.1) 0.156
a UC as the reference group.
b AC as the reference group.
c Higher scores indicate improved vocabulary of personal importance.
d Higher scores indicate improved functional communication ability in conversation. Seven participants had missing TOMs data (video not recorded in error, poor video sound
quality, camera technical issues, participant declined to be videoed, recording failed owing to a technical issue, participant was unwell and did not want to complete the assessment
and participant did not want to complete assessment).
e Higher percentage score indicates improved patient perception of communication effectiveness and its impact on their quality of life. Seven participants had invalid COAST records,
with > 10% of applicable items that were unclear or had no response.
Notes
Sensitivity analysis results from multiple linear regression models adjusted for baseline measures, fixed stratification factors (centre and severity of word-finding) and potential
confounders (length of time post stroke and location of stroke).
The comparisons of interest are CSLT vs. UC and CSLT vs. AC. AC vs. UC is presented for completeness but shaded to indicate that it is not of clinical importance.
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FIGURE 11 Impact of attrition and intervention adherence on functional communication at 6 months. LI, linear interpolation;
MCID, minimum clinically important difference; PP, per protocol. Per-protocol sets are defined in Chapter 3, Analysis populations.
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FIGURE 12 Impact of attrition and intervention adherence on COAST at 6 months. LI, linear interpolation; MCID,
minimum clinically important difference; PP, per protocol. Per-protocol sets are defined in Chapter 3, Analysis populations.
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of puzzle books prespecified as per protocol (six books), as described in Chapter 3, Per-protocol sets.
We further undertook sensitivity analysis based on post hoc classification of per-protocol adherence in
the AC group (sent at least four puzzle books rather than six), as described in Chapter 3, Per-protocol sets.
These results did not differ from the prespecified per-protocol classification to change the interpretation
of findings. For additional information, these post hoc results are accessible online (see section 9.19 of
the statistical report, which is available online as a supplementary appendix to Palmer et al.50).
Subgroup influence on the effectiveness on the co-primary and key secondary
outcome measures
This section presents the results exploring potential heterogeneity in the intervention effect across
prespecified subgroups on word-finding, functional communication in conversation (TOMs) and participant
perception of social participation/quality of life (COAST) at 6 months. The results for CSLT versus UC
and CSLT versus AC comparisons are graphically displayed in forests plots together with the mITT results
(Figures 13–15). In addition, the interaction tests between the intervention and subgroups are presented
in Table 10.
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FIGURE 13 Subgroup influence on word-finding results at 6 months. MCID, minimum clinically important difference;
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Due consideration should be given to the clinical or biological plausibility of subgroup results when
interpreting these findings. In addition, extreme caution should be taken when interpreting the
intervention effect in the severe category of the CAT Comprehension of Spoken Sentences owing to
very small sample sizes.
For word-finding, the results appear to be consistent and similar to the mITT results. However, the
intervention effect seems to be more pronounced in patients who had mild word-finding difficulties and for
those whose comprehension was within normal limits on the CAT Comprehension of Spoken Sentences.
The effect of the intervention on TOMs and COAST appears to be broadly consistent across subgroups.
However, for unclear clinical reasons, probably due to change, TOMs seem to have improved among the
25% of participants whose time post stroke was between the first and second quartiles of the distribution.
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FIGURE 14 Subgroup influence on functional communication results at 6 months. MCID, minimum clinically important
difference; Q1, 25th percentile, ≈1 year; Q2, 50th percentile, ≈2 years; Q3, 75th percentile, ≈4 years; WNL, within
normal limits.
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Long-term effects of the intervention on the co-primary and key secondary outcomes
The fourth research objective was to identify whether or not any effects of the interventions were
evident 12 months after therapy had begun.
Figures 7–9 show the unadjusted average profile response of participants over time for word-finding,
conversation (TOMs) and participant perception of social participation/quality of life (COAST) stratified
by the intervention. The effects of the intervention (CSLT vs. UC and CSLT vs. AC) for word-finding,
TOMs and COAST at 9 and 12 months are displayed in Figures 16–18, together with the primary
results at 6 months (mITT) for comparability.
In summary, the long-term effects of CSLT on word-finding of personal importance at 9 and 12 months
were consistent across analysis sets but marginally lower than those observed at 6 months. However,
all of the 95% CIs include the 10% improvement in word-finding of clinical relevance and excludes the
zero effect of no difference in the intervention effect. Therefore, the sustained long-term intervention
effect on word-finding is potentially of clinical importance. For TOMs and COAST, no changes of clinical
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TABLE 10 Subgroup analysis results: co-primary and key secondary outcomes at 6 months
Co-primary and key secondary
outcomes at 6 months Subgroup
UC AC CSLT CSLT vs. UCa CSLT vs. ACb
n Mean (SD) n Mean (SD) n Mean (SD)
Adjusted MDC
(95% CI)
Interaction
p-value
Adjusted MDC
(95% CI)
Interaction
p-value
Word-finding severity
Change in word-finding (%)c Mild 35 –2.7 (10.3) 35 1.8 (9.5) 36 16.3 (14.2) 20.1 (14.8 to 25.5) 0.255 15.9 (10.5 to 21.2) 0.828
Moderate 29 3.9 (13.1) 17 3.3 (8.6) 26 18.2 (12.5) 13.8 (7.8 to 19.9) 13.9 (6.8 to 21.0)
Severe 22 3.3 (8.1) 19 2.7 (7.8) 21 14.4 (19.9) 12.8 (5.9 to 19.7) 13.2 (6.1 to 20.3)
Change in functional
communicationd
Mild 35 –0.01 (0.65) 35 0.04 (0.59) 35 –0.13 (0.51) –0.08 (–0.35 to 0.18) 0.88 –0.10 (–0.37 to 0.17) 0.145
Moderate 27 0.15 (0.59) 15 0.00 (0.68) 26 0.29 (0.49) 0.08 (–0.23 to 0.39) 0.33 (–0.04 to 0.69)
Severe 22 0.05 (0.51) 17 0.32 (0.58) 19 0.05 (0.69) –0.09 (–0.44 to 0.27) –0.21 (–0.59 to 0.18)
Change in COAST (%)e Mild 34 1.2 (12.3) 35 3.0 (10.2) 36 3.6 (9.7) 2.4 (–3.0 to 7.8) 0.809 1.7 (–3.7 to 7.0) 0.322
Moderate 28 6.0 (13.6) 16 –5.2 (10.3) 24 5.1 (8.9) –0.4 (–6.6 to 5.9) 9.0 (1.6 to 16.4)
Severe 20 0.9 (11.7) 17 –2.6 (17.2) 18 1.3 (16.2) –1.4 (–8.8 to 6.1) 3.0 (–4.7 to 10.6)
CAT comprehension ability
Change in word-finding (%)c Severe 3 14.0 (3.9) 3 4.0 (1.7) 5 13.8 (22.3) 1.5 (–15.1 to 18.2) 0.034 10.9 (–5.7 to 27.6) 0.271
Moderate 20 –0.5 (8.8) 24 2.8 (8.8) 26 17.9 (14.2) 16.9 (10.2 to 23.6) 14.3 (7.9 to 20.7)
Mild 46 2.3 (10.1) 31 2.9 (9.4) 35 13.7 (16.2) 13.0 (7.8 to 18.1) 11.0 (5.5 to 16.6)
WNL 17 –2.6 (15.2) 13 –0.1 (8.4) 17 20.6 (12.4) 25.1 (17.3 to 32.9) 23.6 (15.1 to 32.1)
Change in functional
communicationd
Severe 3 0.83 (0.58) 3 0.50 (0.50) 4 0.13 (0.75) –0.46 (–1.33 to 0.40) 0.587 –0.07 (–0.95 to 0.81) 0.541
Moderate 20 –0.10 (0.53) 22 0.02 (0.59) 25 –0.02 (0.64) 0.07 (–0.27 to 0.41) –0.02 (–0.36 to 0.31)
Mild 45 0.04 (0.63) 29 0.19 (0.67) 35 0.01 (0.55) –0.09 (–0.35 to 0.17) –0.13 (–0.41 to 0.15)
WNL 16 0.13 (0.47) 13 –0.04 (0.52) 16 0.22 (0.48) 0.09 (–0.31 to 0.49) 0.30 (–0.13 to 0.73)
Change in COAST (%)e Severe 3 25.0 (12.3) 3 14.9 (16.3) 4 –3.1 (23.4) –22.1 (–39.7 to –4.4) 0.039 –20.7 (–38.4 to –2.9) 0.049
Moderate 17 –0.5 (9.7) 22 –3.2 (16.4) 23 6.5 (11.9) 5.6 (–1.6 to 12.8) 7.8 (1.1 to 14.6)
Mild 45 1.9 (13.5) 30 0.1 (9.9) 34 2.1 (10.1) –0.7 (–6.0 to 4.6) 2.8 (–2.9 to 8.5)
WNL 17 4.3 (9.8) 13 0.1 (8.6) 17 3.9 (8.6) 0.8 (–7.0 to 8.6) 5.0 (–3.5 to 13.5)
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Co-primary and key secondary
outcomes at 6 months Subgroup
UC AC CSLT CSLT vs. UCa CSLT vs. ACb
n Mean (SD) n Mean (SD) n Mean (SD)
Adjusted MDC
(95% CI)
Interaction
p-value
Adjusted MDC
(95% CI)
Interaction
p-value
Time post stroke
Change in word-finding (%)c <Q1 24 3.4 (9.2) 17 4.4 (6.7) 26 14.6 (19.0) 12.0 (5.5 to 18.6) 0.572 11.6 (4.4 to 18.7) 0.647
Q1–<Q2 21 –1.6 (14.1) 18 2.0 (9.2) 20 18.2 (15.7) 16.5 (9.3 to 23.7) 12.8 (5.4 to 20.3)
Q2–<Q3 20 0.5 (11.4) 12 4.0 (9.8) 21 20.0 (10.5) 20.1 (12.9 to 27.3) 18.5 (9.9 to 27.0)
≥Q3 21 1.8 (10.0) 24 0.4 (9.3) 16 12.5 (13.0) 16.1 (8.4 to 23.9) 13.7 (6.3 to 21.2)
Change in functional
communicationd
<Q1 24 0.19 (0.59) 16 0.22 (0.63) 25 0.02 (0.70) –0.15 (–0.47 to 0.18) 0.052 –0.07 (–0.44 to 0.30) 0.145
Q1–<Q2 21 –0.17 (0.58) 17 –0.03 (0.65) 19 0.24 (0.42) 0.34 (–0.02 to 0.71) 0.34 (–0.04 to 0.73)
Q2–<Q3 19 0.21 (0.54) 12 0.00 (0.74) 21 –0.10 (0.44) –0.30 (–0.66 to 0.07) –0.12 (–0.54 to 0.31)
≥Q3 20 –0.03 (0.62) 22 0.18 (0.50) 15 0.07 (0.65) –0.02 (–0.42 to 0.38) –0.17 (–0.56 to 0.22)
Change in COAST (%)e <Q1 22 1.8 (16.5) 16 2.7 (10.4) 24 1.7 (13.5) 0.0 (–6.7 to 6.8) 0.814 –1.6 (–8.9 to 5.7) 0.047
Q1–<Q2 21 3.9 (12.2) 17 0.1 (14.5) 19 6.4 (9.7) 1.6 (–5.7 to 8.8) 6.2 (–1.4 to 13.8)
Q2–<Q3 19 5.0 (10.9) 12 –8.1 (11.4) 20 6.1 (10.0) 1.7 (–5.6 to 9.1) 12.7 (4.2 to 21.2)
≥Q3 20 0.5 (10.2) 23 1.4 (12.4) 15 –0.5 (9.9) –0.9 (–8.8 to 6.9) –0.1 (–7.7 to 7.5)
Q1, 25th percentile, ≈1 year; Q2, 50th percentile, ≈2 years; Q3, 75th percentile, ≈4 years; WNL, within normal limits.
a UC as the reference group.
b AC as the reference group.
c Higher scores indicate improved vocabulary of personal importance.
d Higher scores indicate improved functional communication ability in conversation.
e Higher percentage score indicates improved patient perception of communication effectiveness and its impact on their quality of life.
Note
Results are based on a multiple linear regression model adjusted for baseline measures and fixed stratification factors (centre and severity of word-finding) with interaction between
intervention group and subgroup.
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FIGURE 16 Long-term intervention effect on word-finding of personal importance. CC, complete case; LI, linear
interpolation; MCID, minimum clinically important difference.
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FIGURE 17 Long-term intervention effect on functional communication. CC, complete case; LI, linear interpolation;
MCID, minimum clinically important difference.
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relevance were observed and the effects are consistent with the primary results at 6 months and across
the considered analysis sets.
Effect of the intervention on generalisation to untreated words
In this section, we present the results exploring whether or not there is a generalisation of word-finding
from words of personal importance (treated words) to untreated words. This was assessed using the CAT
Naming Objects with a possible total score from the picture-naming tasks of 24 untreated words ranging
from 0 to 48.
Table 11 summarises the effect of the intervention on word-finding of untreated words at 6, 9 and
12 months from randomisation. At 6 months, the mean change in word-finding of untreated words
(scores) was 3.9 (SD 7.9), 0.7 (SD 8.5) and 3.3 (SD 7.0) in the UC, AC and CSLT groups, respectively.
This indicates an adjusted MDC of –0.3 (95% CI –2.7 to 2.1) in favour of UC compared with CSLT.
On average, the adjusted word-finding of untreated words in the AC group was lower than those of
the UC and CSLT groups across assessments.
In summary, there is insufficient evidence to support the positive effect of the intervention on improving
the generalisation of word-finding to untreated words in either the short term or long term.
The literature often reports the proportion of participants who do or do not generalise word-finding to
untreated words.51 Therefore, we undertook a post hoc analysis to explore the intervention effect on
the proportion of participants who generalised the word-finding of untreated words as defined by a
clinical improvement of at least 5% and 10% from baseline. In summary, these results do not support
that CSLT increases the proportion of participants achieving a clinical improvement of at least 5%
and 10% in the generalisation of word-finding to untreated words compared with UC or AC. Detailed
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FIGURE 18 Long-term intervention effect on the COAST. CC, complete case; LI, linear interpolation; MCID, minimum
clinically important difference.
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TABLE 11 Intervention effect on generalisation to untreated words at 6, 9 and 12 months
Change in
word-finding of
untreated words
UC AC CSLT CSLT vs. UCa CSLT vs. ACb AC vs. UCa
n Mean (SD) n Mean (SD) n Mean (SD)
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
CC
6 months 86 3.9 (7.9) 69 0.7 (8.5) 82 3.3 (7.0) –0.3 (–2.7 to 2.1) 0.810 2.6 (0.1 to 5.1) 0.045 –2.9 (–5.3 to –0.4) 0.025
9 months 83 4.8 (8.0) 63 2.5 (6.9) 76 4.0 (7.9) –0.7 (–3.1 to 1.6) 0.534 1.4 (–1.2 to 3.9) 0.299 –2.1 (–4.6 to 0.4) 0.100
12 months 83 4.5 (8.5) 60 2.8 (7.1) 74 4.8 (7.3) 0.6 (–1.8 to 3.0) 0.634 1.8 (–0.8 to 4.5) 0.177 –1.3 (–3.9 to 1.3) 0.342
MI
6 months 97 3.9 (8.9) 79 0.8 (8.6) 94 3.4 (7.9) –0.4 (–2.7 to 2.0) 0.754 2.4 (–0.1 to 4.9) 0.058 –2.8 (–5.3 to –0.3) 0.030
9 months 97 5.0 (8.7) 79 2.4 (7.8) 94 3.9 (8.8) –1.0 (–3.3 to 1.3) 0.396 1.4 (–1.2 to 3.9) 0.288 –2.4 (–4.9 to 0.1) 0.064
12 months 97 4.8 (9.2) 79 2.3 (8.3) 94 4.7 (8.4) –0.1 (–2.5 to 2.4) 0.967 2.1 (–0.5 to 4.6) 0.117 –2.1 (–4.7 to 0.5) 0.108
Linear interpolation
6 months 88 3.8 (7.9) 70 0.7 (8.4) 83 3.3 (7.0) –0.2 (–2.5 to 2.2) 0.893 2.5 (0.0 to 5.0) 0.047 –2.7 (–5.1 to –0.2) 0.032
9 months 88 4.6 (8.2) 70 2.0 (8.3) 83 4.0 (7.8) –0.3 (–2.7 to 2.1) 0.808 2.0 (–0.6 to 4.6) 0.131 –2.3 (–4.8 to 0.3) 0.078
12 months 88 4.3 (9.1) 70 2.0 (9.6) 83 4.8 (7.9) 0.8 (–1.9 to 3.4) 0.571 2.7 (–0.2 to 5.5) 0.064 –1.9 (–4.7 to 0.9) 0.179
CC, complete case.
a UC as the reference group.
b AC as the reference group.
Notes
Total score from the picture-naming tasks ranges from 0 to 48. Results are based on a multiple linear regression model adjusted for baseline measures and fixed stratification factors
(centre and severity of word-finding).
Positive higher scores indicate improved word-finding of untreated words.
The comparisons of interest are CSLT vs. UC and CSLT vs. AC. AC vs. UC is presented for completeness but shaded to indicate that it is not of clinical importance.
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results are accessible online (see section 9.14.1 of the statistical report, which is available online as a
supplementary appendix to Palmer et al.50).
Effect of the intervention on generalisation of treated words used in conversation
Here, we present the results exploring the intervention effect on the use of learned vocabulary
(from the word-finding treatment of personally chosen words in conversation). This is based on a
possible total number of unique words retrieved in video conversations ranging from 0 to 100.
The average response profiles in the numbers of treated words used in conversation over time are shown
in Figure 19. The UC and AC groups experienced an average decrease of about two personally chosen
words at 6 months, whereas the CSLT group remained almost the same throughout the trial. This
translated to an adjusted MDC in treated words used in conversation at 6 months of only 2.0 (95% CI 0.6
to 3.4) in favour of CSLT compared with UC and 2.9 (95% CI 1.4 to 4.4) in favour of CLST compared with
AC.The effect diminished at 9 and 12 months as UC and AC participants improved slightly on average.
Table 12 details results that are very consistent across analysis sets considered at 6, 9 and 12 months.
In line with the analysis of generalisation of treated words to untreated words, we performed post hoc
analysis exploring the proportion of participants meeting clinical improvement in the generalisation of
treated words used in conversation (words retrieved during videoed conversations) of at least five and
at least 10 words. As shown in Table 13, 23 (28.4%) participants in the CSLT group, 6 (8.8%) participants
in the AC group and 8 (9.5%) participants in the UC group recorded a clinical improvement of at least
five words at 6 months from baseline. That is, only about 1 in 10 participants in the UC or AC groups
showed a clinical improvement of at least five words, compared with approximately 3 in 10 in the CSLT
group. This translates to a 18.9% or 19.6% (about 2 in 10) increase in the proportion of participants
showing clinical improvement in the generalisation of treated words used in conversation in the CSLT
group compared with the AC or UC groups, respectively, at 6 months. Only a handful of participants
improved by > 10 words across interventions in the short and long term at 6, 9 and 12 months.
Carer-rated communication effectiveness and impact on carers’ quality of life
One of the additional research objectives is to investigate the effect of the intervention on the carer-rated
communication effectiveness (using the first 15 questions from the CaCOAST) and impact on the carers’
quality of life (using the last five questions of the CaCOAST).We refer to these as ‘CaCOAST 15’ and
‘CaCOAST 5’, respectively. It should be noted that this exploratory analysis includes only available carers
who agreed to take part. In addition, the unit of randomisation was the participant and not the carer.
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FIGURE 19 Mean response profile in word-finding of treated words over time.
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TABLE 12 Intervention effect on generalisation of treated words used in conversation
Change in treated words
used in conversation
UC AC CSLT CSLT vs. UCa CSLT vs. ACb AC vs. UCa
n Mean (SD) n Mean (SD) n Mean (SD)
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
CC
6 months 84 –1.9 (5.3) 68 –2.0 (5.2) 81 0.1 (6.6) 2.0 (0.6 to 3.4) 0.006 2.9 (1.4 to 4.4) < 0.001 –0.9 (–2.4 to 0.6) 0.241
9 months 83 –1.0 (5.6) 61 –1.4 (5.7) 73 0.4 (7.0) 1.4 (–0.3 to 3.0) 0.099 2.2 (0.4 to 4.0) 0.017 –0.8 (–2.6 to 0.9) 0.357
12 months 79 –0.4 (5.5) 59 0.1 (6.6) 70 0.5 (5.6) 0.8 (–0.8 to 2.4) 0.351 0.8 (–1.0 to 2.5) 0.401 0.0 (–1.7 to 1.7) 0.996
MI
6 months 97 –2.0 (6.0) 79 –1.7 (5.8) 94 –0.3 (7.0) 2.0 (0.5 to 3.5) 0.009 2.8 (1.2 to 4.3) < 0.001 –0.8 (–2.3 to 0.7) 0.317
9 months 97 –1.3 (6.3) 79 –1.2 (6.5) 94 –0.1 (7.4) 1.3 (–0.3 to 2.9) 0.103 2.2 (0.4 to 4.1) 0.017 –0.9 (–2.7 to 0.9) 0.330
12 months 97 –0.4 (6.2) 79 0.5 (6.8) 94 0.3 (6.6) 0.7 (–0.8 to 2.3) 0.354 0.8 (–0.9 to 2.5) 0.347 –0.1 (–1.8 to 1.6) 0.908
Linear interpolation
6 months 87 –1.9 (5.2) 68 –1.8 (5.3) 81 0.3 (6.8) 2.2 (0.8 to 3.6) 0.003 2.9 (1.4 to 4.4) < 0.001 –0.8 (–2.3 to 0.7) 0.308
9 months 87 –1.1 (5.7) 68 –1.1 (5.7) 81 0.5 (7.4) 1.6 (0.0 to 3.1) 0.047 2.3 (0.7 to 4.0) 0.006 –0.8 (–2.4 to 0.9) 0.361
12 months 87 –0.6 (5.8) 68 0.3 (6.4) 81 0.4 (7.0) 0.8 (–0.8 to 2.5) 0.328 0.9 (–0.9 to 2.7) 0.311 –0.1 (–1.8 to 1.7) 0.915
CC, complete case.
a UC as the reference group.
b AC as the reference group.
Notes
Total numbers of unique words retrieved from the video conversations range from 0 to 100.
Results are based on a multiple linear regression model adjusted for baseline measures and fixed stratification factors (centre and severity of word-finding).
High positive scores indicate improved word-finding of untreated words.
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The mean change in carer-rated communication effectiveness at 6 months was 6.8% in the CSLT group,
compared with 1.0% in the UC group, translating to an adjusted MDC of 4.6% (95% CI 0.3% to 9.0%)
in favour of CSLT (Table 14). This small improvement in carer-rated communication effectiveness in
CSLT was similar when compared with AC: 5.1% (95% CI 0.5% to 9.7%). However, the long-term
effects of the intervention on average change in the carer-rated communication effectiveness were
very small: 0.6% (95% CI –4.4% to 5.7%) and 2.7% (95% CI –1.9% to 7.4%) in favour of CSLT compared
with UC at 9 and 12 months, respectively.
For the carer-rated impact on their quality of life at 6 months, UC decreased by 1% and CSLT
improved by 5.3%, translating to a positive adjusted MDC of 5.3% (95% CI –1.1% to 11.7%) in favour
of CSLT. However, although this seems to be of potential clinical relevance, we cannot rule out the
lack of benefit. The improvement in carers’ quality of life in CSLT compared with AC was close to zero:
0.3% (95% CI –6.4% to 6.9%). In other words, about 5% improvement in carers’ quality of life could be
attributed the attention given rather than the computer therapy alone. The average effect at 9 months
was slightly lower than at 6 months (4.0%, 95% CI –3.3% to 11.2%) in favour of CSLT compared
with UC. Although CIs around observed effects include the null effect of zero (no difference between
groups), clinical judgements need to be made on whether or not the observed treatment effects are
of clinical importance or relevance. In addition, interpretation should be made in consideration of the
observed effect between CSLT and AC.
Safety and negative effects
The incidences of negative effects of computer therapy
Table 15 summarises negative effects of computer therapy among the participants who used a computer
for the intervention. Of the 85 participants who used computer therapy, 23 (27.1%) felt that the computer
practice made them overtired and anxious or worried, translating to an average IR of one episode per
person-year. The incidence of computer therapy causing headaches and affecting eyes was low. The
results based on treatment-as-received (see Table 15) and treatment-as-randomised (Table 16)
principles are very similar.
TABLE 13 Clinical improvement in generalisation of treated words used in conversation
Change
in treated
words used in
conversation
Trial group, n (%) Difference in proportions (95% CI)
UC AC CSLT CSLT vs. UCa CSLT vs. ACb AC vs. UCa
6 months N = 84 N = 68 N = 81
≥ 5 words 8 (9.5) 6 (8.8) 23 (28.4) 18.9 (7.2 to 30.5) 19.6 (7.7 to 31.5) –0.7 (–9.9 to 8.5)
≥ 10 words 1 (1.2) 0 (0.0) 5 (6.2) 5.0 (–0.7 to 10.7) 6.2 (0.9 to 11.4) –1.2 (–3.5 to 1.1)
9 months N = 83 N = 61 N = 73
≥ 5 words 11 (13.3) 8 (13.1) 15 (20.5) 7.3 (–4.5 to 19.1) 7.4 (–5.1 to 20.0) –0.1 (–11.3 to 11.0)
≥ 10 words 3 (3.6) 1 (1.6) 4 (5.5) 1.9 (–4.7 to 8.5) 3.8 (–2.3 to 10.0) –2.0 (–7.1 to 3.2)
12 months N = 79 N = 59 N = 70
≥ 5 words 12 (15.2) 12 (20.3) 18 (25.7) 10.5 (–2.4 to 23.5) 5.4 (–9.1 to 19.9) 5.1 (–7.8 to 18.1)
≥ 10 words 3 (3.8) 4 (6.8) 2 (2.9) –0.9 (–6.7 to 4.8) –3.9 (–11.4 to 3.6) 3.0 (–4.7 to 10.7)
a UC as the reference group.
b AC as the reference group.
Notes
Complete cases only.
CIs estimated using the normal approximation to the binomial distribution.
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TABLE 14 Intervention effect on the carer-rated communication effectiveness and carers’ quality of life
CaCOAST domain
UC AC CSLT CSLT vs. UCa CSLT vs. ACb AC vs. UCa
n Mean (SD) n Mean (SD) n Mean (SD)
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
Adjusted MDC
(95% CI) p-value
Change in CaCOAST 15 (%)c
6 months 48 1.0 (11.5) 38 2.6 (11.3) 51 6.8 (11.5) 4.6 (0.3 to 9.0) 0.038 5.1 (0.5 to 9.7) 0.030 –0.5 (–5.2 to 4.2) 0.846
9 months 43 2.5 (11.7) 37 4.4 (11.3) 47 5.7 (13.2) 0.6 (–4.4 to 5.7) 0.802 0.5 (–4.7 to 5.6) 0.855 0.2 (–5.1 to 5.5) 0.953
12 months 45 3.1 (11.5) 34 4.2 (11.3) 44 6.6 (11.6) 2.7 (–1.9 to 7.4) 0.244 1.9 (–3.1 to 6.9) 0.444 0.8 (–4.2 to 5.8) 0.752
Change in CaCOAST 5 (%)d
6 months 48 –1.0 (15.8) 38 7.2 (14.6) 51 5.8 (17.3) 5.3 (–1.1 to 11.7) 0.105 0.3 (–6.4 to 6.9) 0.940 5.0 (–2.0 to 12.0) 0.156
9 months 43 –0.6 (18.4) 37 8.2 (14.6) 47 8.5 (18.7) 4.0 (–3.3 to 11.2) 0.279 0.2 (–7.0 to 7.5) 0.949 3.7 (–4.0 to 11.4) 0.337
12 months 45 4.0 (20.1) 34 7.2 (13.6) 44 8.5 (19.5) 0.6 (–6.3 to 7.4) 0.871 3.4 (–4.0 to 10.8) 0.363 –2.8 (–10.4 to 4.8) 0.460
CC, complete case.
a UC as the reference group.
b AC as the reference group.
c High positive scores indicate improved carer-rated communication effectiveness.
d High positive scores indicate improved impact on carers’ quality of life.
Note
Results based on a multiple linear regression model adjusted for baseline measures and fixed stratification factors (centre and severity of word-finding); only for CC set.
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The incidences of adverse events
Of the 97 participants randomised to receive CSLT, computer therapy use data were not recorded
for 12 (12.4%), three of whom died before the 6-month assessment. Only one participant who was
allocated to AC died before the 6 months and was never sent a puzzle book. Therefore, in accordance
with the treatment-as-received principle, these 13 participants were technically treated as having
received UC alone. The other four participants who died were allocated to the UC group and as having
not received any other treatments. Thus, the denominators for the treatment-as-received analysis are
101 in the UC group, 79 in the AC group and 85 in the CSLT group.
Table 17 summarises the incidences of AEs using the treatment-as-received principle. The proportion of
participants who experienced any AE was 61 (71.8%) in the CSLT group, 50 (63.3%) in the AC group
and 70 (61.4%) in the UC group. On average, the number of AEs per participant per person-year of
follow-up was 2.18, 1.79 and 1.87 in the CSLT, AC and UC groups, respectively. This indicates a slight
increase in all AEs in the CSLT group, with an IRR of 1.16 (95% CI 0.83 to 1.62) and 1.22 (95% CI 0.85
to 1.77) compared with the UC and AC groups, respectively. However, there is insufficient evidence to
suggest an increased risk of AEs in the CSLT group compared with the AC or UC groups.
Although fits and seizures were not common, the risk of these AEs was more than three times higher
in the CSLT group than in either the UC group or the AC group. The numbers of AEs by category are
also presented in Table 17. Unfortunately, we did not record if participants had had previous seizures
before taking part in the trial; however, the events were all considered unrelated or unlikely to be
related to the intervention by the clinicians at the sites.
For sensitivity analysis, Table 18 summarises AEs using the strict intention-to-treat (ITT) principle
(treatment as randomised). In summary, the interpretation is consistent with the treatment-as-received
results presented in Table 17.
TABLE 15 Negative effects of computer therapy (only those who used the computer)
Has the computer practice:
CSLT (N= 85)
n (%) Total events/person-years IR/person-year (95% CI)
Made you feel overtired? 23 (27.1) 50/42.1 1.18 (0.74 to 1.90)
Affected your eyes? 11 (12.9) 17/42.1 0.40 (0.21 to 0.78)
Given you headaches? 5 (5.9) 6/42.1 0.14 (0.06 to 0.36)
Made you feel anxious/worried? 23 (27.1) 42/42.1 0.99 (0.63 to 1.56)
Results from a negative binomial regression model.
TABLE 16 Negative effects of the computer therapy (treatment as randomised)
Has the computer practice:
CSLT (N= 97)
n (%) Total events/person-years IR/person-year (95% CI)
Made you feel over tired? 26 (26.8) 53/47.1 1.14 (0.73 to 1.78)
Affected your eyes? 11 (11.3) 17/47.1 0.36 (0.18 to 0.70)
Given you headaches? 5 (5.2) 6/47.1 0.13 (0.05 to 0.32)
Made you feel anxious/worried? 26 (26.8) 45/47.1 0.97 (0.63 to 1.49)
Results from a negative binomial regression model.
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TABLE 17 Incidence of AEs (treatment as received)
AE classification UC (N= 114) AC (N= 79) CSLT (N= 85)
IRR (95% CI)
CSLT vs. UCa CSLT vs. ACb AC vs. UCa
Had experienced
at least one AE,
n (%)
70 (61.4) 50 (63.3) 61 (71.8)
Repeated AEs
All AEs
Total events/
person-years
200/105.4 136/74.7 185/84.7
IR/person-year
(95% CI)
1.87
(1.47 to 2.38)
1.79
(1.38 to 2.31)
2.18
(1.72 to 2.77)
1.16
(0.83 to 1.62)
1.22
(0.85 to 1.77)
0.95
(0.67 to 1.35)
Felt more tired than usual
Total events/
person-years
125/105.4 77/74.7 114/84.7
IR/person-year
(95% CI)
1.18
(0.82 to 1.70)
1.01
(0.70 to 1.45)
1.32
(0.95 to 1.84)
1.12
(0.69 to 1.83)
1.32
(0.81 to 2.14)
0.85
(0.51 to 1.42)
Had any fits or seizures
Total events/
person-years
18/105.4 13/74.7 47/84.7
IR/person-year
(95% CI)
0.16
(0.06 to 0.44)
0.17
(0.08 to 0.37)
0.57
(0.29 to 1.12)
3.48
(1.05 to 11.57)
3.41
(1.21 to 9.62)
1.02
(0.29 to 3.63)
Had worsening vision or visual difficulties
Total events/
person-years
47/105.4 34/74.7 71/84.7
IR/person-year
(95% CI)
0.42
(0.22 to 0.80)
0.44
(0.25 to 0.79)
0.83
(0.51 to 1.36)
1.95
(0.87 to 4.37)
1.89
(0.89 to 4.05)
1.03
(0.43 to 2.44)
Had increasing number or increasing severity of headaches
Total events/
person-years
46/105.4 25/74.7 52/84.7
IR/person-year
(95% CI)
0.43
(0.23 to 0.81)
0.31
(0.13 to 0.78)
0.58
(0.34 to 1.01)
1.36
(0.59 to 3.11)
1.84
(0.64 to 5.30)
0.74
(0.24 to 2.21)
Had any accidents (e.g. falls) or injuries
Total events/
person-years
90/105.4 51/74.7 48/84.7
IR/person-year
(95% CI)
0.87
(0.58 to 1.30)
0.66
(0.42 to 1.04)
0.56
(0.35 to 0.89)
0.64
(0.35 to 1.19)
0.85
(0.45 to 1.61)
0.76
(0.42 to 1.39)
Reported any other negative effects or events
Total events/
person-years
64/105.4 29/74.7 44/84.7
IR/person-year
(95% CI)
0.60
(0.40 to 0.92)
0.38
(0.21 to 0.68)
0.55
(0.35 to 0.86)
0.91
(0.49 to 1.68)
1.44
(0.69 to 3.00)
0.63
(0.31 to 1.28)
a UC as the reference group.
b AC as the reference group.
Notes
Results are from a negative binomial regression model.
The column AC vs. UC is exploratory, and therefore shaded, but presented for completeness.
The comparisons of interest are CSLT vs. UC and CSLT vs. AC. AC vs. UC is presented for completeness.
Adapted from Palmer et al.50 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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TABLE 18 Incidence of AEs (treatment as randomised)
AE
classification UC (N= 101) AC (N= 80)
CSLT
(N= 97)
IRR (95% CI)
CSLT vs. UCa CSLT vs. ACb AC vs. UCa
Had
experienced
at least one AE,
n (%)
62 (61.4) 50 (62.5) 69 (71.1)
Repeated AEs
All AEs
Total events/
person-years
186/97.1 136/74.8 199/92.9
IR/person-year
(95% CI)
1.90
(1.46 to 2.48)
1.78
(1.38 to 2.30)
2.13
(1.71 to 2.65)
1.11
(0.80 to 1.56)
1.19
(0.83 to 1.71)
0.93
(0.65 to 1.34)
Felt more tired than usual
Total events/
person-years
122/97.1 77/74.8 117/92.9
IR/person-year
(95% CI)
1.28
(0.84 to 1.93)
1.00
(0.69 to 1.47)
1.21
(0.85 to 1.74)
0.95
(0.56 to 1.61)
1.21
(0.69 to 2.14)
0.78
(0.45 to 1.38)
Had any fits or seizures
Total events/
person-years
15/97.1 13/74.8 50/92.9
IR/person-year
(95% CI)
0.15
(0.04 to 0.52)
0.17
(0.07 to 0.41)
0.53
(0.24 to 1.19)
3.57
(1.01 to 12.67)
3.22
(0.83 to 12.42)
1.11
(0.27 to 4.54)
Had worsening vision or visual difficulties
Total events/
person-years
46/97.1 34/74.8 72/92.9
IR/person-year
(95% CI)
0.45
(0.21 to 0.97)
0.44
(0.23 to 0.84)
0.76
(0.42 to 1.36)
1.69
(0.69 to 4.13)
1.74
(0.67 to 4.57)
0.97
(0.37 to 2.56)
Had increasing number or increasing severity of headaches
Total events/
person-years
44/97.1 25/74.8 54/92.9
IR/person-year
(95% CI)
0.46
(0.21 to 1.00)
0.31
(0.11 to 0.91)
0.54
(0.27 to 1.09)
1.17
(0.39 to 3.52)
1.71
(0.52 to 5.62)
0.69
(0.21 to 2.26)
Had any accidents (e.g. falls) or injuries
Total events/
person-years
86/97.1 51/74.8 52/92.9
IR/person-year
(95% CI)
0.92
(0.58 to 1.45)
0.66
(0.41 to 1.06)
0.55
(0.35 to 0.87)
0.60
(0.32 to 1.13)
0.83
(0.42 to 1.66)
0.72
(0.37 to 1.40)
Reported any other negative effects or events
Total events/
person-years
59/97.1 29/74.8 49/92.9
IR/person-year
(95% CI)
0.61
(0.38 to 0.99)
0.38
(0.20 to 0.71)
0.55
(0.35 to 0.86)
0.90
(0.46 to 1.77)
1.45
(0.68 to 3.08)
0.62
(0.30 to 1.30)
a UC as the reference group.
b AC as the reference group.
Notes
Results are from a negative binomial regression model.
The comparisons of interest are CSLT vs. UC and CSLT vs. AC. AC vs. UC is presented for completeness.
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The incidence of serious adverse events
The incidence of SAEs based on the treatment-as-received principle is summarised in Table 19. The
number of participants who experienced any SAEs was 18 (15.8%) in the UC group, 11 (13.9%) in the
AC group and nine (10.6%) in the CSLT group. The total number of repeated SAEs was 23, 12 and 10
in the UC, AC and CSLT groups, respectively, which were experienced over a total follow-up of 105.4,
74.7 and 84.7 person-years, respectively. The incidence of SAEs was low across interventions such that
participants would need to be followed up for a longer duration to record a single event per participant on
average. For instance, the IR in the CSLT group was 0.11 (95% CI 0.04 to 0.19), meaning that, on average,
a participant will need to be followed up for about 10 person-years to record one SAE. Although the risk of
experiencing any SAEs was lower in the CSLT group than in either the UC group or the AC group, there is
insufficient evidence to suggest differences in risk between groups. All SAEs were not related or unlikely
to be related to the trial activity and the majority resulted in inpatient hospitalisation.
TABLE 19 Incidence of SAEs (treatment as received)
SAE
classification UC (N= 114) AC (N= 79) CSLT (N= 85)
IRR (95% CI)
CSLT vs. UCa CSLT vs. ACb AC vs. UCa
Had experienced
at least one SAE,
n (%)
18 (15.8) 11 (13.9) 9 (10.6)
Repeated SAEs
All SAEs
Total events/
person-years
23/105.4 12/74.7 10/84.7
IR/person-year
(95% CI)
0.23
(0.11 to 0.34)
0.16
(0.06 to 0.26)
0.11
(0.04 to 0.19)
0.51
(0.22 to 1.19)
0.72
(0.28 to 1.87)
0.70
(0.31 to 1.59)
SAE resulted in inpatient hospitalisation (n)
No 4 1 0
Yes 19 11 10
SAE was life-threatening (n)
No 14 8 7
Yes 9 4 3
Expected
No 21 12 9
Yes 1 0 1
Not stated 1 0 0
Relationship to trial activity (n)
Unlikely 1 2 2
Unrelated 22 10 8
Frequency of SAE (n)
Isolated 16 9 7
Intermittent 2 1 0
Continuous 3 0 0
Unknown 2 2 3
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TABLE 19 Incidence of SAEs (treatment as received) (continued )
SAE
classification UC (N= 114) AC (N= 79) CSLT (N= 85)
IRR (95% CI)
CSLT vs. UCa CSLT vs. ACb AC vs. UCa
Intensity of SAE (n)
Mild 3 1 1
Moderate 12 6 5
Severe 8 4 4
Missing 0 1 0
Outcome of SAE (n)
Recovered 10 3 4
Improved 3 3 1
Ongoing 5 5 3
Death 5 1 2
Action taken (n)
None 19 10 9
Reduce
intervention
1 0 0
Intervention
withdrawal
1 1 1
Other 2 1 0
a UC as the reference group.
b AC as the reference group.
Notes
Results are from a negative binomial regression model.
The comparisons of interest are CSLT vs. UC and CSLT vs. AC. AC vs. UC is presented for completeness.
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Table 20 presents the incidences of SAEs based on the strict ITT principle (treatment as randomised). 
In summary, although the incidence is now slightly higher in the CSLT group than in the AC or UC 
groups, the conclusion is similar to that based on results in Table 19 (using treatment as received). That
is, there is insufficient evidence to suggest differences in IRs of SAEs across interventions. Appendix 3, 
Table 29, shows the SAEs by treatment received in categories.
Conclusions
This chapter presented detailed trial results relating to the clinical effectiveness objectives. We explored
the impact of missing data and adherence to the intervention on the results as part of sensitivity analysis. 
In the spirit of good practice and transparency, the statistical analysis methods were pre-planned and 
documented in the SAP, which is accessible online (www.journalslibrary.nihr.ac.uk/programmes/hta/
122101/#). All post hoc analyses have been declared with rationale. The detailed statistical report is also
available online as a supplementary appendix to Palmer et al.50 A detailed discussion of the results with 
strength, limitations and implications are provided in Chapter 6.
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TABLE 20 Incidence of SAEs (treatment as randomised)
SAE classification UC (N= 101) AC (N= 80) CSLT (N= 97)
IRR (95% CI)
CSLT vs. UCa CSLT vs. ACb AC vs. UCa
Had experienced
at least one SAE,
n (%)
13 (12.9) 11 (13.8) 14 (14.4)
Repeated SAEs
All SAEs
Total events/
person-years
15/97.1 12/74.8 18/92.9
IR/person-year
(95% CI)
0.16
(0.06 to 0.25)
0.16
(0.05 to 0.26)
0.19
(0.09 to 0.30)
1.24
(0.56 to 2.76)
1.23
(0.52 to 2.88)
1.01
(0.42 to 2.43)
SAE resulted in inpatient hospitalisation (n)
No 3 1 1
Yes 12 11 17
SAE was life-threatening (n)
No 8 8 13
Yes 7 4 5
Expected (n)
No 13 12 17
Yes 1 0 1
Not stated 1 0 0
Relationship to trial activity (n)
Unlikely 0 2 3
Unrelated 15 10 15
Frequency of SAE (n)
Isolated 11 9 12
Intermittent 2 1 0
Continuous 1 0 2
Unknown 1 2 4
Intensity of SAE (n)
Mild 2 1 2
Moderate 7 6 10
Severe 6 4 6
Missing 0 1 0
Outcome of SAE (n)
Recovered 5 3 9
Improved 3 3 1
Ongoing 3 5 5
Death 4 1 3
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In summary, we demonstrated overwhelming evidence that the CSLT intervention improves the mean
ability of people with aphasia to retrieve vocabulary of personal importance in a confrontation naming
test (16.2%, 95% CI 12.7% to 19.6%; p < 0.0001) compared with UC. These results are strongly supported
by a 14.4% (95% CI 10.8% to 18.1%) average improvement in word-finding of personally selected words
in favour of CSLT compared with AC. Most importantly, the short-term effect of the intervention was
sustained in the long term, at 9 and 12 months after therapy has begun. However, on average, the
CSLT intervention for word-finding did not result in improvement in functional communication ability in
conversation or changes in perceived social participation in daily activities and quality of life in both the
short term and long term.
As for the additional research objectives, on average CSLT did not result in the improved generalisation of
treatment to the finding of untreated words. The intervention resulted in small short-term improvement
in carers’ perception of communication effectiveness, which could be of potential clinical relevance: mean
4.6% (95% CI 0.3% to 9.0%). However, the intervention failed to translate into meaningful impact on the
carers’ reported quality of life based on the perceptions of the carers who were available and agreed to
take part in the trial.
As for safety objectives, the incidences of AEs and SAEs were similar across interventions and were
generally low. The most negative effects of the computer therapy recorded by 27% of the CSLT
participants were feelings of overtiredness and anxiety.
TABLE 20 Incidence of SAEs (treatment as randomised) (continued )
SAE classification UC (N= 101) AC (N= 80) CSLT (N= 97)
IRR (95% CI)
CSLT vs. UCa CSLT vs. ACb AC vs. UCa
Action taken (n)
None 13 10 15
Reduce
intervention
0 0 1
Intervention
withdrawal
1 1 1
Other 1 1 1
a UC as the reference group.
b AC as the reference group.
Notes
Results are from a negative binomial regression model.
The comparisons of interest are CSLT vs. UC and CSLT vs. AC. AC vs. UC is presented for completeness.
Adapted from Palmer et al.50 This is an Open Access article distributed in accordance with the terms of the Creative
Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work,
for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.
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Chapter 5 Health economics
Health economic analysis: summary of key points
A summary of the key health economic findings is presented below to help orientate the reader to the
detailed explanation in the chapter:
l Our best estimates suggest that CSLT does not represent a cost-effective use of health-care resources
for the population included in Big CACTUS, given a cost-effectiveness threshold of £30,000 per
QALY gained. The base-case model-based cost-effectiveness analysis resulted in an ICER of £42,686
per QALY gained for CSLT compared with UC [incremental cost £732.73, 95% credible interval (CrI)
£674.23 to £798.05; incremental QALYs 0.017, 95% CrI –0.05 to 0.10] and an ICER of £40,164 per
QALY gained for CSLT compared with AC (incremental cost £694.59, 95% CrI £636.46 to £760.09;
incremental QALYs 0.017, 95% CrI –0.05 to 0.10). AC was dominated by UC. These ICERs are
higher than the NICE cost-effectiveness threshold of £20,000–30,000 per QALY gained. At a
cost-effectiveness threshold of £30,000 per QALY gained, the probability of CSLT representing
the most cost-effective option is 0.32, compared with 0.45 for UC and 0.22 for AC.
l We estimate that CSLT may represent a cost-effective use of health-care resources for people
with mild or moderate word-finding difficulty. The ICER for CSLT compared with UC was £22,371
per QALY gained in the mild word-finding difficulty subgroup (incremental cost £653.49, 95% CrI
£586.44 to £728.36; incremental QALYs 0.029, 95% CrI –0.06 to 0.17) and was £28,898 per QALY
gained in the moderate word-finding difficulty subgroup (incremental cost £822.77, 95% CrI £715.54
to £942.22; incremental QALYs 0.028, 95% CrI –0.10 to 0.22). The probability of CSLT, UC and AC
being cost-effective at a threshold of £30,000 per QALY gained was 0.34, 0.32 and 0.34, respectively,
in the mild word-finding subgroup, and was 0.41, 0.37 and 0.22, respectively, in the moderate
word-finding subgroup.
l The results of the economic analyses were highly sensitive to the approach used to estimate utility
scores. In our base case, we estimate utility scores using an unofficial accessible version of the
EQ-5D-5L. A more standard approach may have been to use utility scores collected by proxy from the
carers of trial participants. Using this approach, the ICER for the complete trial population reduced
from £42,686 per QALY gained to £28,819 per QALY gained for the comparison of CSLT and UC.
In this scenario, at a cost-effectiveness threshold of £30,000 per QALY gained, the probability of CSLT
representing the most cost-effective option was 0.42, compared with 0.39 for UC and 0.19 for AC.
l The cost of the CSLT intervention was low, and therefore very small increases in the estimated
QALY gain can have a large impact on the ICER.
l CSLT substantially increased the proportion of participants who achieved a ‘good response’, compared
with UC and AC, as defined by an increase of ≥ 10% in treated words of personal relevance named
correctly, or an increase of ≥ 0.5 points in the activity dimension of the TOMs rating scale. However,
the quality-of-life impact of a good response – as measured by the EQ-5D-5L– was small and highly
uncertain, to the extent that we are very uncertain about whether or not a good response results in
any improvement in quality of life. In the base case, the change in utility associated with achieving a
good response to treatment was not statistically significant at any of the 6-, 9- and 12-month time
points. At the 6- and 9-month time points, achieving a good response was associated with a statistically
non-significant reduction in utility; at 12 months, achieving a good response was associated with a
statistically non-significant increase in utility. These utility estimates are crucial determinants of the
results of the economic evaluation, but are highly uncertain, leading inevitably to highly uncertain cost-
effectiveness conclusions. In particular, although the CrI around the incremental QALY gain associated
with CSLT is reasonably narrow, it crosses zero. Given its low cost, only a small QALY gain is required in
order for CSLT to appear cost-effective, but we are uncertain about whether or not the intervention
leads to increased QALYs.
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l In the subgroup analyses, the change in utility associated with achieving a good response at
12 months was marginally higher in the mild and moderate word-finding difficulty subgroups
than in the severe word-finding difficulty subgroup, leading to more favourable cost-effectiveness
estimates. However, these utility improvements were also highly uncertain (and achieving a good
response was again associated with a statistically non-significant reduction in utility at earlier time
points), and therefore a high degree of uncertainty remains in the cost-effectiveness analyses of
these subgroups.
l Uncertain findings on the impact of CSLT on quality of life are consistent with findings on the
co-primary outcome of functional communication ability in conversation and the key secondary
outcome of patient perception of their communication and its impact on their life, for which CSLT
did not show an effect. Research into the translation of word-finding improvements to conversation
and other functional contexts that may lead to quality-of-life benefits may be valuable.
Background
Economic evaluation plays an important role in health technology assessment around the world, with
the aim of ensuring that limited health-care budgets are allocated efficiently. The trial was set in the
UK, where NICE produces guidance on clinical practice and the use of health technologies in the NHS.
NICE produces a Guide to the Methods of Technology Appraisal52 and the analyses presented here follow
that and other good-practice guides,52–56 supplemented with additional analyses that are not usually
considered by NICE (for instance, we present a supplementary analysis including volunteer costs,
representing a broader perspective than that associated with only NHS and PSS costs).
The objective of the health economic analysis is to evaluate evidence on the cost-effectiveness of self-
managed CSLT, AC and UC for patients with persistent aphasia post stroke. The population represents
that included in the Big CACTUS trial, and subgroup analyses were undertaken on the prespecified
trial subgroups (see Subgroup analysis for details). This work builds on a previous economic evaluation
conducted alongside the CACTUS study, a pilot study that led to the Big CACTUS trial.18
Overview of health economics methods
Health economics data on resource use, costs and health-related quality-of-life (HRQoL) scores
associated with the CSLT, AC and UC treatment groups were collected alongside the trial. The HRQoL
data were collected using the EQ-5D-5L, allowing QALYs to be calculated, and therefore a series of
cost–utility analyses were conducted, expressing results in terms of incremental cost per QALY gained.
For context, NICE usually considers interventions to represent a cost-effective use of NHS resources if
the ICER is less than £20,000–30,000 per QALY gained.52
The primary analysis consisted of a model-based analysis with a lifetime time horizon that adopted
an NHS and PSS perspective. This is in line with NICE requirements for interventions that may have
benefits and/or costs that persist beyond the duration of the clinical trial.52 We also present a secondary
within-trial analysis to illustrate the benefits/costs incurred within the trial duration, which avoids the
extrapolation necessary for the model-based analysis. In addition, owing to the importance of volunteers
who helped some participants with their use of the CSLT intervention in the Big CACTUS trial, we
present supplementary model-based and within-trial analyses that adopt a broader perspective, allowing
costs incurred by these volunteers to be incorporated. This does not represent a complete societal
perspective; for example, patient and carer time costs and costs related to participants’ own computers
were not included. However, given that volunteers were used to help implement the intervention,
it is useful to investigate how these costs might influence the economic evaluation.
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For all analyses, a fully incremental analysis was undertaken in which incremental costs and QALYs were
calculated for each of the three treatment options ranked by ascending cost. This allows all possible cost-
effectiveness comparisons to be made (i.e. CSLT vs. UC, CSLT vs. AC, AC vs. UC). However, the comparison
of primary interest for the economic evaluation is CSLT vs. UC, representing what are perceived to be the
two viable/most likely treatment options to be used in clinical practice.
Methods: model-based analysis (primary analysis)
Model design
A Markov model was developed to estimate the long-term cost-effectiveness of the CSLT intervention
for the primary analysis using Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, USA).
The structure of the model was adapted from a previous model developed alongside the pilot CACTUS
study.18 The previously developed model consisted of three health states:
1. aphasia
2. good response
3. dead.
Owing to the additional time points at which data were collected in the Big CACTUS trial, it was possible
to differentiate between responses achieved (or maintained) at the 6-, 9- and 12-month assessments.
Therefore, tunnel states (i.e. states in which participants cannot remain for more than one modelled
cycle) representing ‘good response (6 months)’ and ‘good response (9 months)’ were added to the
model. Whether or not a patient achieved a good response was based on the co-primary outcome
measures of the Big CACTUS trial: relating to change in word-finding ability and change in functional
communication in conversation (see Chapter 3, Word-finding of personally selected words for treatment and
Functional communication in conversation for descriptions of these measures). In the economic model,
participants moved into a ‘good response’ health state if they achieved the defined minimum change for
either one of these measures, where the minimum change was an increase of ≥ 10% in treated words
of personal relevance named correctly for the word-finding outcome, or an increase of ≥ 0.5 points
since baseline in the activity dimension of the TOMs rating scale for the functional outcome. Because
we do not differentiate between good responses depending on which of the co-primary outcome
measures the specified minimum improvement was achieved in, we assume that any person who meets
the ‘good response’ criteria experiences the same utility gain, irrespective of which outcome measure
improved for them.
The model used 3-month cycles. Figure 20 illustrates how participants could move through the model.
All participants began in the ‘aphasia’ health state. Participants could remain in the ‘aphasia’ health
state at 6 months, or transit to the ‘good response (6 months)’ or ‘dead’ health states. Participants in
the ‘good response (6 months)’ health state could transit to the ‘good response (9 months)’ health
state, relapse to the ‘aphasia’ health state or die. Participants in the ‘good response (9 months)’ health
state could transit to the ‘good response (12 months and beyond)’ health state, relapse to the ‘aphasia’
health state or die. No new responses could occur beyond 12 months; participants in the ‘aphasia’
health state at this time point could either remain in that health state or die, whereas participants in
the ‘good response (12 months and beyond)’ health state could remain in that health state, relapse to
the ‘aphasia’ health state or die.
The economic model evaluated the treatment groups included in the Big CACTUS trial, and so transitions
between health states included in the model were based on data from Big CACTUS, combined with
information on post-stroke mortality rates. For the first 5 years of the model, mortality rates were used
from a study of patients who had experienced a stroke ≥ 1 year previously.57 After 5 years, additional
mortality was applied based on Office for National Statistics life tables,58 taking into account the mean
age of the Big CACTUS trial participants. We assumed that which health state people resided in did not
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affect the probability of death, and therefore the same probability of death was applied to all health
states in the model. This means that we assumed that none of the treatment options under investigation
conveyed a survival advantage.
Participants moved into a good response health state if they reported an increase of ≥ 10% in treated
words of personal relevance named correctly between baseline and 6 months [or between baseline
and 9 or 12 months for the ‘good response (9 months)’ and ‘good response (12 months)’ health states,
respectively] or if they reported an increase of ≥ 0.5 points since baseline in the activity dimension
of the TOMs rating scale). Relapse rates between 6 and 9 months and between 9 and 12 months were
estimated by calculating the proportion of participants in the ‘Good response (6 months)’ and ‘Good
response (9 months)’ health states who did not retain that response at the following time point.
Beyond 12 months, the relapse rate was assumed to be equal to that observed between 9 and 12 months.
Health-related quality-of-life utility scores were applied to each health state, and costs were estimated
for each of the treatment options under investigation (see Health-related quality of life and Resource use
and costs). The utility scores applied to each health state were reduced over time to account for ageing
according to multipliers estimated by Ara and Brazier,59 and QALYs were estimated for each cycle of
the model by combining utility scores with life-years, allowing the total QALYs associated with each
treatment strategy to be calculated. QALYs were discounted at a rate of 3.5% each year, in line with
recommendations made by NICE.52
The model structure requires that we assume that patients who reside within the same health state
have the same utility score, regardless of their pathway into that health state. Hence, for example, a
new responder at 12 months has the same utility score as someone who responded at 6 months and
remained in the good response health state. Similarly, someone who responds and then relapses has
the same utility score as someone who never responded. This is a simplification, but modelling further
detail would have required additional health states, which would have resulted in estimating utility
scores for some health states based on extremely small patient numbers. We believe that our model
structure captures the key health states most relevant to the research question.
Health-related quality of life
Big CACTUS trial participants were asked to complete an accessible version of the EQ-5D-5L questionnaire
at each of the data collection time points (baseline and 6, 9 and 12 months). An accessible version of the
EQ-5D-3L questionnaire was trialled in the CACTUS pilot study.18 Although accessible versions of the
EQ-5D-3L and EQ-5D-5L questionnaires have not been validated, they represent a way in which utility
DeadAphasia
Good response
(6 months)
Good response
(9 months)
Good response
(12 months and
beyond)
FIGURE 20 Markov model structure. Navy-coloured health states represent tunnel states.
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(HRQoL) scores can be elicited directly from people with aphasia, whose language difficulties may make
it difficult to complete standard EQ-5D-5L questionnaires.60,61 The accessible version of the EQ-5D-5L
used in Big CACTUS is available online (see www.journalslibrary.nihr.ac.uk/programmes/hta/122101/#/)
and is described in Whitehurst et al.61 Where applicable, carers of Big CACTUS trial participants were
asked to complete a standard EQ-5D-5L questionnaire by proxy at each of the data collection time
points. Carers were also asked to complete a standard EQ-5D-5L for themselves at each time point,
to investigate potential HRQoL impacts on carers. In line with Al-Janabi et al.,62 utility scores from the
EQ-5D-5L were used to investigate carer utility.
The EQ-5D-5L represents the standard questionnaire used to calculate utilities adopted by NICE.52
When the EQ-5D-5L was developed, it was anticipated that this would replace the EQ-5D-3L and
hence the five-level version was used in the Big CACTUS trial. Indeed, NICE supports sponsors of
prospective clinical studies using the five-level version.48,52 However, the English tariff for the EQ-5D-5L
published in 2016 is not currently recommended for use in a NICE economic evaluation (but may be
recommended in future).48,52,63 Instead, NICE currently recommends converting EQ-5D-5L responses to
utility scores using the UK cross-walk mapping algorithm developed by van Hout et al.49 in 2012. This
algorithm maps EQ-5D-5L responses onto the EQ-5D-3L tariff in order to generate utility scores. Given
the preference for patient-elicited utility scores,52 and evidence suggesting suboptimal proxy assessments
of utility in the context of stroke,64 utility scores calculated using the accessible version of the EQ-5D-5L
and the van Hout et al.49 mapping algorithm were used in our ‘base-case’ analysis. Several secondary
analyses were conducted using:
l the standard EQ-5D-5L questionnaire completed by proxy by carers of participants
l EQ-5D-5L scores calculated using the English EQ-5D-5L tariff,47 with no mapping
l an alternative mapping algorithm developed by Hernandez-Alava et al.,63,65 converting EQ-5D-5L
responses to EQ-5D-3L utility scores.
In addition, a secondary analysis was carried out in which QALYs associated with carers were
estimated from their self-reported EQ-5D-5L scores and incorporated into the analysis.
In our base-case analysis, MI was used to impute EQ-5D-5L utility scores where data were missing.
Predictive mean matching using Stata version 1538 was used to impute missing values of EQ-5D-5L
scores at baseline and at the 6-, 9- and 12-month follow-up time points.66 An estimate for the missing
values was obtained for 10 imputed data sets based on recommendations made in the literature,41
and Rubin’s67 framework was used to combine these estimates across imputed data sets to produce an
overall averaged estimate. The imputation models were adjusted for variables that were considered to
be potentially prognostic for the participant’s health status and for which there were full data. These
variables were the participant’s treatment group assignment (UC/AC/CSLT), the participant’s age and
the participant’s gender. EQ-5D-5L scores for the patients who died during the course of the trial were
imputed as zero values after the patient’s death. Patients who died were excluded from the analyses
estimating the change in utility between responders and non-responders. A secondary ‘complete-case’
analysis was conducted, which did not impute missing EQ-5D-5L data.
Using the EQ-5D-5L data collected in the trial, we estimated utility scores associated with the ‘aphasia’,
‘good response (6 months)’, ‘good response (9 months)’ and ‘good response (12 months)’ health states.
The utility score associated with the ‘aphasia’ health state was the mean score across all Big CACTUS
participants at baseline. To estimate the impact of achieving a good response on utility scores, we
calculated the change in utility score between baseline and the 6-, 9- and 12-month time points for
responders and non-responders. By comparing changes in utility score since baseline, we were able to
control for differences in baseline utilities that may have existed between participants who subsequently
responded and participants who did not.
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Resource use and costs
Only costs directly related to the intervention associated with each treatment option were included
in the economic evaluation. The pilot CACTUS study collected data on a wide range of resource use
(such as medication, primary care and hospital care) but did not show important differences associated
with the CSLT intervention with respect to these.18 This led to the decision not to collect such data
in the Big CACTUS trial, and not to include these costs in the economic evaluation. Related to this, it
was assumed that the CSLT and AC treatment options were provided in addition to UC, and that UC
would not differ between treatment options. This is because we were evaluating therapy delivered by
computer in addition to UC received, rather than instead of UC. Given this, the cost over and above UC
associated with the UC-only treatment option in the economic model was zero. For further information
on the UC actually received during the Big CACTUS trial period, see Chapter 2, Usual-care control group.
For the CSLT and AC treatment options, the costs associated with delivering these treatments were
estimated. Costing was based on the standard approach used in economic evaluations following the
three-stage process: identification of resource use, measurement and valuation.54
Identification of resource use
The following resources used (costs) were identified for the CSLT treatment option:
l computers/tablets
l the StepByStep computer software
l headset microphones for use with the computer software
l SLT time, related to –
¢ initial training
¢ senior SLT facilitating training on the CSLT intervention
¢ SLTs receiving training from a senior SLT to deliver the CSLT intervention
¢ delivery of the intervention
¢ SLTs supporting/training SLTAs and volunteers
¢ Setting up and personalising/tailoring the computer and software for each participant
¢ SLT providing technical support to participants
¢ SLT monitoring participant progress
l SLTA time, related to –
¢ delivery of the intervention
¢ SLTA receiving training/support from a SLT
¢ setting up the computer/microphone
¢ encouraging the participant
¢ assisting with word-finding practice with the software
¢ conversations to practise words
l volunteer time, related to –
¢ delivery of the intervention
¢ volunteer receiving training/support from a SLT
¢ setting up the computer/microphone
¢ encouraging the participant
¢ assisting with word-finding practice with the software
¢ conversations to practise words
l travel costs of SLTs, SLTAs and volunteers when visiting the houses of participants to support
the intervention
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The following costs were identified for the AC group:
l cost of puzzle books
l cost of SLT time spent supporting the AC intervention (a research assistant provided this support
during the trial but if the intervention was to be continued in routine clinical practice we assumed
that it would be supported by newly qualified SLT or experienced SLTA).
Measurement of resource use
The proportion of CSLT participants who needed to borrow a computer and the proportion who needed
headsets were recorded. SLT resource use associated with training on how to use the StepByStep
software was based on the number of training workshops held, their length, the average number of
SLTs who attended, and time spent by the facilitator, combined with assumptions on how these training
sessions would be conducted in reality. For instance, we assumed that in reality training sessions would
be held for up to 15 SLTs at a time and that the training would remain beneficial for a 10-year period.
This allowed a per-patient cost associated with training to be estimated. Resource use associated with
SLTs, SLTAs and volunteers related to the delivery of the intervention and travel costs were measured
using activity logs completed by SLTs, SLTAs and volunteers. In these logs, distance travelled for each
participant contact was recorded, as was time in minutes per participant related to each of the activity
categories listed above.
Valuation of resource use
The Personal Social Services Research Unit (PSSRU) Unit Costs of Health and Social Care 201768 were
used to place values on time associated with SLT, SLTA and volunteer resource use, with a cost year of
2016/17. We assumed that a SLT at band 7 would facilitate initial training on the StepByStep software,
and that band 6 SLTs would mainly deliver the CSLT intervention. SLTAs were assumed to be at band 3,
and volunteers were allocated the same unit cost as SLTAs in recognition that they were providing a
similar service. SLT costs associated with delivering the AC intervention were costed at band 5.
Volunteer costs were included only when the economic evaluation was conducted from a broader
perspective. Unit costs associated with each staff type are presented in Appendix 6.
The cost of computers for those who required them was based on the average cost of a laptop/tablet
purchased through the NHS in Big CACTUS (£690). We assumed that these computers would have a
shelf life of approximately 5 years, and that they could be used by 10 people over this time (given the
6-month duration of the CSLT intervention), resulting in a per-participant cost of £69. StepByStep
software costs were based on those charged by the manufacturer.20 Travel costs were based on UK
Government cost-per-mile estimates for business travel,69 and costs associated with the puzzle books
used in the AC treatment group were based on the average cost per book incurred in the Big CACTUS
trial. All unit costs are presented in Appendix 6.
Addressing uncertainty
Distributions were placed around each of the uncertain parameters included in the model (i.e. transition
probabilities, utility scores, resource use/costs) for use in probabilistic sensitivity analysis, which allows
the uncertainty in all of the modelled parameters to be characterised and permits the estimation of
cost-effectiveness acceptability curves (CEACs). The probabilistic sensitivity analysis incorporated
10,000 realisations of the model. Gamma distributions were used for resource use/cost parameters,
a beta distribution was used for the ‘aphasia’ health state utility combined with normal distributions
around utility changes associated with a ‘good response’, and beta distributions were used for probabilities,
with dispersions based on numbers observed in the trial. We also undertook expected value of perfect
information (EVPI) analysis. The value of information framework allows the maximum value of further
research to be estimated, taking into account the uncertainty in the parameters included in the
economic model.70,71 EVPI was assessed using the Sheffield Accelerated Value of Information tool,72
assuming a cost-effectiveness threshold of £20,000 per QALY gained (based on NICE decision rules52)
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over a period of 10 years (assuming that it might take 10 years before a new treatment for these
patients is developed), using a 3.5% discount rate.
Deterministic sensitivity analyses were undertaken using various alternative techniques for estimating
utility scores (see Health-related quality of life) and additional scenario analyses were conducted to
investigate the impact of different assumptions around the cost of the computer program used by the
CSLT intervention. For ease of reference, all secondary analyses are listed in Table 21.
Subgroup analysis
Cost-effectiveness was investigated in the prespecified subgroups detailed in Chapter 3, Subgroup
evaluation:
l Groups with differing severities of word-finding difficulty at baseline, identified using scores
from the CAT Naming Objects. Severity was categorised as mild (31–43), moderate (18–30) or
severe (5–17).
l Groups with differing impairments in their comprehension ability at baseline as assessed by the CAT
Comprehension of Spoken Sentences. Severity was categorised by scores as normal (27–32), mild
(18–26), moderate (9–17) or severe (0–8).
l Groups based on the time that had elapsed following the patient’s stroke, which were categorised
into quantiles ranging from the 25% of patients who entered the trial closest to their stroke to the
25% who had had their stroke longest ago.
TABLE 21 Addressing uncertainty: secondary analyses
Secondary analysis
number Analysis details
1 Complete-case analysis: no imputation for missing EQ-5D-5L data
2 English EQ-5D-5L tariff47 analysis: use tariff directly, with no mapping
3 Carer proxy: using utility scores reported by carers on behalf of patients
4 Alternative EQ-5D-5L mapping algorithm: using Hernandez-Alava et al.63
5 Carer QALYs: including impact on carer HRQoL
6 All CSLT participants borrow a computer and use a clinician StepByStep licence
7 All CSLT participants use their own computer and an individual StepByStep licence
8 75% of CSLT participants use their own computer and an individual StepByStep licence,
25% borrow a computer and use a clinician licence
9 £120 is paid for a 6-month individual StepByStep licence, rather than £250 for a lifetime
licence, reflecting a new payment option
10 Zero cost of StepByStep licence. This is to demonstrate the sensitivity of the cost-effectiveness
results to the price of the computer software
11 Zero SLT and SLTA costs. This is to demonstrate the sensitivity of the cost-effectiveness results
to costs associated with SLTs and SLTAs
12 Halved SLT and SLTA costs. This is to demonstrate the impact of halving the costs associated
with SLTs and SLTAs on the cost-effectiveness results
13 Each intervention group participant received 28 additional hours of face-to-face word-finding
therapy from a band 6 SLT instead of 28 additional hours (mean average) delivered by the
computer approach. This is to give an idea of the relative cost and cost-effectiveness of the
same intervention being provided face to face assuming that it would result in the same
outcomes as the CSLT approach for the delivery of word-finding therapy
14 Broader perspective: including costs incurred by volunteers
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Methods: within-trial analysis (secondary analysis)
The within-trial economic evaluation was undertaken using individual patient-level data collected
within the Big CACTUS trial. The analysis was completed using Stata version 15.38 Utility scores, based
on EQ-5D-5L responses, were calculated for participants at baseline and 6, 9 and 12 months. Utility
scores for patients who died during the course of the trial were set to zero values after the patient’s
death. The utility scores at baseline and all follow-up time points were then combined with time
for calculating the individual patient-level QALYs using the trapezium rule. As for the model-based
analysis, the ‘base-case’ within-trial analysis used utility scores estimated using the accessible EQ-5D-5L
questionnaire and the van Hout et al.49 mapping algorithm, with MI as described in Model inputs:
health-related quality of life used for missing values.
The costs included in the within-trial analysis were the same as those included in the model-based
analysis, with the exception of the costs associated with training SLTs on how to use the StepByStep
software. In the within-trial analysis, this cost reflected exactly what happened in the trial, whereby
small numbers of SLTs were trained at a time as soon as research and development permissions were
granted for individual sites to begin recruitment. In the model-based analysis, we made slight adjustments
to reflect what we would expect to happen in reality (we would expect more SLTs to attend fewer training
sessions than provided in the trial because research and development permissions would not be relevant).
Differences between costs and QALYs in the three treatment groups were estimated over the 12-month
trial period using seemingly unrelated regression (SUR).56 SUR allows for correlation between costs and
utility data,56,73 and has been used in various trial-based cost-effectiveness analyses.74,75 The SUR model
was specified to adjust for baseline EQ-5D-5L values as suggested by Manca et al.55
Uncertainty in the within-trial analysis was explored through the non-parametric technique of bootstrapping
to produce 1000 simulations of randomly matched pairs of trial participants (one in the intervention
group and one in the control group), from which 1000 ICERs were then calculated.66 Cost-effectiveness
planes and CEACs were subsequently generated from the 1000 simulations to illustrate the probability
of the CSLT intervention being cost-effective. Discounting was not applied to cost and QALY estimates
used in the within-trial analysis because the time horizon of the within-trial analysis was 12 months.
Secondary analyses 1–5 and 14 listed in Table 21 and the subgroup analyses described in Subgroup
analysis were conducted for the within-trial analysis. Secondary analyses 6–13 listed in Table 21 were
not conducted for the within-trial analysis because these represent hypothetical scenarios that do not
represent what happened in the trial period.
Results
The long-term model-based analysis results are presented in Model-based analysis. First model input
values for transition probabilities, HRQoL and resource use are described based on the Big CACTUS
data. Then the model results are presented for the base-case, secondary and subgroup analyses.
Results from the within-trial analysis are presented in Within-trial analysis.
Model-based analysis
Model inputs: transition probabilities
Transition probabilities between the ‘aphasia’ health state and the ‘good response’ health states were
based on response rates observed in Big CACTUS. The probability of achieving a good response at
6 months was 0.78 in the CSLT group, compared with 0.46 in the UC group and 0.49 in the AC group.
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The probabilities of new responses between 6 and 9 months and between 9 and 12 months were similar
between groups (0.33 and 0.39, respectively, for CSLT; 0.37 and 0.37, respectively, for UC; and 0.35 and
0.19, respectively, for AC). Relapse rates between 6 and 9 months and between 9 and 12 months were
slightly lower in the CSLT group (0.19 and 0.08, respectively) than in the UC (0.22 and 0.22, respectively)
and AC groups (0.28 and 0.19, respectively). Parameter values, distributions and CIs for all transition
probabilities included in the model are presented in Table 22.
Brønnum-Hansen et al.57 analysed long-term data on the annual risk of death after stroke. They estimated
that after 1 year since stroke the annual risk of death remains approximately constant at 10%.
In Big CACTUS, the mean time since stroke was 2.99 years, and hence the 10% risk estimated by
Brønnum-Hansen et al.57 is relevant. This mortality rate was applied to all health states in the model up
to year 6, at which point an additional risk of death due to increasing age was added based on mortality
data from the Office for National Statistics58 and the age and gender split observed in Big CACTUS. This
ensured that mortality rates in the model always remained higher than those observed in the age- and
gender-matched background population. Notably, Wolfe et al.76 also present information on long-term
outcomes in people who have had a stroke, in a sample collected in London, with people followed up for
up to 10 years. The sample size 1 year after stroke was approximately 1000 smaller than that reported
by Brønnum-Hansen et al.57 but results were very similar. The authors provide details of the number of
patients followed up annually and the number who died in each 1-year period. These numbers indicate
an annual hazard of death of approximately 10% beyond 1 year after stroke. This provides confidence
that the mortality rates included in our model are reasonable.
Model inputs: health-related quality of life
The mean baseline utility score across all Big CACTUS participants was 0.61, using MI for missing data,
and using the van Hout et al.49 mapping algorithm. Appendix 7 shows the proportion of complete data for
the EQ-5D-5L questionnaires collected during Big CACTUS. Completion rates were high for the accessible
EQ-5D-5L measure and therefore low levels of imputation were required for the base-case analysis.
The change in utility score associated with each response state compared with baseline is presented
in Table 23, together with the distribution placed around this value in the economic model. Importantly,
it can be seen that at 6 and 9 months achieving a good response was associated with a marginal
reduction in utility score, whereas at 12 months the difference was positive. All of these estimates
were highly uncertain and were not statistically significant.
Similar patterns in utility scores were found when the alternative valuation techniques were used, as
shown in Appendix 8. Notably, the baseline utility score was significantly lower based on carer proxy
questionnaires, but changes in utility associated with response were similarly marginal.
Model inputs: resource use and costs
The cost associated with the CSLT intervention was estimated to be £728.50 in the base-case analysis,
compared with £37.70 for AC and £0.00 for UC. Costs in the CSLT group increased to £785.33 when a
broader perspective was taken, including costs incurred by volunteers. Details on the breakdown of
resource use and cost categories are presented in the following sections.
Hardware and software costs
The majority (66/97, 68%) of CSLT participants needed to borrow a computer to take part in Big
CACTUS. In addition, 32 out of 97 (33%) needed headsets to be provided. Hence, hardware costs for
the CSLT group were £51.73 per participant (£69 × 0.68 for computers; £14.50 × 0.33 for headsets).
AC participants used 4.35 puzzle books on average, resulting in a per-patient hardware cost of £10.89
(£2.50 × 4.35) for the AC group.
We assumed that the 32% of CSLT participants who used their own computers used individual
StepByStep software licences, amounting to a per-patient cost of £79.90 (£250 × 0.32). We assumed
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TABLE 22 Model parameters: transition probabilities
Parameter
CSLT UC AC
SourceMean
Distribution
(alpha, beta) Logit 95% CI Mean
Distribution
(alpha, beta) Logit 95% CI Mean
Distribution
(alpha, beta) Logit 95% CI
Probability of good response
(0–6 months)
0.78 Beta (73, 21) 0.67 to 0.85 0.46 Beta (45, 52) 0.36 to 0.56 0.49 Beta (49, 40) 0.38 to 0.60 Big CACTUS
Probability of relapse (6–9 months) 0.19 Beta (14, 59) 0.11 to 0.30 0.22 Beta (10, 35) 0.12 to 0.37 0.28 Beta (11, 28) 0.15 to 0.44 Big CACTUS
Probability of new good response
(6–9 months)
0.33 Beta (7, 14) 0.15 to 0.57 0.37 Beta (19, 33) 0.24 to 0.51 0.35 Beta (14, 26) 0.21 to 0.51 Big CACTUS
Probability of relapse (9–12 months) 0.08 Beta (5, 61) 0.03 to 0.17 0.22 Beta (12, 42) 0.12 to 0.35 0.19 Beta (8, 34) 0.09 to 0.34 Big CACTUS
Probability of new good response,
or renewed response in people who
responded at 6 months and relapsed
at 9 months (9–12 months)
0.39 Beta (11, 17) 0.22 to 0.59 0.37 Beta (16, 27) 0.23 to 0.53 0.19 Beta (7, 30) 0.08 to 0.36 Big CACTUS
Probability of relapse (12 months
onwards)
0.08 Beta (5, 61) 0.03 to 0.17 0.22 Beta (12, 42) 0.12 to 0.35 0.19 Beta (8, 34) 0.09 to 0.34 Big CACTUS
Probability of death (annual) 0.10 Beta (233, 2203) 0.09 to 0.11 0.10 Beta (233, 2203) 0.09 to 0.11 0.10 Beta (233, 2203) 0.09 to 0.11 Brønnum-Hansen
et al. (2001)57
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3
that the 68% of CSLT participants who borrowed computers had clinician licences, and assumed that
these were bought through the clinician five-licence bundle offered by the StepByStep manufacturer.
We assumed that the software had a lifetime of 10 years, and that, although it was feasible that two
patients per year could use a licence (for 6 months each), the utilisation rate would be approximately
50%. Thus, 10 patients could benefit from each clinician licence over the lifetime of the product at a
per-patient cost of £44 [(£2200/5)/10], amounting to a per-patient cost of £29.94 (£44 × 0.68). The
combined per-patient cost of the StepByStep software, taking into account individual and clinician
licence costs, was therefore estimated to be £109.84 (£79.90 + 29.94). Hence, we assumed that CSLT
participants treated with an individual StepByStep licence would retain that licence for their lifetime
(as individual licences cannot be transferred), whereas participants treated with a clinician licence
would retain the licence for only 6 months before it is passed on to the next participant, given that the
Big CACTUS trial investigated 6 months’ usage of CSLT. Appendix 9 presents details on the computer
and software costs associated with scenarios 6 to 10 (for description of scenarios, see Table 21).
Notably, any scenario that reduces the combined computer plus software cost may also reduce the
time for which a patient has access to the computer program, which may affect long-term outcomes.
Uncertainty in hardware and software costs was characterised in the probabilistic sensitivity analysis
by placing distributions around proportions of participants who required computers (and therefore
those who were treated with individual/clinician licences), the utilisation rate of clinician software
licences and the number of puzzle books used (see Appendix 11).
Speech and language therapist training costs
Eight 4-hour sessions were held to train 27 SLTs on the use of the StepByStep software. The facilitators
estimated that they spent a total of 14 hours preparing for these sessions, with the majority of that
time spent preparing for the first session. This amounted to a total of 46 hours of facilitator time and
108 hours of SLT (i.e. trainee) time. Ninety-seven CSLT participants benefited from this training over
the 21-month trial period (the recruitment period was 15 months and the intervention period was
6 months). We estimated that the training would remain beneficial for 10 years and that 554 patients
[(97 × 12/21) × 10] could therefore benefit from the training over that time period. This resulted in a
cost per patient associated with this training of £13.25. In reality, we assumed that only two training
sessions would be held to train 27 SLTs, reducing facilitator time to 16 hours (8 hours of training plus
8 hours of preparation). This reduced the per-patient cost estimate to £10.33, which was used in the
model-based analysis. In reality, more than 97 participants might benefit from the training in each
21-month period, which would reduce the per-patient cost further. Although we believe that this
costing may be conservative, the cost is very low and makes up only a small part of the intervention
cost. The uncertainty around speech and language therapy training costs was characterised in the
economic model by placing a gamma distribution around the number of patients who could benefit
annually from the training (see Appendix 11).
TABLE 23 Model parameters: utility scores (accessible EQ-5D-5L)
Parameter Mean Distribution (alpha, beta) 95% CI
Utility score (aphasia health state) 0.61 Beta (650.36, 407.99) 0.59 to 0.64
Difference in utility score associated with Mean Distribution (standard error) 95% CI
Good response (6 months) –0.04 Normal (0.03) –0.09 to 0.01
Good response (9 months) –0.02 Normal (0.03) –0.07 to 0.03
Good response (12 months) 0.02 Normal (0.03) –0.03 to 0.07
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Speech and language therapist, speech and language therapy assistant and
volunteer time costs
Per-patient time and associated costs incurred by SLTs, SLTAs and volunteers on the tasks described in
Resource use and costs are presented in Appendix 10. Note that costs incurred by volunteers are not
included in the base-case analysis. Costs associated with SLTs and SLTAs in the CSLT treatment group
totalled £499.22 per patient, more than three times higher than the costs associated with the CSLT
computer hardware and software; thus, SLT/SLTA time represents by far the largest cost component
of the CSLT intervention. Most SLT time (5.77 hours per patient) was spent setting up the computer
software. Costs associated with volunteer time (which are not included in the base-case analysis) were
low, totalling £46.22 per CSLT patient. SLT/SLTA costs in the AC group were also low, at £27.29 per
patient. Travel costs contributed a further £57.38 to costs incurred by SLTs/SLTAs and £10.61 to costs
incurred by volunteers in the CSLT group. Uncertainty around the costs associated with SLT, SLTA and
volunteer time was characterised in the economic model by placing distributions around the mean total
hours incurred in each of the categories presented in Appendix 10 (see Appendix 11).
Characterising uncertainty
The hardware and software costs, SLT training costs, SLT, SLTA and volunteer time costs and travel
costs detailed above are all estimated with uncertainty. Appendix 11 presents the resource use model
parameters that were fitted with distributions to characterise their uncertainty. These were combined
with unit costs presented in Appendix 6 and summed to calculate the costs associated with the CSLT
and AC treatment options.
Model inputs: subgroup analyses
Parameter values for transition probabilities, utilities and resource use are presented for all model
parameters for the subgroup analyses in Appendix 12.
Model results: base case
The model-based long-term cost-effectiveness results (primary analysis) are presented in Table 24.
The results presented are probabilistic rather than deterministic. This means that they represent the
average of 10,000 runs of the model, in which values for the model parameters are randomly drawn
from their specified distributions (as defined in Tables 22 and 23 and Appendix 11, Table 35, for
transition probabilities, utilities and resource use, respectively). This explains the slight difference in
costs estimated compared with the deterministic figures presented in Model inputs: resource use and
costs. We estimate an incremental cost per patient of £732.73 (95% CrI £674.23 to £798.05) for
CSLT compared with UC, and of £694.59 (95% CrI £636.46 to £760.09) for CSLT compared with AC.
TABLE 24 Model-based results: base-case analysis
Analysis Outcome Intervention Comparator Difference in mean
CSLT vs. UC Costs (£) 732.73 0.00 732.73 (95% CrI 674.23 to 798.05)
QALYs 4.2164 4.1992 0.0172 (95% CrI –0.05 to 0.10)
ICER £42,686 per QALY gained
CSLT vs. AC Costs (£) 732.73 38.14 694.59 (95% CrI 636.46 to 760.09)
QALYs 4.2164 4.1991 0.0173 (95% CrI –0.05 to 0.10)
ICER £40,164 per QALY gained
AC vs. UC Costs (£) 38.14 0.00 38.14 (95% CrI 34.94 to 41.50)
QALYs 4.1991 4.1992 –0.0001 (95% CrI –0.02 to 0.02)
ICER Dominated
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We estimated incremental QALY gains per patient of 0.0172 (95% CrI –0.05 to 0.10) for CSLT compared
with UC, and of 0.0173 (95% CrI –0.05 to 0.10) for CSLT compared with AC. These result in estimated
ICERs of £42,686 per QALY gained for CSLT compared with UC, and of £40,164 for CSLT compared
with AC. We estimate that AC is dominated by UC as it is costlier and provides fewer QALYs.
Figures 21–23 depict the cost-effectiveness planes for the comparisons of CSLT vs. UC, CSLT vs. AC and
AC vs. UC, respectively. Plots are presented on the same axis scales to aid comparability. These illustrate
the results of the model for each of the 10,000 realisations run in the probabilistic analysis, and
therefore illustrate the degree of uncertainty associated with the results. The figures show considerable
dispersion across the x-axis for all three comparisons, reflecting the high level of uncertainty associated
with the estimation of incremental QALYs. It is clearly highly uncertain as to which treatment option is
likely to result in the most QALYs gained; for instance, CSLT is estimated to result in more QALYs than
UC in 69% of the realisations of the model. There is less uncertainty around costs, demonstrated by a
much narrower dispersion across the y-axis.
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FIGURE 21 Cost-effectiveness plane: base-case analysis – CSLT vs. UC.
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FIGURE 22 Cost-effectiveness plane: base-case analysis – CSLT vs. AC.
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Figure 24 presents the CEAC for the base-case analysis, illustrating the probability of each strategy
representing the most cost-effective use of resources for a range of cost-effectiveness thresholds
(i.e. the threshold of willingness to pay for an additional QALY). Assuming a cost-effectiveness threshold
of £20,000 per QALY gained, the treatment option with the highest probability of representing the most
cost-effective strategy is UC, with a probability of 0.56. CSLT and AC both have a probability of 0.22
of representing the most cost-effective strategy at this threshold. At a cost-effectiveness threshold of
£30,000 per QALY gained, the probability of UC representing the most cost-effective option is 0.45,
compared with 0.32 for CSLT and 0.22 for AC. Hence, although CSLT was estimated to result in the
greatest number of QALYs in the majority of the realisations of the model, it provided an ICER of below
£20,000–30,000 per QALY gained in a minority of realisations.
The results of the EVPI analysis is presented in Appendix 13. We estimated a population-level EVPI of
£34.6M. The utility difference associated with a good response at 12 months was the most important
parameter in the model, and obtaining perfect information on this parameter was valued at £20.4M at
the population level. Hence, if further research was planned, it should be targeted at obtaining further
information on this parameter.
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FIGURE 23 Cost-effectiveness plane: base-case analysis – AC vs. UC.
0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
10 20 30 40 50
Cost-effectiveness threshold (£000 per QALY)
P
ro
b
ab
ili
ty
 t
h
at
 t
re
at
m
en
t 
is
 t
h
e
m
o
st
 c
o
st
-e
ff
ec
ti
ve
 o
p
ti
o
n
UC
AC
CSLT
FIGURE 24 Cost-effectiveness acceptability curve: base-case analysis.
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Model results: secondary analyses
Appendix 14 presents results from the 14 secondary analyses undertaken (see Table 21). The secondary
analyses that investigated alternative costing assumptions (i.e. analyses 6–9) did not result in substantially
different estimates of cost-effectiveness. Similarly, conducting the analysis from a broader perspective
(including volunteer costs) made little difference, with the ICER increasing slightly to £44,279 per QALY
gained for CSLT compared with UC, because volunteer costs were relatively low and affected only the
CSLT treatment option. Secondary analyses 10–13 resulted in some more substantial changes in the ICER.
Analysis 10 demonstrated that, even if the computer software had zero cost, the ICER would be £36,081
per QALY gained for CSLT compared with UC, because software costs made up a relatively small part
of the total intervention cost. In contrast, analysis 11 showed that, if software costs remained the same
as in the base-case analysis, but SLT and SLTA costs were zero, the ICER would reduce to £9619 per
QALY gained compared with UC. Analysis 12 showed that if software costs remained the same as in the
base case, but SLT and SLTA costs were halved, the ICER for CSLT compared with UC would be £26,153
per QALY gained. Analysis 13 aimed to demonstrate the relative cost-effectiveness of the same word-
finding intervention delivered face to face rather than via computer software, if the average time that
CSLT participants spent doing therapy with the StepByStep computer program (28 hours) was instead
delivered face to face by a SLT. Such face-to-face delivery would be appreciably more expensive (with
costs approximately double those of the CSLT approach to delivery). Assuming the same effectiveness
as the CSLT delivery, face-to-face delivery of additional hours of repetitive word-finding practice would
almost certainly not be regarded as cost-effective compared with UC, with an ICER of £78,068.
Cost-effectiveness estimates varied much more substantially in secondary analyses 1–5, which investigated
alternative techniques for estimating the QALYs associated with the three treatment options. This further
highlights that it is the utility score estimates that represent the key uncertainty in the economic
evaluation of the CSLT intervention. Based on a complete-case analysis, the ICER fell to £28,248 per
QALY gained, and, importantly, an analysis using utility scores provided by carers by proxy resulted in
an ICER of £28,819 per QALY gained for CSLT compared with UC. Using the utility scores provided by
carers by proxy, at a cost-effectiveness threshold of £30,000 per QALY gained, the probability of CSLT
representing the most cost-effective option was 0.42, compared with 0.39 for UC and 0.19 for AC.
Using the Hernandez-Alava et al.63 mapping algorithm instead of that of van Hout et al.49 resulted in
an ICER of approximately £35,000 per QALY gained for CSLT compared with UC. In contrast, directly
using the English tariff for the EQ-5D-5L instead of using a mapping algorithm resulted in an increased
ICER of £55,639 per QALY gained for CSLT compared with UC. Our base-case analysis represents
our preferred analysis because it uses utility scores elicited directly from patients, and uses the NICE-
preferred technique for obtaining utility scores from EQ-5D-5L questionnaires. However, all analyses
have important weaknesses; for instance, complete-case analyses may be biased owing to selective
dropout over time, utility scores reported by proxy may not be representative of the feelings of
patients60 and the accessible version of the EQ-5D-5L used in our base-case analysis is not validated.
Overall, it is clear that the estimated cost-effectiveness of the CSLT intervention depends importantly
on how utility scores are estimated.
When we estimated the QALYs associated with the 175 carers who completed the EQ-5D-5L at baseline
(analysis 5), we found that CSLT resulted in fewer carer QALYs gained than UC did. This is because carers
of participants who achieved a good response at 12 months reported a 0.02 reduction in utility score
compared with baseline. This reduction was highly uncertain and is at odds with the 0.01 increase in
utility reported by carers of good responders at 9 months. This further highlights the extremely small
utility score differences observed in the Big CACTUS trial, and demonstrates that very small positive or
negative differences in utility scores (which may have occurred by chance) can substantially change the
cost-effectiveness results. We weighted the carer QALYs by a factor of 0.71, because 71% (198/278) of
patients had carers at baseline, and then summed patient and carer QALYs to estimate a total QALY gain.
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Over the lifetime modelled period, the reduction in carer QALYs was marginally greater than the increase
in patient QALYs in the CSLT group compared with the UC group, and hence CSLTwas dominated by UC;
that is, it was more expensive and provided fewer QALYs. Incorporating carer QALYs could have been
done in a variety of ways (e.g. with carer QALYs afforded different weightings), but we did not pursue
these further given the finding that including carer QALYs would not improve the ICER for CSLT regardless
of the technique used.
Model results: subgroup analyses
Appendix 15 provides cost-effectiveness results associated with the subgroups described in Subgroup
analysis. Results differed importantly by subgroup, ranging from CSLT being dominated by UC to CSLT
being associated with an ICER of < £10,000 per QALY gained. Incremental costs did not change
substantially, but QALY increments ranged from positive to negative, resulting in substantially changing
ICERs. Again, this highlights the high level of uncertainty associated with the size of the estimated
QALY gain associated with CSLT, but also further highlights the uncertainty over the direction of the
QALY change; in several subgroups, CSLT resulted in fewer QALYs than UC did.
Perhaps most importantly, the ICER for CSLT compared with UC was < £30,000 per QALY gained for
participants with mild (£22,371 per QALY gained) and moderate (£28,898 per QALY gained) word-finding
difficulty at baseline, but CSLT was dominated by UC for participants with severe word-finding difficulty
at baseline. This was due to slightly larger increases in utility score associated with good responders at
12 months in the mild and moderate word-finding difficulty groups (and also at 9 months for the moderate
group) and decreases in utility scores for responders in the severe word-finding difficulty group (see
Appendix 12 for parameter values for subgroups). However, even in these groups, differences in utility
scores associated with responders were very small and highly uncertain. The probability of CSLT, UC and
AC being cost-effective at a threshold of £30,000 per QALY gained was 0.34, 0.32 and 0.34, respectively,
in the mild word-finding subgroup, and was 0.41, 0.37 and 0.22, respectively, in the moderate word-finding
subgroup. In the severe word-finding subgroup, these probabilities were 0.09, 0.57 and 0.35, respectively.
It is notable that CSLT is dominated by UC in all comprehension ability subgroups, except the moderate
group, for which the ICER is £13,235 per QALY gained. Again, this is driven by whether the estimated
utility difference associated with a good response at 12 months is positive or negative. For the moderate
comprehension ability subgroup, the estimate utility increase associated with a good response at
12 months is relatively large (0.08), although again this is highly uncertain and, indeed, utility differences
associated with a good response at 6 and 9 months were negative in this subgroup.
The subgroup analysis investigating cost-effectiveness according to time since stroke seem to indicate
that CSLT represents a cost-effective intervention compared with UC (with ICERs < £20,000 per
QALY gained) for all but the quartile of participants who had a stroke most recently. However, further
analysis of these subgroups suggests that this is somewhat misleading. For instance, in the third
quartile subgroup, the difference in utility score associated with a good response at 12 months was
negative; achieving a good response was associated with a reduction in utility. In this subgroup, the
response rate was higher for CSLT than for UC, but the relapse rate was also higher for CSLT, leading
to fewer CSLT patients than UC patients residing in the ‘good response (12 months and beyond)’
health state in the long term. This led to CSLT appearing to be beneficial owing to the reduced utility
score associated with achieving a good response.
Model results: summary
Our base-case analysis suggests that CSLT is unlikely to represent a cost-effective use of NHS
resources compared with UC given a cost-effectiveness threshold of £20,000–30,000 per QALY
gained. Incremental costs are relatively low (£732.73), but the incremental QALY difference is also
small (0.0172 QALYs), resulting in a base-case ICER of £42,686 per QALY gained. The QALY change
is highly uncertain, with CSLT resulting in more QALYs than UC in 69% of the 10,000 realisations of
the model run for probabilistic sensitivity analysis. In the base case, the AC treatment option provided
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almost exactly the same number of QALYs as UC (–0.0001 incremental QALYs) but was more expensive
(although costs were very low, at £38.14 per patient). This resulted in AC being dominated by UC (more
expensive and less effective). CSLT produced marginally more QALYs than AC (0.0173-QALY increment)
and was associated with an incremental cost of £694.59, resulting in an ICER of £40,164 per QALY
gained. At a cost-effectiveness threshold of £30,000 per QALY gained there is a 0.32 probability of
CSLT representing the most cost-effective treatment option, a 0.22 probability of AC representing the
most cost-effective treatment option and a 0.45 probability of UC representing the most cost-effective
treatment option.
Expected value of information analysis demonstrated that the utility difference associated with a good
response at 12 months is by far the most important uncertain parameter in the economic model.
The magnitude of the change in utility score is important, as is its direction; because the CI associated
with the utility change at this time point crosses zero, we cannot be confident that achieving a good
response is associated with an improved utility score.
In the base case, achieving a good response was associated with a statistically non-significant decrease
in utility at 6 and 9 months, and a statistically non-significant increase in utility at 12 months. The lack
of a clear finding around the quality-of-life impact of CSLT is consistent with findings on the co-primary
outcome of functional communication ability in conversation and the key secondary outcome of patient
perception of their communication and its impact on their life, for which CSLT did not show an effect.
The uncertainty around the quality-of-life impact – and the sensitivity of the cost-effectiveness results
to this – was further highlighted in secondary analyses in which different techniques for estimating utility
scores from the EQ-5D-5L questionnaire resulted in importantly different ICERs for CSLT, ranging from
approximately £28,000 per QALY gained to approximately £56,000 per QALY gained compared with UC.
Importantly, the ICER was reduced to £28,819 per QALY gained when carer proxy utility scores were
used and, in this case, CSLT was the treatment option most likely to represent a cost-effective use of
resources at a cost-effectiveness threshold of £30,000 per QALY gained. Subgroup analyses also produced
drastically varying results, with CSLT being dominated by UC in some subgroups but producing ICERs
< £20,000 per QALY gained in others. Results in the word-finding difficulty subgroups appear more
consistent between categories than those found in other subgroup analyses, and we estimate that CSLT
is the intervention most likely to represent a cost-effective use of resources in the mild and moderate
word-finding difficulty subgroups, given a cost-effectiveness threshold of £30,000 per QALY gained.
The CrI around the incremental QALY gain associated with CSLT is reasonably narrow, but it crosses
zero. Given its low cost, only a small QALY gain is required in order for CSLT to appear cost-effective,
and very small changes in QALY estimates can have large impacts on the ICER. However, we are
uncertain about whether the intervention leads to increased QALYs or not. Furthermore, when QALY
increments are close to zero it may be expected that some subgroups will result in point estimates of
QALY reductions whereas others will result in point estimates of QALY increases. Overall, we are
highly uncertain about whether the CSLT intervention provides more or fewer QALYs than UC and AC.
In contrast, the value of information analysis demonstrated that the uncertainty around cost parameters
included in the model was not valuable and secondary analyses that investigated alternative software and
computer costs had little impact on the ICER. However, these analyses also demonstrated that the cost-
effectiveness results were sensitive to the most important cost driver, which was SLT time. If SLT and SLTA
costs could be halved, the ICER for CSLT compared with UC would be £26,153 per QALY gained. Most SLT
time was spent setting up the computer program, and it may be feasible that cost savings could be made.
For instance, if it were possible for SLTs to set up the computer software in 1 hour, instead of the average
5.77 hours observed in Big CACTUS, SLT and SLTA costs would be reduced by approximately 38%,
resulting in an ICER of £30,181 per QALY gained.
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Within-trial analysis
Inputs: health-related quality of life
The advantage of a within-trial analysis is that the uncertainty associated with extrapolating beyond
the trial period is avoided. The disadvantage is that this results in an evaluation of only the short-term
cost-effectiveness of the interventions, with longer-term impacts being ignored.
For the within-trial analysis, a model was not needed; QALYs were simply estimated for each treatment
option according to EQ-5D-5L responses reported during the trial, adjusted for any baseline differences
between treatment groups using SUR.
Figure 25 illustrates the trend of mean accessible EQ-5D-5L scores with 95% CIs at baseline and the
follow-up points (6, 9 and 12 months) for the UC, AC and CSLT treatment groups, where missing
scores were imputed as described in Health-related quality of life, and where utility scores were derived
using the van Hout et al.49 algorithm. Similar figures are presented in Appendix 16 for a ‘complete-case’
analysis (where missing values were not imputed) and for an analysis where only data from participants
who provided responses at all follow-up time points were included. Appendix 16 also includes these results
in tabular form, and presents similar results for proxy EQ-5D-5L scores and carer EQ-5D-5L scores.
Results suggest that imputation had a small impact on estimated utility scores, although differences
were slightly larger when comparing the utility scores based on imputed data with those estimated
including only patients who provided complete responses at all time points. This is not unexpected,
because most data are lost when only patients who provide complete responses at all time points are
included. Importantly, changes in utility over time are extremely marginal for all treatment groups.
However, it appears that utility scores decline slightly in the CSLT group whereas they increase slightly
in the UC group.
Inputs: resource use and costs
Costs associated with the three treatment options were identical to those included in the modelled
analysis (seeModel inputs: resource use and costs), with the exception of the cost associated with training on
the StepByStep software for SLTs. For the model-based analysis, we made an assumption that, in practice,
training sessions larger than those in the Big CACTUS trial would be held. For the within-trial analysis,
we instead based this cost on exactly what was observed during the trial. This makes very little difference:
the per-patient cost associated with this training was £10.33 for the model-based analysis, and is £13.25
in the within-trial analysis (see Model inputs: resource use and costs). The mean incremental cost of CSLT
compared with UC was £732.37 (£789.57 from the broader perspective) across the 1000 bootstrapped
simulations of randomly matched pairs of trial participants undertaken for the within-trial analysis.
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FIGURE 25 Means and 95% CIs of accessible EQ-5D-5L scores by treatment group at each time point after missing
EQ-5D-5L scores are imputed.
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The mean incremental cost of CSLT compared with AC was £694.65 (£751.85 from the broader
perspective). Appendix 17 presents histograms for the distributions of costs in the CSLT and the AC
groups, respectively. In the CSLT group, costs were positively skewed, demonstrating that the vast
majority of CSLT participants incurred costs of between approximately £250 and £1000, but a small
number of participants incurred costs of > £1500. In the AC group, costs follow a more normal
distribution. These costs were much less prone to variation between participants owing to the much
smaller role of SLTs.
Results: base case
Table 25 presents the results of the SUR used to conduct the within-trial analysis, complete with
non-parametric bootstrapping to characterise uncertainty. QALYs during the trial period were estimated
to be higher in the UC and AC treatment groups than in the CSLT treatment group, but this was highly
uncertain, with CIs crossing zero. The incremental QALYs of CSLT compared with UC were estimated
to be –0.007 (p = 0.71). The incremental QALYs of CSLT compared with AC were estimated at –0.007
(p = 0.73). CSLT led to an increase in costs compared with UC (£732.37, p < 0.001) and AC (£694.65,
p < 0.001) and therefore CSLT was dominated by UC and AC in the within-trial base-case analysis. AC
was estimated to result in fewer QALYs during the trial period than UC (–0.004 increment, p = 0.83)
and was more expensive; therefore, UC dominated AC.
The cost-effectiveness plane for the within-trial base-case analysis comparing CSLT with UC is presented
in Appendix 18. The plane shows considerable uncertainty in relation to estimation of incremental QALYs
with a wide scattering of points across the x-axis. Approximately 36% of the estimates resulted in a QALY
gain for CSLT, and approximately 64% resulted in a QALY gain for UC.
The cost-effectiveness plane for the within-trial base-case analysis comparing CSLT with AC is presented
in Appendix 18. The plots are very similar to those for the comparison of CSLT with UC; there is a high
degree of uncertainty around incremental QALY estimates, with approximately 38% of the estimates
resulting in a QALY gain for CSLT and approximately 62% resulting in a QALY gain for AC.
The cost-effectiveness plane for the within-trial base-case analysis comparing AC with UC are presented
in Appendix 18. Again, there is a high level of uncertainty as to which treatment option will result in the
most QALYs. Approximately 42% of the estimates resulted in a QALY gain for AC and approximately
58% resulted in a QALY gain for UC.
TABLE 25 Within-trial analysis results: base case
Analysis Outcome Intervention, mean (SD) Comparator, mean (SD) Difference in mean (95% CI)
CSLT vs. UC Costs (£) 732.37 (344.22) 0.00 (0.00) 732.37 (665.59 to 799.15)
QALYs 0.6058 (0.23) 0.6259 (0.19) –0.007a (–0.05 to 0.03)
ICER Dominated
CSLT vs. AC Costs (£) 732.37 (344.22) 37.72 (16.02) 694.65 (619.54 to 769.75)
QALYs 0.6058 (0.23) 0.5987 (0.21) –0.007a (–0.05 to 0.03)
ICER Dominated
AC vs. UC Costs (£) 37.72 (16.02) 0.00 (0.00) 37.72 (34.61 to 40.82)
QALYs 0.5987 (0.21) 0.6259 (0.19) –0.004a (–0.04 to 0.04)
ICER Dominated
a The difference in mean QALYs was adjusted for baseline EQ-5D-5L utility scores.
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The CEAC for the within-trial base-case analysis is presented in Appendix 18. The CEAC illustrates
the probability that each strategy is the most cost-effective option for a range of cost-effectiveness
thresholds (£0–50,000 per QALY). At a cost-effectiveness threshold of £20,000 per QALY gained,
the treatment option with the highest probability of representing the most cost-effective strategy is
UC, with a probability of 0.5. CSLT has a probability of 0.15 and AC has a probability of 0.35 of
representing the most cost-effective strategy at this threshold. At a cost-effectiveness threshold of
£30,000 per QALY gained, the probability of UC representing the most cost-effective option is 0.48,
compared with 0.18 for CSLT and 0.34 for AC.
Results: secondary analyses
The results from the six secondary analyses described in Table 21 are presented in Appendix 19.
Note that results for analysis 14 are not included for the comparison of AC and UC because volunteer
costs were not incurred in the AC and UC groups.
Results of the secondary analyses demonstrate that the technique used to estimate utilities from the
EQ-5D-5L questionnaire is very important; depending on the technique used, CSLT either produces
QALY gains or QALY losses compared with UC. QALY losses are estimated for the base-case analysis
(using the van Hout et al.49 algorithm to estimate utility scores), when the English EQ-5D-5L tariff is
used (with no mapping algorithm) and when the Hernandez-Alava et al.63 mapping algorithm is used.
In contrast, QALY gains are estimated for CSLT compared with UC when carer proxy EQ-5D-5L utility
scores are used and when complete data are used at each time point (with no imputation for missing
values). However, even when QALY gains are estimated, the ICER for CSLT compared with UC remains
> £50,000 per QALY gained.
When the utility scores associated with the 175 carers who completed the EQ-5D-5L at baseline were
incorporated into our analysis (analysis 5), the ICER for CSLT compared with UC reduced to approximately
£127,000 per QALY gained, and for CSLT compared with AC reduced to approximately £81,000 per QALY
gained. This is in contrast to the results of the model-based analysis when carer utilities were incorporated,
which resulted in CSLT being dominated by UC. In the model-based analysis, utility scores reported
at 12 months are most important, because these are extrapolated into the future. In the within-trial
analysis, the HRQoL experienced during the trial period is of most importance, with the 12-month utility
score playing a relatively small part. This suggests that during the trial period carers of CSLT participants
fared better than carers of UC participants. However, again, incremental QALY estimates were highly
uncertain in this scenario, with CIs crossing zero.
As for the model-based analysis, adopting a broader perspective (including volunteer costs) has very
little impact on the within-trial cost-effectiveness analysis results. The incremental cost associated with
CSLT is marginally increased compared with UC and AC, with no difference made to QALYs, and thus
CSLT remains dominated by both other treatment options.
The sensitivity of results to the technique used to calculate utility scores from the EQ-5D-5L responses
is further highlighted by the results comparing AC with UC (see Appendix 19). Although AC was
dominated in the base-case within-trial analysis, it is associated with ICERs of approximately ≤ £10,000
per QALY gained using all alternative valuation techniques. Differences between QALYs estimated
for AC and UC are even smaller than for CSLT compared with UC, which explains why the results
of comparisons between AC and UC are even more sensitive to the technique used to derive utility
scores than for the CSLT and UC comparison.
Results: subgroup analyses
Appendix 20 reports within-trial analysis cost-effectiveness results for the subgroups described in
Subgroup analysis. Again, results differed importantly by subgroup, ranging from CSLT being dominated
by UC to CSLT being associated with an ICER of < £30,000 per QALY gained. Similar fluctuations in
results were observed for the comparison with AC and for the comparison between AC and UC. As for
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the model-based analyses and the secondary within-trial analyses, incremental costs did not change
substantially between groups, but QALY increments ranged from positive to negative, resulting in
substantially changing ICERs. Again, this highlights the high level of uncertainty associated with both
the size and direction of the estimated QALY gain or loss associated with CSLT.
Few consistent patterns can be observed when comparing the results across subgroups. However,
it is worthy of note that CSLT is dominated by UC in the mild and moderate word-finding difficulty
subgroups, but has an ICER of < £30,000 per QALY gained in the severe subgroup. This is in direct
contrast to the results produced by the model-based analyses.
Summary
Our base-case within-trial analysis suggests that CSLT is unlikely to represent a cost-effective use of
health-care resources compared with UC and AC treatment options. Over the trial period, UC and AC
were both estimated to result in marginally more QALYs than CSLT, while costing less. The number of
QALYs associated with each of the treatment options was very similar and differences between the
treatment options were highly uncertain. Secondary analyses demonstrated that using different
techniques to derive utility scores from the EQ-5D-5L responses could change the direction of the
estimated differences for all comparisons. This emphasises the very small magnitude in the difference
between QALYs gained associated with the different treatment options. Results of subgroup analyses
were also extremely variable, making it very difficult to draw conclusions on cost-effectiveness.
It is notable that the base-case results of the within-trial analysis are in direct contrast to the base-case
results of the model-based analysis. This is due to the shorter time frame considered in the within-trial
analysis. At the 6- and 9-month time points, good response was associated with very small reductions in
utility compared with no response; it was only at the 12-month time point that this difference became
positive. As a result, if the time frame of the base-case model-based analysis is set to 12 months, it also
results in CSLT producing fewer QALYs than UC and AC. It is the positive difference in the utility score
associated with good response at 12 months that leads to the estimated increase in QALYs associated
with CSLT compared with UC and AC in the model-based analysis. This utility score is extrapolated into
the future and because CSLT results in more participants residing in the ‘Good response’ health state in the
long term, QALY gains are accrued. The within-trial analysis is restricted to a 12-month time frame and
therefore does not project this gain into the future; hence, potential future QALY gains are not accrued.
The health economic analysis is further discussed in Chapter 6.
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Chapter 6 Discussion and conclusions
Summary and interpretation of clinical findings
The co-primary outcome measures in this trial were chosen to establish whether or not self-managed
CSLT tailored by SLTs and supported by volunteers or assistants for word-finding:
l increases the ability of people with aphasia to retrieve vocabulary of personal importance
l improves functional communication ability in conversation.
Impact on word-finding
The improvement in retrieval of treated words at 6 months post randomisation was substantially greater
with CSLT than with UC or AC. On average, CSLT improved word-finding by 16.2% more than UC (95% CI
12.7% to 19.6%; p < 0.0001) and 14.4% more than AC (95% CI 10.8% to 18.1%), showing that the effect
was largely due to speech and language therapy components of the CSLT intervention and not just extra
activity and attention. The effect was in excess of the prespecified minimal clinically important difference
of 10%. This effect was mostly maintained at 9 and 12 months, suggesting maintenance of the treatment
effect following the 6-month intervention period. It should be noted that 57 (61%) of the participants
in the CSLT group continued to use the computer therapy unsupported beyond 6 months, which may
have supported this maintenance. Of the 57 who practised beyond 6 months, 33 practised between
6 and 9 months and 24 practised beyond 9 months.
Functional communication, patient perception and quality of life
There was no significant improvement in the co-primary outcome measure of functional communication
in conversation in any of the groups, providing no evidence that the CSLT approach we evaluated for
word-finding improves communication in conversation. Our key secondary outcome measure suggests
that CSLT did not result in improvement in participants’ own perceptions of their communication and
participation and the impact of these on their life, which is unsurprising given that no improvement in
functional communication was seen. These findings indicate that CSLT supported participants with
aphasia to make significant improvements in their ability to retrieve words of personal importance at the
impairment level, but these gains did not generalise to functional communication settings, thus limiting
the impact of the improvements in their lives.
Generalisation of improvement in word-finding to conversation was further explored through a secondary
outcome measure specifically identifying the difference in the number of treated words used in
conversations structured around topics that provided the opportunity to use those words. In keeping
with the co-primary outcome measure of conversation, the groups were similar with respect to the
number of words used in conversation. However, a post hoc analysis showed that 1 in 10 participants
in the AC and UC groups, and 3 in 10 participants in the CSLT group used at least five more treated
words in conversation at 6 months than at baseline, suggesting that there may be a small treatment
effect of the use of treated words in the functional context of conversation in a few participants. The
lack of carryover of improvement from retrieval of treated words in a confrontation naming task to
use in functional communication situations may be a result of people being used to communicating in a
different way (e.g. gesture) and therefore not remembering to use new words when they have the
opportunity. In addition, retrieving words in functional communication settings is likely to be a subtly
different to or a more difficult task than naming a picture. Further intervention may be required to help
people with aphasia use their ‘new’ words in useful situations.
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Generalisation to untreated words
A further secondary research objective of the trial was to investigate whether or not learning of treated
words generalises to being able to retrieve words that were not specifically treated. There was no
significant difference between the three trial groups in retrieval of untreated words between baseline
and 6 months. Therefore, improved word-finding of treated words did not result in generalisation to
untreated words. This suggests that people get better at saying what they practise saying > 4 months
post stroke. Because individuals with long-term aphasia may learn only the words they practice, it is
most useful to them if these words are of personal relevance.
Impact of aphasia profile, word-finding severity and length of time post stroke
Prespecified subgroup analyses indicated that the effect of CSLT on word-finding was slightly higher
for participants with mild word-finding difficulties and for those whose verbal comprehension was
within normal limits. It is likely that the brain lesions of these participants were smaller, allowing
greater retained potential to relearn words with practice. Importantly, subgroup analyses showed that
the treatment effect was broadly consistent regardless of the time post stroke, suggesting that people
with aphasia may learn new words at any time after stroke (range of 4 months to 36 years in our trial).
Carer perception of communication effectiveness and impact on their quality of life
The carers also rated their perception of the participant’s communication effectiveness and their own
quality of life. For communication effectiveness, there was a MDC of 4.6% (95% CI 0.3% to 9.0%) in
favour of CSLT compared with UC at 6 months and a MDC of 5.1% (95% CI 0.5% to 9.7%) in favour of
CSLT compared with AC, indicating a small improvement in the carers’ perception of communication
effectiveness with CSLT. However, the long-term effects of the intervention on the average change in
the carer-rated communication effectiveness were very small: 0.6% (95% CI –4.4% to 5.7%) and 2.7%
(95% CI –1.9% to 7.4%) in favour of CSLT compared with UC at 9 and 12 months, respectively. This
indicates that any perception of improvement in communication effectiveness is unlikely to be maintained
long term. There was also a 5.3% (95% CI –1.1% to 11.7%) MDC in perception of carers’ quality of life in
favour of CSLT compared with UC at 6 months. However, the improvement in carers’ reported quality of
life in the CSLT group compared with AC was close to zero (0.3%, 95% CI –6.4% to 6.9%). This suggests
that the small improvements seen in carers’ quality of life at 6 months may be due to the increased levels
of activity their relative is engaged in and the receipt of increased amounts of attention in the CSLT and
AC interventions compared with UC alone.
Safety
We investigated the safety of the CSLT intervention. Negative effects of CSLTwere low, with 27% of
participants in the CSLT group reporting fatigue or anxiety at some point, which translates to an average of
only one event per person per year. Effects on eyes or headaches were very rarely reported. On average,
the incidence of AEs per participant per person-year of follow-up was 2.18, 1.79 and 1.87 in the CSLT, AC
and UC groups, respectively. This indicates a slight increase in all AEs in the CSLT group, with an IR of 1.16
(95% CI 0.83 to 1.62) and 1.22 (95% CI 0.85 to 1.77) compared with the UC and AC groups, respectively,
although we cannot rule out similarity in incidences between groups as the CIs include an IRR of 1. Fits and
visual difficulties were uncommon, but the incidence of fits was reported to be three times higher in the
CSLT group than in the UC or AC groups, although such events were rare in all groups. Similarly, slightly
more AEs were reported in the CSLT group than in the UC or AC groups; however, the CSLT group had
more opportunity for reporting AEs as participants were prompted with a negative effects form each month
in addition to the 3-monthly check by outcome assessors received by all groups, whereas participants in
the AC and UC groups were not. Differences in the incidence of AEs between groups were insufficient to
suggest differences in risk levels. The number of SAEs was 18 (15.8%) in the UC group, 11 (13.9%) in the
AC group and 9 (10.6%) in the CSLT group. Although there were fewer SAEs in the CSLT group, there is
insufficient evidence to suggest differences in IRs of SAEs across interventions.
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Summary and interpretation of health economic findings
In this trial, we sought to establish whether or not CSLT is cost-effective for persistent aphasia post
stroke. Unfortunately, estimates of the quality-of-life benefit associated with the intervention were
unstable and highly uncertain. Although the CrI around the incremental QALY gain associated with
CSLTwas reasonably narrow, it crosses zero, and we are uncertain about whether or not the intervention
leads to increased QALYs, making it very difficult to make firm conclusions on its cost-effectiveness.
A model-based analysis in which costs and QALYs were extended over a lifetime period formed the
primary analysis. A within-trial analysis was also conducted in which the costs and QALYs were measured
over the 12-month trial period and were not extended further.
Main findings
The base-case (primary) model-based cost-effectiveness analysis resulted in an ICER of £42,686 per
QALY gained for CSLT compared with UC, and an ICER of £40,164 per QALY gained for CSLT compared
with AC. AC was dominated by UC, meaning that the UC group cost less and had greater quality-of-life
gains (measured on EQ-5D-5L for the health economic analysis) than the AC group. These ICERs are
higher than the current NICE cost-effectiveness threshold of £20,000–30,000 per QALY gained,52
suggesting that in the UK the CSLT approach we evaluated is unlikely to be considered to represent a
cost-effective use of health-care resources for the whole population with word-finding difficulties as a
result of post-stroke aphasia.
However, cost-effectiveness estimates were highly uncertain. Although results were robust to altering
assumptions around software and computer costs, they were very sensitive to the utility score estimates
associated with achieving a good response to treatment, which were highly uncertain. It is not clear
whether or not the intervention leads to an increase in quality of life as measured by the EQ-5D-5L.
The cost-effectiveness results were sensitive to using different techniques to derive utility scores
(a measure of HRQoL) from EQ-5D-5L responses. The base-case (primary) analysis used the EQ-5D-5L
mapping algorithm developed by van Hout et al.49 to calculate utility scores, as recommended in NICE
guidelines for cost–utility analysis.52 However, an unvalidated accessible version of the EQ-5D-5L61 was
used so that utility scores could be derived directly from trial participants. In circumstances in which
trial participants cannot complete a standard EQ-5D-5L questionnaire themselves, a typical approach
is to use scores derived from standard EQ-5D-5L questionnaires completed by carers by proxy. When
we conducted secondary analyses using this technique, the ICER for CSLT compared with UC fell to
£28,819, potentially representing a cost-effective use of health-care resources. Using an alternative
mapping algorithm (that developed by Hernandez-Alava et al.63) to derive utility scores from the accessible
version of the EQ-5D-5L also led to a reduced ICER for CSLT compared with UC, equal to £34,921 per
QALY gained. These results are consistent with findings from work by the NICE Decision Support Unit
comparing the mapping methods.63 In contrast, directly using the English tariff for converting EQ-5D-5L
responses to utility scores (with no mapping algorithm) led to an increase in the ICER, to £55,639 per
QALY gained.
In addition, we found that important reductions in the ICER could be achieved if SLT costs could be
reduced substantially. For instance, if the computer software could be set up for participants by SLTs
in 1 hour instead of the average 5.77 hours observed in the Big CACTUS trial, the ICER for CSLT
compared with UC would decrease to £30,181 per QALY gained. However, this ICER would remain
highly uncertain owing to the uncertainty surrounding the QALY gain. In the trial, we did not evaluate
the impact of the involvement of SLTs in the intervention. However, as SLT tailoring of the software
incurred a significant proportion of the intervention cost, it is important to understand if and how this
is related to the clinical outcomes. The relationship between SLT support and intervention effectiveness
is the focus of a completed PhD.
DOI: 10.3310/hta24190 Health Technology Assessment 2020 Vol. 24 No. 19
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Palmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
97
Explanation of findings
The sensitivities on the ICERs according to the method used to derive utility scores demonstrate that
the key uncertainty in this economic evaluation surrounds the size and direction of the QALY gain or
loss associated with CSLT compared with UC and AC. A key message is that CSLT did lead to significantly
more participants achieving a ‘good response’ in naming of words with personal relevance or conversation
than UC and AC did. However, the impact on utility of achieving a good response appeared to be small
and highly uncertain. Given the low cost associated with CSLT, very small increases or decreases in the
estimated QALY gain can have a large impact on the ICER. In the vast majority of analyses completed
(primary, scenario and subgroup analyses), the CIs for the QALY gain associated with CSLT compared
with UC ranged from negative to positive. A related issue surrounds the definition of a ‘good response’.
Although CSLT led to substantially more participants achieving a ‘good response’, large proportions of
participants in the AC and UC groups also achieved a ‘good response’. Potentially, the definition of
response (improvement of 10% in word-finding or an improvement of 0.5 on the TOMs) may have been
too lenient; differences in quality of life may be more likely in participants who achieve a greater response.
Related to this, an alternative modelling approach could have split the response state according to whether
a response was achieved through a word-finding improvement or an improvement on TOMs (or both).
In practice, as would be expected given the clinical results, the majority of responses were due to
improvements in word-finding; for instance, at 6 months only 8 of the 73 responders in the CSLT group
achieved a response based on TOMs and not on word-finding, and 23 achieved a response on both
measures. Hence, splitting the response category would have involved estimating utility scores for different
response groups based on very small patient numbers and would have been prone to substantial error.
In the base case (the primary health economic analysis), the utility score in patients who achieve a
good response is estimated to be worse at 6 and 9 months than that in patients who do not achieve a
good response. At 12 months, good responders are estimated to have marginally higher utility than
non-responders. Given that all CIs overlap, these alternative directions in utility differences may be
due to chance. Alternatively, they may suggest that it takes time for a good response to lead to utility
gains as measured by the EQ-5D-5L.
Given the clinical results observed in Big CACTUS, it may not be surprising that CSLT had little impact
on utility scores. Although the intervention had a significant impact on word-finding ability, it had no
discernible impact on functional communication measured or on participants’ perceptions of communication
effectiveness or impact on their lives. Therefore, it seems unlikely that a response would have an impact on
the EQ-5D-5L domains to indicate quality of life, and indeed our within-trial analysis estimated marginally
more QALYs for the UC and AC treatment groups than for the CSLT group, although this was highly
uncertain. If the improvement in word-finding ability could be converted into a functional improvement,
it is possible that QALY gains could be derived and, given the low cost of the intervention, this could
result in CSLT being deemed cost-effective. Research to investigate this further may be valuable. In our
value of information analysis, we found that the expected value of obtaining perfect information on the
change in EQ-5D-5L score associated with a good response at 12 months is £20.4M. This suggests that
it would be highly valuable to collect more data on this model parameter to enable it to be quantified
more accurately.
Subgroup analysis
Importantly, the prespecified subgroup analyses (of the model-based health economic evaluation)
suggested that the CSLT approach we evaluated may represent a cost-effective use of health-care
resources for participants with mild or moderate word-finding difficulty. In these groups, CSLT was
associated with ICERs of £22,371 and £28,898 per QALY gained, respectively, compared with UC, and
of £30,911 and £18.855 per QALY gained compared with AC. In contrast, CSLT was associated with a
higher cost and lower quality-of-life scores than AC and UC for participants with severe word-finding
difficulty (CSLT was dominated by AC and UC). The proportion of CSLT participants who achieved a
good response was similar in the different word-finding difficulty subgroups, but cost-effectiveness was
improved in the mild and moderate groups owing to a slightly increased utility difference associated
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with a good response at 12 months in these groups, and a negative difference (compared with no response)
in the severe subgroup. However, these analyses remain highly uncertain and, as for the base-case analysis,
achieving a good response was associated with a reduction in utility at earlier time points for both the
mild subgroup and the moderate subgroup. Again, the direction of the utility changes may have been
due to chance. In addition, within-trial analyses in the same subgroups provided opposite results
(whereby CSLT was dominated by UC in the mild and moderate word-finding difficulty subgroups).
Related to this, it is important to reiterate that cost-effectiveness results based on within-trial and
model-based analyses were often substantially different because the estimated higher EQ-5D-5L score
associated with CSLT at the 12-month time point was extrapolated for the remaining lifetime period of
the model-based analysis, but was not extrapolated in the within-trial analysis.
Cost of computerised speech and language therapy intervention
The intervention cost £733 per participant, which is relatively low. This enabled a mean of 28 hours of
independent, repetitive word-finding practice. Although we do not know the relative effectiveness of
28 hours of therapy provided face to face by a SLT, providing an additional 28 hours of face-to-face
speech and language therapy by a mid-grade (Agenda for Change band 6) SLT would cost £1400,
almost twice as much as supporting an individual to practise independently with a computer. If the
time taken by SLTs to set up the computer program could be reduced, the cost-effectiveness of the
intervention could improve markedly.
Fidelity to the interventions
Intervention coverage was excellent as all participants received a computer with the software on it.
Quality of computerised speech and language therapy intervention delivery
Measures used as indicators of quality of intervention delivery included training, intervention knowledge
of providers, appropriate tailoring of the computer therapy and provision of support to the participants.
There was high/good fidelity to these measures of intervention delivery quality. Regarding support
provided by volunteers/SLTAs, 85% of the participants received support for using their newly learned
words in conversation or functional contexts; however, these skills were practised with the volunteer
or SLTA for a total of only 45 minutes (median) per participant across the 6-month intervention period.
Increased amounts of time spent on these transfer activities may be required to assist with greater use
of the newly learned words in conversation. Only 52% of feedback forms from volunteers/SLTAs were
monitored by SLTs, indicating lower adherence to the role of monitoring the SLTA/volunteer support
provided to the participant.
Adherence to computerised speech and language therapy practice
The CSLT participants practised for a mean of 28 hours, just above the recommended minimum for
high adherence (26 hours); the median was below this at 21 hours, with just fewer than half of the
participants (46%) meeting this minimum for high adherence. Sixty-four per cent of participants
practised for a minimum of 10 hours, indicating some adherence to the intervention. Although we are
able to report the amount of practice time, further analysis has been conducted during a PhD study
regarding the content of the practice and motivation to practise.
Conclusion for computerised speech and language therapy
Overall fidelity to the CSLT intervention was judged to be high to fair.
Fidelity to attention control
The AC intervention was to complete a puzzle each day with a supportive telephone call from the
research team each month for 6 months. As we expected periods of illness and holiday as with the
CSLT group, we expected a minimum of four telephone calls to have taken place and four to six puzzle
books to be completed. It was difficult to measure the adherence to puzzle book practice. Only 18% of
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participants had six books and four telephone calls but 61% of participants had a minimum of four
puzzle books and four telephone calls, suggesting that adherence to the AC group was fair and therefore
similar or slightly lower than the adherence to the CSLT intervention.
Fidelity to usual care
The UC received during the trial was generally similar between groups, suggesting that the adherence
to the provision of UC was consistent across groups. During the 6-month intervention period, the mean
amount of UC received by all participants in the UC, AC and CSLT groups, respectively, was 3.8 hours,
3.2 hours and 3.2 hours. The amounts of UC provided decreased over the trial period in all groups. This
is likely to be because participants progressed along the stroke pathway of care as the trial progressed.
The pre-baseline UC data indicated that patients receive reduced amounts of UC with time post stroke.
Trial results in the context of other studies
Age and gender
The age and gender profile of the participants of the Big CACTUS trial was in keeping with that seen in
other aphasia studies (not all RCTs, therefore open to selective sampling), 60.7% male being consistent
with 60.8% of the Rehabilitation and recovery of people with aphasia after stroke (RELEASE) data set77
of 5573 aphasic trial participants being recorded as male. The mean age of participants in Big CACTUS
was 65.4 years. Again, this is similar to the median age of 63 years for 5871 aphasic participants in
the RELEASE data set.77 This is also consistent with the average age seen in stroke rehabilitation trials
(64.3 years) and is almost a decade younger than those seen by physicians in daily practice.78
Computer use
The mean amount of self-managed practice with the computer therapy in Big CACTUS was 28 hours
over 6 months. This is consistent with the amount of self-managed practice conducted in the pilot
study: a mean of 25 hours over 5 months.21 In a recent systematic review of computerised aphasia
therapy interventions, the protocols varied with recommended practice schedules of 10 to 11 hours
over 2 months, 20 hours over 20 sessions, 24 hours over 11 to 12 weeks and 78 hours over 6 months.17
These studies were all conducted in clinical facilities with at least some therapist supervision, unlike Big
CACTUS, which was a pragmatic study of computer therapy self-managed by the person with aphasia
at home, encompassing greater participant control and choice over amounts of practice. The total
amount of practice carried out by the Big CACTUS participants was similar to that in two of the studies
described in the systematic review but over a longer duration of time. In addition, 61% of the Big
CACTUS participants continued to practise beyond the 6-month supported self-managed trial period,
suggesting that participants may choose to practise less intensively for a longer duration than provided
in therapist-supervised protocols studied. In the Oral Reading for Language in Aphasia (ORLA) study,10
a study of computer-based reading therapy for people with aphasia, there was also some variation in
the amount of practice participants chose to carry out.
Word-finding
The Big CACTUS trial demonstrated significant improvements in word-finding at the impairment level
of 16.2% (95% CI 12.7% to 19.6%; p < 0.0001) in favour of CSLT compared with UC in the chronic
phase (> 4 months) post stroke. This finding is very similar to the findings of the pilot study, based on
34 participants, which showed improvements of 19.8% (95% CI 4.4% to 35.2%; p = 0.014) in favour of
the computer therapy compared with usual stimulation (support groups but no therapy intervention)
more than 6 months post stroke. The Cochrane review4 included three studies that compared naming
therapy to social support using impairment-based naming outcome measures. On pooling the data, no
differences were seen (standardised mean difference 0.14, 95% CI −0.10 to 0.38; p = 0.26).4 However,
the word-finding measures used were standardised and therefore will have been observing improvement
to words that were not specifically treated in therapy. A small case series study (16 participants) by
Best et al.51 suggested that only one in four participants improved on untreated words, and then they
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improved by only a small amount (4%) between pre and post therapy measures. With control groups,
the Big CACTUS trial showed no effect of the CSLT word-finding therapy on finding words that were
not treated, in keeping with the findings in the 2012 Cochrane review of aphasia therapy79 and previous
studies of word-finding therapy.80–84
Functional communication, participation and quality of life
The CSLT for word-finding did not result in improvements at the level of communication activity and
participation or quality of life in the Big CACTUS trial. A common criticism of impairment-based aphasia
therapies is that improvements are not reflected in real-life, day-to-day communication.85 The lack of
generalisation of new word-finding ability to functional contexts is therefore consistent with findings
from other, smaller studies of word-finding therapy. For example, Best et al.85 demonstrated carryover
of naming therapy into conversation for some individuals (as seen in Big CACTUS) but not for the
group of study participants as a whole. This underlines the need for additional therapy components to
be added to impairment-based intervention to aid use of new language skills.
Improvements in communication activity, participation or quality of life were not measured quantitatively
in the CACTUS pilot study; however, some participants described functional improvements during
qualitative interviews (e.g. use of their new words in conversation or in functional contexts, and
improvements in confidence to communicate in functional communication settings).22 The quantitative
findings from the full trial therefore diverge from these qualitative findings. One explanation of the
differences could be that ‘response shift’ may occur in patient-rated outcomes, whereby the internal
standards against which the participants rate themselves do not stay constant between one time point
and another.86 This could lead to descriptive improvements in interviews that are not accounted for in
responses on patient-rated outcome measures.
Health economics
For the heath economic evaluation, the base-case (primary) model-based cost-effectiveness analysis
resulted in an ICER of £42,686 per QALY gained for CSLT compared with UC. This is much higher
than the ICER estimated from the pilot study (£3127 per QALY).18 Reasons for this difference are
that incremental costs associated with the intervention were lower in the pilot than in the main study
(£469 compared with £733) and incremental QALYs were higher (0.15 compared with 0.02). In the
pilot study, the intervention was delivered predominantly by a SLT who was part of the research team
and more familiar with the computer program than the therapists delivering the intervention in the
full, pragmatic trial in routine clinical practice conditions. In addition, only 48 bespoke words were
prepared by the SLT in the pilot, whereas 100 words were prepared in the full trial. The amount of
therapist time taken to deliver the intervention was therefore lower in the pilot (5 hours and 20
minutes rather than 9 hours) and had a lower cost. The full study has shown QALY measurement in
this population with this intervention to be highly variable, which may account for the difference in
QALY gains seen in the two studies. Of particular note is that the utility gain associated with a ‘good
response’ was 0.07 (95% CI –0.15 to 0.29) in the pilot study, compared with 0.02 (95% CI –0.03 to
0.07) at 12 months in Big CACTUS. Caution must be taken with this comparison because the definition
of a response differed between the two studies. However, clearly the CIs around the utility change
have been reduced by Big CACTUS, but they have centred around the lower end of the interval
estimated in the pilot study, which is also the area that overlaps zero. For this reason, the value of
the uncertainty that remains is almost as high after Big CACTUS as it was after the pilot study:
a population-level EVPI of £37.0M was estimated from the pilot study, compared with £34.6M based
on Big CACTUS. This is due to the increased ICER and also the finding that we still cannot be certain
about whether or not the intervention results in a QALY gain.
An additional factor is that the EQ-5D-5L was used in Big CACTUS, whereas the EQ-5D-3L was used
in the pilot study. Research has shown that the EQ-5D-5L is likely to reduce the utility increment or
decrement associated with a quality-of-life change, compared with the EQ-5D-3L, and in fact a NICE
Decision Support Unit report on this topic87 used the CACTUS pilot as a case study and estimated that
DOI: 10.3310/hta24190 Health Technology Assessment 2020 Vol. 24 No. 19
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Palmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
101
the utility gain associated with a good response would have been 0.02 had the EQ-5D-5L been used.
However, in line with NICE recommendations,48 in our base-case economic evaluation we used the van
Hout et al.49 cross-walk algorithm to map EQ-5D-5L responses onto the EQ-5D-3L tariff in order to
generate utility scores; hence, the decrement associated with using the EQ-5D-5L should not be
present. The utility gain associated with a good response was marginally lower when the EQ-5D-5L
tariff was directly used, but the difference was marginal (0.017 compared with 0.02).
Discussion of using co-primary outcomes
Computerised speech and language therapy is predominantly impairment focused with recognition of
the need to transfer any impairment-based gains to function with support, in this case conversation
and functional activities with an SLTA or volunteer (it should be noted that adherence to the functional
activities/conversational part of the intervention was low). It is commonplace in speech and language
therapy to work on the impairment first so that patients can ‘do’ the task (in this case retrieving
words). The new skills then need to generalise to function to be useful in everyday life. The majority of
studies of aphasia have only impairment-based outcomes. In this trial, we recognised the importance
of evaluating functional gains, but if we had only a functional outcome we would not know whether
or not the impairment-focused intervention improved the impairment as intended and therefore
would not know if it helped patients to retrieve words at any level. As both of these were considered
clinically important to know, and the international aphasia community agrees that it is important to
measure across the dimensions of the ICF, the trial was designed with co-primary outcomes. During
trial design, we discussed what would be considered beneficial with both SLTs and people with aphasia.
Impairment or functional gains or both were considered beneficial. Therefore, a Hochberg testing
procedure prespecified that the intervention would be interpreted as beneficial if both outcomes were
significant or if either outcome was very significant alone. The benefit of taking this approach is that it
is possible to see whether or not the intervention shows benefit in any dimension of the ICF [i.e. just
what the intervention primarily targets (impairment) or whether or not there is any desired carryover
to functional communication (activity)]. The disadvantage of this approach is that, although interpretation
is based on what was prespecified using the Hochberg procedure, the result in this case is not binary
‘it works’/‘it does not work’, making it more complex to report. However, the finding that it is beneficial
for improving word-finding impairment but does not generalise to function is useful. If only a functional
outcome was used, the intervention would be rejected altogether, but this would be inappropriate given
the marked improvements in impairment. Rather, the results of the co-primary outcomes indicate that
the intervention needs to be built on to help impairment-based gains generalise to function.
Strengths of the trial
The Big CACTUS trial was a fully powered, pragmatic, multicentre RCT. The SLTs all worked in routine
NHS clinical practice from where they recruited and treated the participants. The large number of sites
(21 departments across 20 NHS trusts) included representation from all devolved nations of the UK,
both urban and rural areas, and different NHS information technology services, which required a range
of computer and software procurement strategies, policies and governance standards to be followed in
the implementation of the CSLT intervention being tested in this trial. These real-world considerations
support the generalisability of the trial findings.
A further strength of the trial is that the interventions were well described using the TIDieR template,
and the CSLT intervention was manualised and is publicly available, enabling understanding and replication.
Training on the intervention was also provided and described. The intervention was complex, including
a skill mix of qualified SLTs to tailor the computer therapy to individual participant need and to train
and monitor SLTAs or volunteers to provide lower-cost ongoing support. Fidelity, not only to treatment
adherence but also to quality of intervention delivery, was measured to aid transparency of how well
the intended complex intervention was delivered.
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To our knowledge, Big CACTUS is the largest trial of computerised aphasia therapy to date. The trial
recruited 278 participants to time and target, stopping seven participants short of the sample size
calculation owing to a lower than predicted drop-out rate from the trial, requiring fewer participants to
detect an effect of 10% on the primary outcome measures with the intended 90% power. The drop-out
rate was only 9%, 6% lower than predicted from the pilot study. Fewer than one-third of trials meet
their recruitment targets, with more than half requiring extensions.88 We based our recruitment rate
on that seen in the pilot study: one participant per month per site. We also built in contingency of
having sufficient funding for four extra sites in addition to the 20 sites we predicted we needed should
the recruitment rate be lower. The actual average recruitment rate was 0.8 participants per month per
site (range 0.5–1.2). We also took into consideration that the participants all had aphasia and therefore
it would take a longer time and more skill to ensure informed consent. This meant that the trial was
planned based on realistic recruitment rates with a sufficient number of sites and recruitment time.
The Big CACTUS trial therefore shows that trials with participants with post-stroke aphasia can be
successfully conducted. The Big CACTUS team put considerable effort into recruitment and retention
to the trial. Strategies included:
l funding 1 dedicated half-day per week of a SLT’s time at each site to recruit participants
l a stepped approach to gaining informed consent from people with aphasia with differing needs of
support, with different styles of information to suit different language abilities, all designed in
collaboration with the trial PPI group
l use of a Consent Support Tool31 by SLTs with specialist skills in communication to indicate when to
use which style of information
l including people identified as being unable to consent with support through carer/relative declarations
l monthly newsletters to encourage and maintain motivation for recruitment with a competitive element
l availability of a researcher centrally during office hours to answer questions and support
recruiting therapists
l monthly aphasia-friendly newsletters thanking participants and informing them of the progress of
the trial to help retention (these were also designed in collaboration with the PPI group).
Strengths of the trial design
The trial compared the CSLT intervention under study with UC, but also had a third, AC, group so
any effect of CSLT seen over and above UC can be attributed to the speech and language therapy
components of the intervention as opposed to the receipt of extra attention. There is debate about the
use of appropriate AC in the aphasia literature, suggesting that often social support AC interventions
are so closely matched to speech and language therapy (in terms of materials and support) that any
difference between the interventions is eroded, making it more difficult to establish the effectiveness
of one intervention over another.89 In the CSLT intervention, owing to it taking a self-management
approach, the extra attention gained by the participants is limited to the monthly support with computer
exercises from volunteers or SLTAs. Therefore, our third group uniquely attempted to control for both
additional activity (the focus of self-managed therapy) and additional attention. The attention provided
was the same frequency as for the CSLT group, but was kept distinct from the attention received in the
CSLT group by focusing on different materials (puzzle books).
Our eligibility criteria were inclusive and therefore representative of the population treated in practice.
For example, it is standard practice to exclude people who have had more than one stroke in many
stroke studies; however, eligibility was not limited to only having had one stroke in Big CACTUS to
reflect that people who have had more than one stroke do routinely receive treatment. We included
practical tests to see whether or not individuals were able to see and manipulate the computer
software as part of our eligibility criteria. Similar screening is likely to be carried out in clinical practice.
However, assumptions that older people struggle to use computers may reduce the number of older
people screened using these practical tests in practice.
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A range of outcome measures were used to explore the effect of CSLT on all dimensions of the ICF
(impairment, activity and participation) and on quality of life. An international core outcome set for
aphasia using these dimensions has been developed.24,90 Best et al.85 identified that aphasia studies
often measure only impairment-based improvement, stating ‘attempts to measure carryover to
everyday conversation are conspicuous by their absence’. This was supported by the outcomes of
the 2016 Cochrane review4 for aphasia in which only 31 out of 71 randomised comparisons used
a functional communication outcome for word-finding therapy. Although the co-primary outcome
measures were conducted by qualified SLTs, secondary outcome measures considered the participant’s
own view and the views of carers using patient- and carer-rated outcome measures. An accessible
variant of the EQ-5D-5L designed in collaboration with the PPI group enabled participants to record
their own views regarding quality of life for the health economic analysis.
Random allocation to the trial groups was concealed and therefore not predictable for any trial staff.
The conduct of blinded outcome measure assessments was a strength of the trial. (Our co-primary
outcome measures were blinded, although the secondary patient-rated outcome measures could not
be conducted blind to group allocation.) Blinding was relatively successful, with only 28 participants
having at least one unblinded 6-month outcome measure conducted in total, which is negligible in
terms of the numbers of assessments made in the trial. It is of note that the possibility of unblinding
applied to only the co-primary word-finding measure as conversation videos were rated on the TOMs
by SLTs independent of the trial, allowing blinding to group allocation and time point to be maintained.
Reliability testing between SLTs scoring the conversations with the TOMs and those scoring the
naming test at each site was a further strength of the design.
The trial benefited from comprehensive SAPs and health economic analysis plans being agreed before
unblinding of the data for analysis (see www.journalslibrary.nihr.ac.uk/programmes/hta/122101/#).
The trial was adequately designed and powered to address multiple primary and key research questions
while controlling for the chances of making false-positive conclusions about the effects of the
intervention. In addition, statistical analysis explored the impact of missing data on the results under a
number of scenarios for sensitivity analysis, as well as the impact of adherence to the components of
the CSLT and AC interventions.
The strengths of the health economic evaluation include its comprehensive investigation of many different
scenarios and analyses. The use of an accessible version of the EQ-5D-5L is novel and permits the
elicitation of utility scores from a patient group that is not well provided for with respect to preference-
based utility measures.60,61 The collection of EQ-5D-5L questionnaires completed by carers by proxy
and also for themselves allowed two additional valuable analyses to be conducted. Given the current
uncertainty around how best to use the EQ-5D-5L measure, it was important to conduct analyses using
all the valuation options. The economic evaluation undertaken alongside the CACTUS pilot study was
simplistic and results were highly uncertain.18 Although this more complex evaluation has also produced
highly uncertain results, we have gained important information on where the uncertainties lie. Finally,
this evaluation has been conducted in line with best-practice guidelines and includes a rigorous
investigation into the uncertainty associated with the decision-making problem.
Patient and public involvement
Patient and public involvement was a huge strength of this trial, meeting all four of its aims to:
1. facilitate the recruitment and inclusion of people with aphasia in the trial.
2. ensure that trial materials and processes were accessible to people with aphasia.
3. ensure that the interventions and trial procedures were appropriate and manageable for people
with aphasia.
4. ensure that dissemination of trial results reached a broad audience in accessible formats.
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Collaborating on the production of accessible information formats, including trial information, consent
forms, wording to be used in trial procedures, computer-support guides, accessible outcome measures
and monthly newsletters, has been described throughout the report. The PPI group led on the development
of the study dissemination plan, considering all of the groups we need to target with the results, including
people with aphasia, carers, SLTs, health professionals, guideline developers, commissioners, providers of
services, voluntary sector organisations and researchers. The PPI group instigated and collaborated on
the production of a film showing what aphasia is like, the CSLT intervention and our findings; a results
booklet to accompany the film with key information facts and figures, and aphasia-friendly summaries
of key points alongside; and flyers containing a simple summary of the key findings to send to all the
participants of the trial and to display in public spaces in health and social care venues.
Limitations of the trial
The CSLT intervention has four key components: a computer with word-finding software on it, a SLT to
set it up, independent practice by the person with aphasia and a volunteer/SLTA for support. There are
a growing number of software options available that could be used as the ‘software’ component of this
intervention and for consistency we limited this to just one option in the trial: StepByStep. Numerous
apps are available at low cost; however, the majority of apps designed for word-finding have a limited
range of words to practise, do not enable choice of personally relevant words or adding of personally
relevant words and require the person with aphasia to make their own judgement about whether or
not they said the correct word. They often also focus on naming at the word level and not use of
words in sentences. Tactus Therapy (Tactus Therapy Solutions Ltd, Vancouver, BC, Canada) provides a
suite of apps to help with word-finding, including ‘Naming Therapy’, which has a reasonable number of
words available (418) and enables the addition of personally relevant words. The Tactus ‘Advanced
Naming Therapy’ app focuses on use of words in sentences and conversations, which may help with
generalisation of words to functional contexts. However, the Tactus apps do not provide feedback on
whether or not the word has been named correctly. StepByStep is one of the most expensive word-
finding software options available but has advantages over most other software in having thousands
of words to choose from, the ability to add new words of personal importance and the provision of
feedback on successful word-finding attempts. It also moves through a hierarchy of exercise difficulty
to practise words in sentences.
Another limitation of working with software is that it evolves over time. StepByStep version 5 was new
at the start of the trial and some instability in its functioning, particularly with the speech-recognition
feedback function, increased the amount of time it took the SLTs to set it up, increased the time they
needed to support participants with software problems and potentially limited exercises available to
practice. These difficulties gradually resolved over the course of the trial. Only 33% of participants
used their own computer, with 66% requiring a computer to be loaned by the NHS trust. This was
because it was possible to install the software only on a PC, laptop or tablet running Microsoft
Windows® 7 (Microsoft Corporation, Redmond, WA, USA) or above during the trial, restricting use of
their own devices for users of Macs or iPads (Apple Inc., Cupertino, CA, USA). Since the trial ended,
the software has become available for use on iPads, which will increase the number of people who
could use their own device and automatically increases or decreases the level of exercise difficulty in
response to user responses rather than relying on volunteers or assistants to identify the correct level
of difficulty. Although the concept of the intervention remains unchanged, software may come down in
price over time, exercises could be added to aid transfer to conversation and web-based options may
open it up to a greater number of people using their own devices, etc. Such evolution may lead to
changes in the cost and effectiveness of the intervention, meaning that, although the trial findings will
remain informative, consideration will need to be given to the Big CACTUS results in relation to the
time period in which the trial was conducted.
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The AC group was intended to control for attention and activity carried out in the CSLT group. This
was a difficult intervention to design and measure fidelity for. It is possible that puzzle books may
not control for activity on a computer as well as if the puzzles were presented and completed on a
computer. It may have also been easier to measure adherence to puzzles completed on the computer
for a better comparison with the CSLT group adherence. The telephone calls were designed to control
for attention received by volunteers/SLTAs in the CSLT group. Limitations of the telephone calls
include that support was not face to face and was often received by the carer rather than directly by
the person with aphasia.
Although the eligibility criteria aimed to be inclusive to represent treated populations in routine clinical
practice, those who required treatment in a language other than English had to be excluded because
the computer software was available only in English. In routine practice, guidelines urge SLTs to
provide therapy in the language required by the patient.91 The inclusion criteria were kept broad as we
have little knowledge of who benefits from CSLT. This can also be considered a limitation in some
respects as the intervention was not targeted at those likely to be motivated to self-manage or likely
to have good outcomes. Similarly, the trial design expected SLTs to set up therapy for 100 personally
chosen words after randomisation to the CSLT group. In practice, it may be more likely that a SLTwould
see how motivated a patient is when using the software and whether or not any gains are indicated over
a short trial period before investing the time in detailed set-up for a long duration.
Randomisation was stratified by severity of word-finding and by site, which was important to ensure
that all sites had some participants in each of the three groups; this was particularly important so
that UC was represented by all 20 NHS trusts. However, despite blocking of the allocation sequence,
slightly more participants were randomised to the CSLT and UC groups than to the AC group. This
was solely due to chance and not an error or subversion of the randomisation system. Too many sites
recruiting small numbers of participants each and termination of recruitment after 278 patients may
have contributed to this chance imbalance. The slight imbalance resulted in higher power than expected
for the CSLT and UC primary comparison and slightly lower power than expected for the supportive CSLT
and AC comparison, although power was adequate to address the intended research objectives.
The observed attrition, especially at 12 months, was slightly higher than anticipated, which may have
limited our inference of the long-term effects of the intervention. However, we conducted sensitivity
analyses to explore the impact of missing data at different time points.
As mentioned previously, ‘attempts to measure carryover to everyday conversation are conspicuous by
their absence’.85 This is perhaps because it is difficult to know how best to capture changes and what
changes to look for in conversation. We used the activity scale of the TOMs to rate the conversations
elicited and recorded as it has good reliability and is likely to detect clinically meaningful change.
However, concerns about the sensitivity of the measure have been raised as it is unlikely to detect
small changes.92
As patient participants were randomised, and any carers of these participants were invited to join the
trial if they wished, carers were not randomised to the trial but were self-selecting. Outcomes for
carers of people with aphasia were measured in the trial. Although characteristics were recorded for
the patient participants, characteristics were not recorded for their carers.
In order to limit burden on the participants, it was not possible to measure all of the potential confounding
variables (e.g. cognitive function and location of stroke using magnetic resonance imaging). Although
randomisation was used to control for measured and unmeasured confounders, what we did not
measure limited us from describing the trial population as fully as we would have liked, and hence from
exploring potential heterogeneity of treatment effects in specific subgroups of potential unmeasured
confounders.
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A key limitation of the health economic evaluation is that base-case analyses rely on utility scores
derived from an accessible version of the EQ-5D-5L that has not yet been validated beyond the face
validity it has from being developed with people with aphasia. The need for a validated accessible
version of the EQ-5D-5L for people with aphasia has been discussed in the literature.60,61 As there was
no testing of how well people with aphasia understand the questions in the accessible EQ-5D-5L, it is
possible that lack of understanding, particularly by participants with more severe aphasia, may have
influenced the results. It appears that our use of the accessible EQ-5D-5L in our base-case analysis
may have been conservative, given that cost-effectiveness results using carer proxy utility scores using
a standard EQ-5D-5L questionnaire are more favourable for CSLT.
A further limitation of the health economic analysis is that only direct intervention costs are included.
It is therefore assumed that there are no indirect resource use implications associated with CSLT, AC
or UC. This was based on findings from the CACTUS pilot study, which found no important differences
in indirect resource use between CSLT and UC, leading to a decision not to collect such data for the
health economic analysis in Big CACTUS.18,93 However, some information on UC (in the form of SLT
contact) was collected [see Chapter 4, Usual-care speech and language therapy offered (fidelity/adherence
to provision of usual care)]. Mean SLT contact time reduced in the CSLT, UC and AC groups throughout
the trial, and there may be an indication towards this reducing by slightly more (by approximately 0.5
to 1 hour) in the CSLT group than in the UC and AC groups. If this were the case, and there was an
approximate 1 hour of SLT time cost saving associated with CSLT compared with UC and AC, the impact
on the model-based base-case ICER would be relatively minor; an approximate £50 cost reduction for
CSLT would reduce the ICER for CSLT compared with UC to approximately £40,000 per QALY gained.
Implications of the Big CACTUS trial findings
The implication of this trial is that people with aphasia can increase the number of hours of repetitive
practice to improve word-finding by self-managing their practice of exercises tailored to their needs by
a SLT and supported by an assistant or volunteer. This additional practice comes at a lower cost than if
it was provided through an increase in face-to-face speech and language therapy.
The number of hours of repetitive practice achieved independently by people with aphasia leads to
significant improvements in the ability to find words of personal importance and these improvements
are maintained. Improvements in ability to find words of personal relevance were seen any time post
stroke; therefore, time post stroke is not a barrier to learning new words with therapy.
However, the improvement in word-finding in the chronic phase (> 4 months) post stroke is limited to
the words used in therapy and does not generalise to other words. It is therefore important that words
used in therapy are chosen carefully to be personally relevant and therefore functionally useful for the
lives of each individual being treated.
The aim of speech and language therapy is to improve the ability of people with aphasia to communicate
in everyday situations and thus improve their participation in daily life with consequent increases in their
quality of life. Although the Big CACTUS trial demonstrated significant improvements in word-finding,
these improvements were seen only at the level of the impairment and did not lead to improvements in
conversation or using the new words when given the opportunity in a functional context. It is therefore
unsurprising that participants did not perceive improvements in their communication, participation or
quality of life. The implication of this finding is that generalisation of impairment-based improvements
may not occur with speech and language therapy without additional support.
The cost-effectiveness of CSLT remains uncertain; however, given the cost-effectiveness thresholds
used by NICE in the UK, it is unlikely to be cost-effective for the whole group of people with aphasia.
Subgroup analyses are prone to greater uncertainty than analyses of full trial populations, but our
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analyses suggest that CSLT is more likely to be cost-effective for people with mild and moderate word-
finding difficulties owing to a greater change in quality of life in these groups. For people with severe
word-finding difficulties, our model-based analysis estimated quality-of-life improvements that were
lower with computer therapy than with UC alone.
Further research
Areas of further research in order of priority include the following:
1. Investigating ways to assist with generalisation of newly learned vocabulary into use in conversation
and other functional communication contexts. This should be informed by new knowledge of the
neuroscience of recovery. The results of the Big CACTUS trial showed that some participants did
use a few of their new words in conversation. It would be useful to explore the characteristics,
personal and neurological, and behaviours of these people to compare with those who showed no
generalisation to gain insights into what may help with generalisation.
2. Identification of what was practised and whether or not all of the exercises set up by the SLT were
used. Currently, we have only looked at how much practice the participants of the study conducted.
Further fidelity research into what was practised and whether or not all of the exercises set up by
the SLT were used will help to further our understanding of the content of therapy practice that led
to the Big CACTUS results and any changes that could usefully be made to the intervention.
3. Exploration of further cost and time efficiencies. The approach used in the Big CACTUS trial led to
low-cost self-managed repetitive practice and consequent successful impairment-based word-finding
improvement. Ways of making further cost and time efficiencies to explore include use of telehealth
to set up and monitor exercises to save travel time, use of assistants/volunteers personalising the
set of words to use in therapy instead of qualified SLTs and identification of people with aphasia
who are motivated to use the software before investing time in setting it up.
4. Exploration of whom to target the intervention towards. We offered the intervention to a wide
range of people with aphasia. It is important to investigate the characteristics of those who do well
with the intervention and those who do not, in terms of demographic characteristics, personality
and motivation, and the pattern of brain lesions resulting from the stroke.
5. Implementation of an optimised CSLT approach as part of NHS speech and language therapy
provision. As a pragmatic trial, the Big CACTUS trial can offer insights into factors affecting
implementation of self-managed computer therapy approaches within the NHS. Further research
into the implementation of this approach as part of NHS speech and language therapy needs to be
conducted to assist with making the approach available to people with aphasia for repetitive
language practice components of their therapy provision.
6. Validation of the accessible variant of the EQ-5D-5L. Measurement of quality of life in people with
aphasia for use in health economic analysis presents a challenge. We developed an accessible
variant of the EQ-5D-5L for the Big CACTUS trial. We plan to carry out further validation of this
tool. Development of accessible forms of other tools to measure quality-of-life changes resulting
from communication therapies also needs to be carried out. In addition, finding out more about
the utility benefit of the CSLT intervention would be highly valuable as the utility associated with
achieving a good response to treatment was the most important parameter within the economic model.
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Appendix 1 List of participating
NHS trusts
l Sheffield Teaching Hospitals NHS Foundation Trust.
l Humber NHS Foundation Trust.
l Newcastle Upon Tyne Hospitals NHS Foundation Trust.
l Northern Health and Social Care Trust.
l Belfast Health and Social Care Trust.
l Essex Partnership University NHS Foundation Trust.
l NHS Greater Glasgow and Clyde.
l Cwm Taf Morgannwg University Health Board.
l Derbyshire Community Health Services NHS Trust.
l Nottinghamshire Healthcare NHS Trust.
l Northern Lincolnshire and Goole NHS Foundation Trust.
l Livewell Southwest (Plymouth Community Healthcare).
l Norfolk Community Health and Care NHS Trust.
l Somerset Partnership NHS Foundation Trust.
l Cambridgeshire and Peterborough NHS Foundation Trust.
l Northamptonshire Healthcare NHS Foundation Trust.
l Dorset HealthCare University NHS Foundation Trust.
l City Hospitals Sunderland NHS Foundation Trust.
l Abertawe Bro Morgannwg University Health Board.
l NHS Ayrshire and Arran.
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Appendix 2 Process for selection of
Therapy Outcome Measures raters and
scoring procedure
The TOMs is one of the co-primary outcome measures for Big CACTUS. It is a rating of participants’ability to communicate in conversation. Each participant will have a 10-minute video-recorded
conversation at baseline and 6, 9 and 12 months with a SLT (different therapists at different time points).
Some videos recorded are longer than the advised 10 minutes. Two research SLTs rated a sample of videos
based on the first 10 minutes and the whole video. The scores given after watching the whole video were
the same as those given after watching only the first 10 minutes; therefore, only the first 10 minutes of
each video will be used for rating purposes. The videos will be rated by independent SLTs using the activity
scale of the aphasia TOM. As there will be > 1000 videos to rate, we need a number of raters.
Our primary comparison is the difference in change in scores between time points between groups.
It is proposed that all of the videos at all time points of all participants at each site will be rated by
the same rater. Therefore, it is important to know that raters have good intrarater reliability to give us
confidence that any change in the scores across time points is likely to be due to change in the participant’s
communication ability and not due to variability in a rater’s scoring (intrarater reliability). The raw scores
will also be presented at each time point and data will be adjusted for baseline differences between groups.
To ensure that the differences between scores are a true reflection of the differences in scores between
participants, we need to minimise the variation in scoring between raters (inter-rater reliability).
The TOMs scale has six descriptors corresponding to 0, 1, 2, 3, 4 and 5. It is an 11-point scale as scores
between two descriptors can be given (e.g. 1.5, 3.5). Previous work conducted with the TOMs suggests
that the measure can be used reliably and that a variation of 0.5 in scores of different raters is acceptable.
To ensure confidence in the scoring of the raters who were used to rate the videos in the Big CACTUS
trial, 18 raters wishing to participate attended a benchmarking session in which a sample of videos
were watched and scores were discussed. Discrepancies in interpretation of the scoring system were
highlighted and resolved. An agreed set of scoring instructions was compiled. The 18 raters agreed
that 0.5 would be an acceptable amount of variation in the scores. The 18 raters then used the refined
scoring instructions alongside the TOMs activity scale to rate 10 videos (five pairs of videos from five
different participants at different time points). All 18 raters rated all of the same 10 videos (time point 1).
After 6 weeks, the same 10 videos were sent back to the raters in a different order. Seventeen of the
18 original raters provided ratings of the videos (time point 2).
We need to understand the intrarater and inter-rater reliability of the rating given by these raters in
order to have confidence in the scores provided by them, which constitute our co-primary outcome
measure. Raters will be used to score videos for the study only if their intrarater reliability is ≥ 70%
(of scores within 0.5 between time points 1 and 2). We also need to ensure that raters are rating in a
similar way to each other. As there is no gold standard rater, we have taken the median as the benchmark
of ‘what most people think the score should be’. We have included only raters that rate ≥ 70% of their
scores within 0.5 of the median, taking into consideration time points 1 and 2.
The intraclass correlation coefficients take account of the difference between scores at time points 1
and 2 (not only whether they are within 0.5 or not). Although all raters fall into the category of having
‘excellent’ intrarater reliability, these are arbitrary cut-off points. As JH’s intrarater reliability is significantly
lower than the rest of the group of raters, this rater will not be used in rating the videos for the Big
CACTUS project. This is consistent with the fact that this rater had < 70% of scores within 0.5 between
time points 1 and 2.
DOI: 10.3310/hta24190 Health Technology Assessment 2020 Vol. 24 No. 19
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Palmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
121
TABLE 26 Therapy outcome measures ratings of 10 videos by all raters: time point 1
Videos
Rater
MedianHW EJ AM AF VSm JR JC JB LM HH JH MJ SP NU JB VSp AP SM
1 3.5 3.5 3.5 4 4 4 4 3.5 3.5 4 4 4 4 3.5 3.5 4 4 3.5 4
2 4 4 4 4.5 4.5 4 4 4 4 4.5 4.5 4.5 4.5 4 4 3 3 4 4
3 1.5 2 2 2.5 2.5 1 1 2 1 1.5 1 2 1 1.5 1 1 1.5 2 1.5
4 2.5 2.5 2.5 3 3 1.5 1.5 2.5 1.5 2 2.5 2.5 1.5 1.5 1.5 1.5 2 2 2
5 1.5 2 1.5 1.5 2 1 1.5 1.5 1.5 1.5 1 2 1 1.5 1 0.5 1 1.5 1.5
6 2.5 2.5 2 2 2.5 1.5 2 2 2 1.5 2 3 1 1.5 1.5 1 2 2.5 2
7 3 3 3 3 4 3.5 3 3 3 3.5 3 3.5 2 3 3 1.5 2 3.5 3
8 2 3 3 3 4 3 3 3 3 3 2.5 3.5 3 3 3 1.5 1 3.5 3
9 3 2.5 2 1.5 2.5 1 1 1.5 2 2.5 1.5 2 1 2 1.5 0.5 1 1.5 1.5
10 3 2.5 2.5 2.5 2.5 2 1.5 2 1.5 2.5 2.5 2.5 1 2.5 2 1 1.5 2 2.25
■ 2.0 below 0.5 from median score
■ 1.5 below 0.5 from median score
■ 1.0 below 0.5 from median score
■ 0.5 below 0.5 from median score
■ 0.5-0.75 above 0.5 from median score
■ 1.0 above 0.5 from median score
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TABLE 27 Inter-rater reliability of raters at time point 2 (excluding raters with low inter-rater reliability at time point 1 and/or low intrarater reliability)
Videos
Rater
MedianHW EJ AM AF VSm JR JB LM HH JH MJ SP NU JB VSp AP SM
1 4 3.5 4 4 4 4.5 4 4 4 4 4 3.5 4 3.5 4 3 3.5 4
2 4.5 4 4.5 4 4.5 4 4.5 4.5 4.5 5 4.5 4 4 4 3 4 4 4
3 2 2.5 1 1.5 2.5 1 1.5 1.5 2 2.5 2.5 1 1.5 1.5 1 1 2 1.5
4 2.5 3 1.5 3 2.5 1 2.5 2 2.5 3 2.5 1 2 1.5 1.5 2 2.5 2.5
5 1 2.5 1.5 2 3 1.5 1.5 2 2 1.5 2.5 1 1.5 1 0.5 1 2 1.5
6 2 3 2 3 2 1 1 2.5 1.5 2 2 1 1 1 1 1.5 1.5 1.5
7 2 3.5 3.5 3.5 3.5 4.5 4 3 4 4 4 2.5 3.5 3.5 1.5 2 3.5 3.5
8 1.5 3 3.5 3 3.5 4 3.5 3.5 4 3.5 3.5 3.5 3 3 1.5 1 3 3.5
9 2.5 2.5 3 2 3 1.5 1.5 2.5 2.5 3 2.5 1.5 1.5 1.5 0.5 1.5 2 2
10 3 2.5 2.5 2 2.5 2 2 3 3 2.5 2 1 1.5 2 1 2 1.5 2
■ 2.0 below 0.5 from median score
■ 1.5 below 0.5 from median score
■ 1.0 below 0.5 from median score
■ 0.5 below 0.5 from median score
■ 0.5-0.75 above 0.5 from median score
■ 1.0 above 0.5 from median score
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TABLE 28 Intrarater reliability for each rater in Tables 26 and 27: TOMs benchmarking, reliability scores and intrarater reliability scores
Indicators of reliability
Rater
HW EJ AM AF VSm JR JB LM HH JH MJ SP NU JB VSp AP SM
Inter-rater reliability
Number of scores within 0.5 of median out of 20 (T1 +T2) 14 16 18 17 13 17 19 17 18 19 17 14 20 19 7 14 20
Percentage of scores within 0.5 of median 70 80 90 85 65 85 95 85 90 95 85 70 100 95 35 70 100
Intrarater (test–retest) reliability
Number of scores within 0.5 between T1 and T2 9 10 7 8 9 8 8 9 9 6 9 10 9 10 10 8 9
Percentage of scores within 0.5 between T1 and T2 90 100 70 80 90 80 80 90 90 60 90 100 90 100 100 80 90
ICCs for intrarater reliability 0.85 0.83 0.80 0.81 0.83 0.92 0.85 0.81 0.91 0.75 0.86 0.96 0.90 0.95 1.0 0.83 0.86
ICC, intraclass correlation coefficient; T1, time point 1; T2, time point 2.
Interpretation of ICCs: < 0.40 = poor; 0.40–0.59 = fair; 0.60–0.74 = good; 0.75–1.00 = excellent.
Shading denotes scores that fall below the reliability cut-off point for inclusion of raters to score all of the videoed conversations.
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Fourteen raters were selected to rate videos for Big CACTUS. In all, 86% of their ratings were
within 0.5 of the median (inter-rater reliability) and 88% of the ratings were within 0.5 between time
points 1 and 2.
Although we have selected the 14 raters who rate most consistently compared with the median, and
between time points 1 and 2, some variability still exists between raters. To maximise the chance that
a change in score between time points represents a change in communication ability rather than a
slight difference between raters, each participant will have all four videos rated by the same rater.
To ensure that any differences in raters are spread evenly across the three trial groups, participants
from the same site will be allocated to the same rater so each rater scores participants from each
trial group.
A slight upwards trend was observed between ratings at time points 1 and 2, suggesting that there
may be a familiarity effect. To account for this possibility, the order of presentation of videos from
each participant will be randomised (e.g. participant 1, pair 1: 6 months–baseline; participant 1, pair 2:
9–12 months).
In some instances, there are only baseline videos available (due to withdrawal, etc.). In the SAP, the
ITT analysis will be conducted based on only participants for whom there is an outcome measure.
However, all data will be used to conduct a sensitivity analysis; therefore, baseline-only videos will
be rated, but this will be conducted after all available pairs of videos have been rated.
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Procedure for Therapy Outcome Measures rating document
Procedure for TOMS rang
You will receive videos in pairs, e.g. R01-01 A1 and R01-01 B1 (both of the 
same parcipant)
1) Use a mer to watch only the first 10 minutes of the first video in the pair and score 
according to the acvity scale of the TOMs for Aphasia
- Start at the top or boom of the TOMs scale based on your first impression of whether it
is good/poor and work up or down through the descriptors.
- Remember that you can select a score half way between two of the wrien descriptors 
(scoring .5) 
- Focus on the underlined part of the descriptors as these can be judged through watching
a video
2) Use a mer to watch only the first 10 minutes of the second video of the pair and score 
according to the acvity scale of the TOMs for Aphasia 
- Start at the top or boom of the TOMs scale based on your first impression of whether it
is good/poor and work up or down through the descriptors.
- Remember that you can select a score half way between two of the wrien descriptors 
(scoring .5) 
- Focus on the underlined part of the descriptors as these can be judged through watching
a video
3) Check you are happy with the scores you have allocated for both videos. Modify if
needed to ensure that if one video seemed beer than the other, that the scores reflect 
this (NB this is likely to be a small change to the score only) 
4) Document the final scores for both videos before moving on to the next pair of videos
Prompng/cueing includes: 
- Therapist checking what the paent meant if it was ambiguous 
- Therapist giving cues (e.g. semanc or phonemic)
- Therapist providing lead in phrases
NOT summarising/recapping what has been said in the conversaon
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TOM descriptors with clarifications following benchmarking session
KEY QUESTIONS to help choose starting point: 
1) How successful is the participant at getting their message across?
2) How much help do they need in order to do this? 
0 Unable to communicate in any way. No effective communication. No 
interaction. 
1 Occasionally able to make *basic needs known with familiar persons or
trained listener in familiar contexts. Minimal communication with maximal 
assistance.
*Basic needs = everyday needs such as needing the toilet/ a drink
2 Limited functional communication. Consistently able to make *basic
needs/conversation understood but is heavily dependent on cues and 
context. Communicates better with trained listener or family members or in
familiar settings. Frequent repetition required. Maintains meaningful 
interaction *related to here and now.
*Basic needs/conversation = everyday needs/simple conversation
*Related to here and now = things that are in the immediate physical 
environment and can be pointed to/shown to the listener
3 Consistently able to *make needs known but can sometimes convey more
information than this. Some inconsistency in unfamiliar settings. Is less 
dependent for intelligibility on cues and context. Occasional repetition 
required. *Communicates beyond here/now with *familiar persons; needs
cues and prompting. 
*Make needs known = or able to engage in simple conversation
*Communicates beyond here/now = talking about things are outside the 
immediate physical environment i.e. things that can be seen/heard from
where the conversation is had. (This would include talking about things in the 
past/future but would not be limited to this).
*Familiar person = or trained listener
4 Can be understood most of the time by any listener despite communication 
irregularities. Holds conversation; requires occasional prompts, particularly 
with a wider range of people.
5 Communicates effectively in all situations
*Half points can be allocated
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Appendix 3 Definitions of adverse events
and serious adverse events and categories
of serious adverse event results
Safety assessments
Adverse events associated with the intervention are not anticipated given the low-risk intervention
(in line with similar studies managed by Sheffield CTRU). However, if adverse events do occur these
will be recorded by the therapist on the case report form and database. Adverse events do not need to
be reported by fax to the CTRU.
Adverse events may include increased fatigue, fits or seizures, worsening vision or visual difficulties,
increasing frequency or severity of headaches, accidents (e.g. falls) or injuries.
If a hospital admission or any other event considered serious occurs, these will be reported as serious
adverse events (SAEs). We will not report further stroke-related events as SAEs as these are expected
within this population.
The following criteria will be used when assessing SAEs.
Intensity (severity):
l mild – does not interfere with routine activities
l moderate – interferes with routine activities
l severe – impossible to perform routine activities.
Relationship to the trial activity (computerised speech therapy or puzzle books):
l Unrelated – there is no evidence of any causal relationship.
l Unlikely – there is little evidence to suggest that there is a causal relationship. There is another
reasonable explanation for the event (e.g. the participant’s clinical condition).
l Possible – there is some evidence to suggest a causal relationship. However, the influence of other
factors may have contributed to the event (e.g. the participant’s clinical condition).
l Probable – there is evidence to suggest a causal relationship and the influence of other factors
is unlikely.
l Definite – there is clear evidence to suggest a causal relationship and other possible contributing
factors can be ruled out.
l Not assessable – there is insufficient or contradictory information that cannot be supplemented
or verified.
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TABLE 29 Category of SAE (treatment as received), unrelated or unlikely to be related to trial activity
SAE category
Trial group, number of events
UC (n= 23) AC (n= 12) CSLT (n= 10)
Abdominal pain 0 1 0
Admission, cause unknown 0 0 2
Cardiac problems 0 1 1
Chest infection 1 0 1
Death, cardiac arrest 2 0 1
Death, cause unknown 1 1 0
Death, illness 1 0 0
Death, influenza 0 0 1
Death, sepsis 1 0 0
Diarrhoea and vomiting 2 0 0
Fall 4 0 1
Fall, fracture 3 3 1
Fracture 0 1 0
Infection 2 0 0
Muscular chest pain 0 1 0
Overdose 2 0 0
Possible seizure 0 1 0
Rectal bleeding 1 0 0
Seizure 0 0 1
Seizures, urine infection 1 0 0
Septicaemia 0 2 0
Urinary problems 1 1 0
Urinary tract infection 1 0 1
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Appendix 4 Big CACTUS flow diagrams
of activity
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No Yes
Thank person for their time
and include in numbers not
interested in participating
on screening log. Record
reason if known
Send project summary to potential participant (via post, e-mail or
voluntary group leader)
CACTUS project SLT to identify potential participants from past and
current patient lists, voluntary groups and response to posters. Check:
• Stroke  
• Aphasia  
• ≥ 4 months post onset  
• Aged ≥ 18 years  
After 1–2 weeks contact potential participant via telephone to see if
interested in finding out more about the study
Arrange visit to confirm eligibility and to
provide further information about project in
the most appropriate way for the individual
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The baseline assessment and randomisation (guidance for taking consent
and baseline information for CACTUS participants)
Suggest patient takes time to decide if they want to participate
Arrange appointment to take consent and baseline measures
Go over the participant information sheet and answer any questions
If not eligible, explain
that the study is not
right for them, discuss
their usual activities
and thank them for
their time
V
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it
 1
 (l
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Perform consent support tool language screen – identify
appropriate participant information sheet
Discuss project with potential participant, explain that you need to
ask them a few questions to check the study is right for them
Perform basic screening to check eligibility
• Aged ≥ 18 years
• Diagnosis of stroke(s)
• Onset of stroke ≥ 4 months prior to randomisation
• Diagnosis of aphasia, subsequent to stroke, as confirmed by a trained SLT
• Word-finding difficulties tested by the Naming Objects test of the CAT30
    (score of 10–90%, 5–43/48)
• Ability to perform a simple matching task with the StepByStep program (to
    confirm sufficient vision and cognitive ability to participate in the intervention)
• Ability to repeat at least 50% of words in simple word-repetition task in
    StepByStep program (score of at least 5/10)
Ask the patient to think about topics/words
they might like to be able to say
Refer to FAQ for guidance
Help the participant choose 100 words
On the therapist CACTUS laptop, set up a new profile for the
participant and add new word sets
Use StepByStep library and categories as a prompt and chat
about what the participant’s interests are, what types of things
it would be really useful to be able to say. Take photographs of
anything required that isn’t in the StepByStep library, or
download their digital photographs onto a memory stick
Arrange next appointment to take final baselines and randomise
Follow the same procedures to
obtain carer consent for them to
provide information about
themselves. Answer questions,
provide sufficient time to decide
and invite to complete the
consent form
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Baseline measures
• CAT Comprehension of Spoken Sentences
• COAST
• EQ-5D-5L patient
• EQ-5D-5L by proxy
Carer baseline measures (if applicable)
• CaCOAST
• EQ-5D-5L carer
• CarerQoL
Informed consent
Answer questions about the study (refer to FAQ if required)
Ask yes/no questions to check patient understands what the study involves
Take consent – use the consent form for patients with the date that matches
the information sheet provided (make sure patient initials all boxes, signs and
dates the form. If unable to do this, ask carer to witness the mark made to
declare willingness to participate)
Enter all scores on case report form
Enter all scores on case report form
Refer to list they may already have created
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Baseline measure (continued)
Personal vocabulary naming test of 100 chosen words (see guidance)
Video short conversation using completed video conversation
question guide (see guidance)
Randomisation
Randomise participant in their home if internet access available, or telephone CTRU from participant’s 
home and CTRU will randomise for you, or randomise back at office (arrange to visit again once 
randomised to discuss group randomised to)
Before visit 3
Select 100 items of vocabulary under a new person profile (print the
score sheet from StepByStep four times for use at the different
assessment points – store three in participant’s CACTUS file)
Write out open-ended questions for video-recorded conversation
(see question guide)
V
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UC
Explain about continuing usual
activities, discuss these and
remind the participant about
the possibility of still having
a go with the computer at a
later date
Find out what types of puzzle
books they would prefer to do
(refer to puzzle book guide to
select book of appropriate level)
Leave first book with them and
recommend they do one each day
Modify standard steps, using the
treatment fidelity form, according
to the individual’s aphasia profile
Let the participant know you will
return to introduce volunteer/
assistant
AC + UC
Intervention +
UC
The 3-month follow-up assessments
3 months from randomisation date, make a telephone call to participant
(or visit participant if more appropriate)
Ask participant about the usual care they receive for their communication
difficulties and use adverse event prompt form to ask questions about
their health in the last 3 months
If any serious health events have occurred, record on adverse events
prompt form, and follow serious adverse event procedure, if applicable
See instructions at bottom of
adverse event prompt form
3
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The 6-, 9- and 12-month follow-up assessments
Record all scores on the case report form
If you were unblinded at any
time to the participant’s trial
arm allocation, please record
this on the ‘unblinding’ form
If you were unblinded at any
time to the participant’s trial
arm allocation, please record
this on the ‘unblinding’ form
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Input completed case report form onto database (or return case
report form to CTRU  if you are having difficulty
accessing the database)
Contact the participant by telephone to arrange follow-up visit
Record all scores on the case report form
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Input completed case report form onto database (or return case
report form to CTRU if you are having difficulty
accessing the database)
Contact the participant by telephone to arrange follow-up visit
Complete the following:
• Naming test of 100 chosen words (see scoring guidelines on score sheet)
• COAST
• EQ-5D-5L patient
• EQ-5D-5L by proxy
• Video conversation
• Naming Objects (CAT)
Complete the following with the participant’s carer:
• EQ-5D-5L carer
• CaCOAST
• CarerQoL
Complete the following:
• Naming test of 100 chosen words (see scoring guidelines on score sheet)
• COAST
• EQ-5D-5L patient
• EQ-5D-5L by proxy
• Video conversation
• Naming Objects (CAT)
6-month outcome measures
Complete the following with the participant’s carer:
• EQ-5D-5L carer
• CaCOAST
• CarerQoL
Carer outcome measures (if applicable)
9-month outcome measures
Carer outcome measures (if applicable)
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If you were unblinded at any
time to the participant’s trial
arm allocation, please record
this on the ‘unblinding’ form
Record all scores on the case report form
1
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Input completed case report from onto database (or return case
report form to CTRU if you are having difficulty
accessing the database)
Contact the participant by telephone to arrange follow-up visit
Complete the following:
• Naming test of 100 chosen words (see scoring guidelines on score sheet)
• COAST
• EQ-5D-5L patient
• EQ-5D-5L by proxy
• Video conversation
• Naming Objects (CAT)
12-month outcome measures
Complete the following with the participant’s carer:
• EQ-5D-5L carer
• CaCOAST
• CarerQoL
Carer outcome measures (if applicable)
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Appendix 5 Computer practice
0
0
15
30
45
60
75
90
105
120
135
150
165
180
C
o
m
p
u
te
r 
u
se
 (m
in
u
te
s)
195
210
225
240
255
270
285
300
30 60 90 120 150 180 210 240 270
Time to computer use from randomisation (days)
300 330 360 390 420 450 480 510
FIGURE 26 Computer therapy practice time per participant over time. Each line, regardless of colour, represents the
participant’s computer practice activity. The vertical dotted line is the expected 6-month assessment from randomisation.
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Appendix 6 Unit costs
TABLE 30 Unit costs applied for valuation of resource use
Item description Unit cost (£) Source of unit cost Note
Laptop/tablet loan for 6 months
(for participants who did not
have their own computer)
69.00 Big CACTUS trial Unit cost calculated from the average
cost of a laptop/tablet purchased
through the NHS (£690) and divided
by 10 users over its shelf life
StepByStep software individual
licence
250.00 StepByStep website20
StepByStep software clinician
licence
550.00 StepByStep website20
StepByStep software clinician
five-licence bundle
2200.00 StepByStep website20
Headsets 14.50 Big CACTUS trial
Puzzle books 2.50 Big CACTUS trial Average cost of a puzzle book
purchased in the Big CACTUS trial
SLT band 7 cost per minute 0.90 PSSRU 201768 Delivery of training on StepByStep
software
SLT band 6 cost per minute 0.75 PSSRU 201768 Delivery of CSLT intervention
SLT band 5 cost per minute 0.57 PSSRU 201768 Delivery of AC intervention
SLTA band 3 cost per minute 0.41 PSSRU 201768 Delivery of CSLT intervention
Volunteer cost per minute 0.41 PSSRU 201768 Only included in broader perspective;
volunteers costed the same as a SLTA
for providing an equivalent service
Travel cost per mile 0.45 GOV.UK69
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Appendix 7 EuroQol-5 Dimensions,
five-level version completion information
Table 31 shows the proportions of complete data for the EQ-5D-5L questionnaires collected duringBig CACTUS. Complete data for the EQ-5D-5L means that the patient completed all five items
of the EQ-5D-5L questionnaire. Before assessments of data completeness were made, the EQ-5D-5L
scores for the patients who died during the course of the trial were imputed as zero values after the
patient’s death. Note that the total numbers at baseline reported in Table 31 include the total number
randomised to each trial group, including participants who subsequently died. Completion rates were
high for the accessible EQ-5D-5L measure and therefore low levels of imputation were required for
the base-case analysis.
TABLE 31 Data completeness for EQ-5D-5L questionnaires
Parameter
Trial group, n (%)
UC AC CSLT
EQ-5D-5L accessible 101 (100) 80 (100) 97 (100)
Baseline 101 (100) 80 (100) 96 (99)
6 months 89 (88) 71 (89) 84 (86)
9 months 86 (85) 64 (80) 80 (82)
12 months 87 (86) 62 (77) 77 (79)
EQ-5D-5L carer proxy 76 (75) 57 (71) 65 (65)
Baseline 76 (75) 57 (71) 65 (65)
6 months 53 (53) 44 (55) 57 (58)
9 months 47 (47) 35 (44) 51 (52)
12 months 49 (49) 34 (43) 45 (46)
EQ-5D-5L carer self-complete 62 (61) 49 (61) 64 (65)
Baseline 62 (61) 49 (61) 64 (65)
6 months 49 (48) 38 (47) 53 (55)
9 months 44 (44) 36 (45) 48 (50)
12 months 46 (45) 34 (42) 45 (46)
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Appendix 8 Secondary analysis model
parameters: utility scores
TABLE 32 Secondary analysis model parameters: utility scores (complete case, carer proxy, Hernandez-Alava et al.63
mapping and English EQ-5D-5L tariff)
Parameter Mean Distribution (alpha, beta) 95% CI
Complete-case analysis
Utility score (aphasia health state) 0.61 Beta (645.55, 405.25) 0.58 to 0.64
Difference in utility score associated with: Distribution (standard error)
Good response (6 months) –0.04 Normal (0.02) –0.09 to 0.01
Good response (9 months) 0.01 Normal (0.03) –0.04 to 0.06
Good response (12 months) 0.03 Normal (0.03) –0.02 to 0.07
Carer proxy analysis
Utility score (aphasia health state) 0.51 Beta (642.11, 612.12) 0.48 to 0.54
Difference in utility score associated with: Distribution (standard error)
Good response (6 months) –0.01 Normal (0.03) –0.06 to 0.04
Good response (9 months) –0.00 Normal (0.03) –0.05 to 0.06
Good response (12 months) 0.02 Normal (0.03) –0.04 to 0.08
Hernandez-Alava et al.63 analysis
Utility score (aphasia health state) 0.61 Beta (645.98, 421.65) 0.58 to 0.63
Difference in utility score associated with: Distribution (standard error)
Good response (6 months) –0.04 Normal (0.02) –0.09 to 0.00
Good response (9 months) –0.02 Normal (0.03) –0.07 to 0.03
Good response (12 months) 0.02 Normal (0.02) –0.02 to 0.07
English EQ-5D-5L tariff analysis
Utility score (aphasia health state) 0.71 Beta (895.15, 367.62) 0.68 to 0.73
Difference in utility score associated with: Distribution (standard error)
Good response (6 months) –0.04 Normal (0.02) –0.09 to 0.00
Good response (9 months) –0.01 Normal (0.02) –0.06 to 0.04
Good response (12 months) 0.02 Normal (0.02) –0.03 to 0.06
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Appendix 9 Computer and software costs
scenario analysis
Table 33 presents the combined computer and software costs associated with the scenario analysesdescribed in Chapter 5, Model inputs: resource use and costs. There is an appreciable change in costs
under these different scenarios. It is important to note that when an individual lifetime licence is used
it could be used beyond the 6-month intervention period (as was the case for participants with these
licences in Big CACTUS). A clinician licence can be used by only one patient at a time and, therefore,
would be taken away from a patient when it is transferred to another patient. Similarly, a 6-month
individual licence would be usable for only a 6-month period. Therefore, the scenarios in Table 33 that
lead to reduced computer/software combined costs may also reduce the time for which a patient has
access to the computer program, which may affect long-term outcomes.
TABLE 33 Computer and software costs scenario analyses
Scenario
Cost per patient (£)
Computer Software
Combined computer
and software
Base case (32% use own computer with an individual licence) 46.95 109.84 156.79
All CSLT participants borrow a computer and use a clinician
StepByStep licence
69.00 44.00 113.00
All CSLT participants use their own computer and an individual
StepByStep licence
0.00 250.00 250.00
75% of CSLT participants use their own computer and an individual
StepByStep licence, 25% borrow a computer and use a clinician
licence
17.25 198.50 215.75
£120 is paid for a 6-month individual StepByStep licence, rather
than £250 for a lifetime licence, reflecting a new payment option
46.95 68.29 115.24
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Appendix 10 Speech and language
therapist, speech and language therapy
assistant and volunteer costs
TABLE 34 The SLT, SLTA and volunteer costs
Description of cost
Time (hours per
patient) Unit cost (£) per hour (band) Per-patient cost (£)
CSLT time and costs
SLT time directly related to CSLT participants
Setting up software 5.77 45.00 (band 6) 320.72
Providing technical support 0.99
Monitoring progress 0.35
Total 7.13
SLT time related to support/training of SLTAs and volunteers
Providing training 0.89 45.00 (band 6) 82.47
Supporting SLTA/volunteer 0.48
Providing technical support 0.22
Monitoring feedback form 0.24
Total 1.83
SLTA time directly related to CSLT participants
Setting up computer/microphone 0.47 25.00 (band 3) 68.24
Encouraging the participant 0.98
Assisting with software 0.58
Conversations to practise words 0.51
Other non-face-to-face contact 0.18
Total 2.73
SLTA time related to support/training
Total time spent under supervision/
training from SLT
1.11 25.00 (band 3) 27.79
Volunteer time directly related to CSLT participants
Setting up computer/microphone 0.11 25.00 (assumed equal to SLTA) 28.20
Encouraging the participant 0.50
Assisting with software 0.30
Conversations to practise words 0.20
Other non-face-to-face contact 0.01
Total 1.13
continued
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TABLE 34 The SLT, SLTA and volunteer costs (continued )
Description of cost
Time (hours per
patient) Unit cost (£) per hour (band) Per-patient cost (£)
Volunteer time related to support/training
Total time spent under supervision/
training from SLT
0.72 25.00 (assumed equal to SLTA) 18.03
AC time and costs
Total time spent administering
puzzle books
0.80 34.00 (band 5) 27.29
Total SLT/SLTA/volunteer costs
Total SLT/SLTA costs associated
with CSLT
12.80 – 499.22
Total volunteer costs associated
with CSLT
1.85 – 46.22
Total SLT/SLTA costs associated
with AC
0.80 – 27.29
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Appendix 11 Model parameters:
resource use
TABLE 35 Model parameters: resource use
Parameter Mean
Distribution
(parameters) 95% CI Source
CSLT resource use parameters
Proportion who need to borrow a computer 0.68 Beta (66, 31) Big CACTUS
Utilisation rate of software licences 0.50 Beta (5, 5) Assumption
Number of patients who could benefit from
speech and language therapy StepByStep
software training annually
55.43 Gamma (11.09) Big CACTUS, with
assumed standard
error equal to 20%
of the mean
Proportion who need a headset 0.33 Beta (32, 65) Big CACTUS
Mean SLT time spent with participant (hours) 7.13 Gamma (0.54) 6.06 to 8.19 Big CACTUS
Mean SLT time spent supervising/training
SLTAs and volunteers (hours)
1.83 Gamma (0.14) 1.55 to 2.10 Big CACTUS
Mean SLTA time spent with participants (hours) 2.73 Gamma (0.28) 2.17 to 3.28 Big CACTUS
Mean SLTA time spent under supervision of
SLT (hours)
1.11 Gamma (0.12) 0.86 to 1.35 Big CACTUS
Mean SLT/SLTA mileage 127.52 Gamma (13.50) 100.67 to 154.35 Big CACTUS
Mean volunteer time spent with participants
(hours)
1.13 Gamma (0.20) 0.72 to 1.52 Big CACTUS
Mean volunteer time spent under supervision
of SLT (hours)
0.72 Gamma (0.14) 0.44 to 1.01 Big CACTUS
Mean volunteer mileage 23.57 Gamma (6.70) 10.29 to 36.83 Big CACTUS
AC resource use parameters
Mean number of puzzle books 4.35 Gamma (0.20) 3.96 to 4.74 Big CACTUS
Mean SLT time spent administering AC (hours) 0.80 Gamma (0.05) 0.70 to 0.89 Big CACTUS
Parameters for beta distribution: alpha, beta.
Parameter for gamma distribution: standard error.
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Appendix 12 Model parameters used for
base-case, secondary and subgroup analyses
DOI: 10.3310/hta24190 Health Technology Assessment 2020 Vol. 24 No. 19
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Palmer et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
151
TABLE 36 Model parameters used for base-case, secondary and subgroup analyses
Model
parameter Distribution
Distribution
parameters
Values in each analysis modelled
Base
case
Stroke time quartile SGs Comprehension ability SGs Word-finding ability SGs Secondary analyses
Q1 Q2 Q3 Q4 Mild Moderate Severe Norm Mild Moderate Severe
1. Complete-
case analysis
2. English
EQ-5D-5L
tariff
3. Proxy
report
4. EQ-5D-5L mapping
of Hernandez-Alava
et al.63
5. Including
carer QALYs
6-month good
response: CSLT
Beta Alpha 73 21 17 22 13 31 24 4 14 30 26 19 73 73 73 73 73
Beta 21 6 4 4 7 12 5 1 3 11 4 6 21 21 21 21 21
6-month good
response: UC
Beta Alpha 45 11 13 12 9 24 7 3 11 19 18 10 45 45 45 45 45
Beta 52 11 14 12 15 26 17 0 9 21 19 14 52 52 52 52 52
6-month good
response: AC
Beta Alpha 39 10 9 9 11 21 11 2 5 19 9 12 39 39 39 39 39
Beta 40 8 11 7 14 15 13 4 8 19 13 10 40 40 40 40 40
9-month new
response: CSLT
Beta Alpha 7 2 4 2 3 4 3 0 0 3 1 3 7 7 7 7 7
Beta 14 4 0 2 4 8 2 1 3 8 3 3 14 14 14 14 14
9-month new
response: UC
Beta Alpha 19 4 3 5 7 10 5 0 4 9 9 2 19 19 19 19 19
Beta 33 7 11 7 8 16 12 0 5 12 10 12 33 33 33 33 33
9-month new
response: AC
Beta Alpha 14 6 4 2 2 3 6 2 3 7 3 4 14 14 14 14 14
Beta 26 2 7 5 12 12 7 2 5 12 10 6 26 26 26 26 26
9-month relapse:
CSLT
Beta Alpha 14 5 4 3 2 5 8 1 0 4 5 5 14 14 14 14 14
Beta 59 16 13 19 11 26 16 3 14 26 21 14 59 59 59 59 59
9-month relapse:
UC
Beta Alpha 10 3 1 4 2 5 1 0 4 7 3 1 10 10 10 10 10
Beta 35 8 12 8 7 19 6 3 7 12 15 9 35 35 35 35 35
9-month relapse:
AC
Beta Alpha 11 2 1 4 4 5 5 1 0 3 2 6 11 11 11 11 11
Beta 28 8 8 5 7 16 6 1 5 16 7 6 28 28 28 28 28
12-month new
response: CSLT
Beta Alpha 11 2 4 3 2 5 6 0 0 3 4 4 11 11 11 11 11
Beta 17 7 4 2 4 8 4 2 3 9 4 4 17 17 17 17 17
12-month new
response: UC
Beta Alpha 16 4 3 7 2 8 4 0 4 8 2 6 16 16 16 16 16
Beta 27 6 9 4 8 13 9 0 5 11 11 7 27 27 27 27 27
12-month new
response: AC
Beta Alpha 7 1 1 2 3 4 3 0 0 3 1 3 7 7 7 7 7
Beta 30 3 7 7 13 13 9 3 5 12 11 9 30 30 30 30 30
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Model
parameter Distribution
Distribution
parameters
Values in each analysis modelled
Base
case
Stroke time quartile SGs Comprehension ability SGs Word-finding ability SGs Secondary analyses
Q1 Q2 Q3 Q4 Mild Moderate Severe Norm Mild Moderate Severe
1. Complete-
case analysis
2. English
EQ-5D-5L
tariff
3. Proxy
report
4. EQ-5D-5L mapping
of Hernandez-Alava
et al.63
5. Including
carer QALYs
12-month
relapse: CSLT
Beta Alpha 5 0 0 3 2 3 2 0 0 2 1 2 5 5 5 5 5
Beta 61 18 13 18 12 27 17 3 14 27 21 15 61 61 61 61 61
12-month
relapse: UC
Beta Alpha 12 5 1 1 5 8 3 1 0 5 4 3 12 12 12 12 12
Beta 42 7 14 12 9 21 8 2 11 16 20 8 42 42 42 42 42
12-month
relapse: AC
Beta Alpha 8 3 4 0 1 4 3 1 0 3 4 1 8 8 8 8 8
Beta 34 11 8 7 8 15 9 2 8 20 6 9 34 34 34 34 34
Baseline
EQ-5D-5L
Normal Mean 0.61 0.64 0.65 0.61 0.56 0.64 0.6 0.58 0.58 0.62 0.63 0.59 0.61 0.71 0.51 0.61 0.77
Standard
error
0.01 0.03 0.03 0.03 0.03 0.02 0.03 0.09 0.04 0.02 0.03 0.03 0.02 0.01 0.01 0.01 0.02
6-month EQ-5D-
5L difference
Normal Mean –0.04 –0.07 –0.04 –0.03 –0.01 0.03 –0.08 –0.18 –0.1 –0.03 –0.03 –0.04 –0.04 –0.04 –0.01 –0.04 –0.01
Standard
error
0.03 0.07 0.05 0.05 0.05 0.04 0.05 0.15 0.07 0.04 0.05 0.06 0.03 0.02 0.03 0.02 0.03
9-month EQ-5D-
5L difference
Normal Mean –0.02 –0.12 –0.03 –0.06 0.1 0.01 –0.01 –0.24 –0.07 –0.04 0.08 –0.06 0.01 –0.01 0 –0.02 0.01
Standard
error
0.03 0.06 0.05 0.05 0.06 0.04 0.05 0.15 0.07 0.04 0.04 0.06 0.03 0.02 0.03 0.02 0.03
12-month
EQ-5D-5L
difference
Normal Mean 0.02 0.01 0.07 –0.1 0.06 –0.01 0.08 –0.1 0.02 0.03 0.02 –0.01 0.03 0.02 0.02 0.02 –0.02
Standard
error
0.03 0.06 0.04 0.06 0.05 0.04 0.04 0.14 0.06 0.04 0.04 0.06 0.03 0.02 0.03 0.02 0.03
SLT with
participant (mean
number of hours)
Gamma Mean 7.13 7.48 7.75 6.83 6.34 6.39 8 10.88 6.5 5.73 8.6 8.03 7.13 7.13 7.13 7.13 7.13
Standard
error
0.54 0.83 1.47 0.99 1.09 0.77 1.14 3.37 0.77 0.62 1.12 1.09 0.54 0.54 0.54 0.54 0.54
SLT with SLTA/
volunteer (mean
number of hours)
Gamma Mean 1.83 1.46 1.79 2.3 1.76 1.67 1.99 2.72 1.75 1.76 1.82 1.95 1.83 1.83 1.83 1.83 1.83
Standard
error
0.14 0.22 0.23 0.34 0.25 0.23 0.24 0.76 0.22 0.22 0.23 0.26 0.14 0.14 0.14 0.14 0.14
SLTA with
participant (mean
number of hours)
Gamma Mean 2.73 2.48 2.92 3.02 2.49 2.26 3.53 1.92 2.79 2.48 3.48 2.6 2.73 2.73 2.73 2.73 2.73
Standard
error
0.28 0.5 0.63 0.51 0.65 0.39 0.56 0.92 0.63 0.4 0.54 0.57 0.28 0.28 0.28 0.28 0.28
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TABLE 36 Model parameters used for base-case, secondary and subgroup analyses (continued )
Model
parameter Distribution
Distribution
parameters
Values in each analysis modelled
Base
case
Stroke time quartile SGs Comprehension ability SGs Word-finding ability SGs Secondary analyses
Q1 Q2 Q3 Q4 Mild Moderate Severe Norm Mild Moderate Severe
1. Complete-
case analysis
2. English
EQ-5D-5L
tariff
3. Proxy
report
4. EQ-5D-5L mapping
of Hernandez-Alava
et al.63
5. Including
carer QALYs
SLTA with SLT
(mean number of
hours)
Gamma Mean 1.11 0.96 1.13 1.27 1.08 0.98 1.35 1.83 0.86 0.89 1.38 1.21 1.11 1.11 1.11 1.11 1.11
Standard
error
0.12 0.23 0.26 0.23 0.3 0.18 0.23 1.01 0.2 0.16 0.26 0.24 0.12 0.12 0.12 0.12 0.12
Volunteer with
participant (mean
number of hours)
Gamma Mean 1.13 0.84 1.19 1.13 1.45 1.12 1.13 1.08 1.16 1.1 0.97 1.27 1.13 1.13 1.13 1.13 1.13
Standard
error
0.2 0.29 0.47 0.41 0.49 0.31 0.41 0.7 0.39 0.29 0.37 0.43 0.2 0.2 0.2 0.2 0.2
Volunteer with
SLT (mean
number of hours)
Gamma Mean 0.72 0.5 0.66 1.03 0.68 0.68 0.63 0.88 0.89 0.87 0.43 0.74 0.72 0.72 0.72 0.72 0.72
Standard
error
0.14 0.18 0.24 0.41 0.22 0.23 0.25 0.61 0.3 0.25 0.16 0.29 0.14 0.14 0.14 0.14 0.14
Number of
puzzle books
Gamma Mean 4.35 3.83 4.75 3.88 4.72 4.42 4.17 4.2 4.57 4.38 4.27 4.43 4.35 4.35 4.35 4.35 4.35
Standard
error
0.2 0.44 0.49 0.39 0.25 0.31 0.32 0.73 0.52 0.32 0.33 0.31 0.2 0.2 0.2 0.2 0.2
SLT administering
AC (mean hours)
Gamma Mean 0.8 0.73 0.95 0.78 0.75 0.77 0.86 0.7 0.84 0.86 0.8 0.71 0.8 0.8 0.8 0.8 0.8
Standard
error
0.05 0.11 0.1 0.1 0.07 0.08 0.09 0.17 0.09 0.07 0.09 0.08 0.05 0.05 0.05 0.05 0.05
OHE, Office of Health Economics; Q, quartile; SG, subgroup.
Note
For beta distributions, alpha= number of people with the event and beta= number without the event.
A
P
P
E
N
D
IX
1
2
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
1
5
4
Appendix 13 Expected value of
information results
Based on EVPI analysis conducted on the base-case model analysis, we estimate that the per-patientvalue of perfect information is £160.55 given a cost-effectiveness threshold of £20,000 per QALY
gained.We extrapolated the per-patient value of information estimates to a population level by estimating
the number of participants who would be likely to receive the treatment over a 10-year period. It is
estimated that the prevalence of aphasia in the UK is 350,000.94 Thirty-three per cent of people with
aphasia screened for potential recruitment into Big CACTUS were not eligible and, conservatively, we
assume that the intervention would not be offered to people with severe word-finding difficulty (26% of
the Big CACTUS population). Hence, we estimate that 172,640 people in the UK would be eligible for
CSLT treatment (350,000 × 0.67 × 0.74). It is estimated that the incidence of aphasia is 11,400 per year
in Great Britain.95 Twenty-four per cent of these people recover in the first 6 months, but 76% do not.95
Given the eligibility for CSLT treatment described above, we estimate that the annual incidence population
who would be eligible for CSLT treatment is 4274 (11,400 × 0.76 × 0.67 × 0.74). Over a 10-year period,
we therefore estimate that 215,376 people could be treated with CSLT in the UK, with an average of
21,538 treated per year. Based on this, we estimate a population-level EVPI of £34.6M. The overall EVPI
per patient for a range of cost-effectiveness thresholds is presented in Figure 27.
A further analysis was undertaken to gain an insight into which areas would deliver the most value for
further research. The Sheffield Accelerated Value of Information tool72 was used to estimate the value
of obtaining perfect information for one parameter or group of parameters. The following parameters
were included in the analysis:
l utility score in aphasia health state
l utility difference associated with response in each of the response health states (6, 9, 12 months
and beyond)
l probability of good response at each time point for CSLT (6, 9 and 12 months)
l probability of good response at each time point for AC (6, 9 and 12 months)
l probability of good response at each time point for UC (6, 9 and 12 months)
l probability of relapse at each time point for CSLT (6–9 months, 9–12 months and beyond 12 months)
l probability of relapse at each time point for AC (6–9 months, 9–12 months and beyond 12 months)
l probability of relapse at each time point for UC (6–9 months, 9–12 months and beyond 12 months)
l proportion who need to borrow a computer
l software cost
l total SLT and SLTA costs for CSLT
l total SLT costs for AC
l mortality rate.
Only four parameters resulted in per-patient EVPI of > £0.03: utility difference associated with
response at 12 months, and the relapse rates from 9 months onwards for each of the three treatment
options. The expected value of partial perfect information for each of these parameters is presented in
Table 37.
Clearly, the utility difference associated with a good response at 12 months is the most important
parameter in the model, and obtaining more information on this would be highly valuable. This is
unsurprising because this utility score is extrapolated into the future; it is primarily this score that
dictates the QALY benefit associated with increasing the response rate. The importance of the longer-
term relapse rates is also expected because it is these that dictate at what rate people return to the
aphasia health state from the good response health state.
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TABLE 37 Expected value of partial perfect information: base-case analysis
Parameter
Per person
EVPPI (£)
Standard
error (£)
EVPPI for UK over
10 years (£)
Utility difference associated with response at 12 months 94.66 1.82 20,390,000
Probability of relapse from 9 months onwards for CSLT 5.20 1.26 1,119,000
Probability of relapse from 9 months onwards for AC 16.36 0.70 3,525,000
Probability of relapse from 9 months onwards for UC 7.64 0.80 1,645,000
EVPPI, expected value of partial perfect information.
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FIGURE 27 Overall EVPI (per patient).
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Appendix 14 Results of model-based
secondary analyses
Tables 38–40 present results from the 11 secondary analyses undertaken, which are described inChapter 5, Model results: secondary analyses. Note that results for analyses 6 to 11 are not included
in Table 40, which presents cost-effectiveness results for AC compared with UC, because these
scenarios made no changes to the UC and AC treatment options.
TABLE 38 Cost-effectiveness results from base-case and secondary analyses: CSLT vs. UC model-based analysis
Analysis
CSLT
cost (£)
UC
cost (£)
Incremental cost
(£): CSLT vs. UC
(95% CrI)
CSLT
QALYs
UC
QALYs
Incremental
QALYs: CSLT vs.
UC (95% CrI)
ICER (£ per
QALY gained)
Base-case
analysis
(cross-walk)
732.73 0.00 732.73
(674.23 to 798.05)
4.2164 4.1992 0.0172
(–0.05 to 0.10)
42,686
1. Complete-case
analysis
733.08 0.00 733.08
(672.13 to 800.63)
4.2302 4.2042 0.0260
(–0.03 to 0.11)
28,248
2. Using English
EQ-5D-5L tariff
732.25 0.00 732.25
(673.19 to 797.84)
4.8537 4.8406 0.0132
(–0.04 to 0.09)
55,639
3. Using carer
proxy EQ-5D-5L
measure
733.06 0.00 733.06
(672.70 to 800.01)
3.5339 3.5084 0.0254
(–0.05 to 0.12)
28,819
4. Use EQ-5D-5L
mapping of
Hernandez-Alava
et al.63
732.96 0.00 732.96
(672.60 to 798.22)
4.1568 4.1358 0.0210
(–0.04 to 0.11)
34,921
5. Including carer
QALYs
732.17 0.00 732.17
(673.70 to 798.05)
7.9251 7.9275 –0.0025
(–0.10 to 0.10)
Dominated
6. Assume that all
CSLT participants
loaned computer
and use clinician
licence
690.85 0.00 690.85
(632.45 to 766.49)
4.2133 4.1958 0.0175
(–0.04 to 0.10)
39,480
7. Assume that all
CSLT participants
use own computer
and individual
licence
822.16 0.00 822.16
(771.69 to 876.82)
4.2165 4.1985 0.0180
(–0.04 to 0.10)
45,813
8. Assume that
75% of CSLT
participants use
own computer
789.12 0.00 788.80
(736.66 to 844.44)
4.2187 4.2014 0.0173
(–0.04 to 0.10)
45,552
9. Pay £120 for a
6-month licence
instead of £250
for lifetime
licence
691.27 0.00 691.27
(635.30 to 754.07)
4.2135 4.1962 0.0173
(–0.05 to 0.10)
39,844
10. Zero cost of
software
619.35 0.00 619.35 (NC) 4.2164 4.1992 0.0172
(–0.05 to 0.10)
36,081
continued
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TABLE 38 Cost-effectiveness results from base-case and secondary analyses: CSLT vs. UC model-based analysis (continued )
Analysis
CSLT
cost (£)
UC
cost (£)
Incremental cost
(£): CSLT vs. UC
(95% CrI)
CSLT
QALYs
UC
QALYs
Incremental
QALYs: CSLT vs.
UC (95% CrI)
ICER (£ per
QALY gained)
11. Zero SLT and
SLTA costs
165.11 0.00 165.11 (NC) 4.2164 4.1992 0.0172
(–0.05 to 0.10)
9619
12. SLT and SLTA
costs halved
448.92 0.00 448.92 (NC) 4.2164 4.1992 0.0172
(–0.05 to 0.10)
26,153
13. Assume same
outcomes with
28 hours of band
6 face-to-face SLT
time and travel
1342.78 0.00 1342.78 (NC) 4.2164 4.1992 0.0172
(–0.05 to 0.10)
78,068
14. Broader
perspective
789.39 0.00 789.39
(728.09 to 858.03)
4.2166 4.1988 0.0178
(–0.05 to 0.10)
44,279
NC, not calculated.
TABLE 39 Cost-effectiveness results from base-case and secondary analyses: CSLT vs. AC model-based analysis
Analysis
CSLT
cost (£)
AC
cost (£)
Incremental cost
(£): CSLT vs. AC
(95% CrI)
CSLT
QALYs
AC
QALYs
Incremental
QALYs: CSLT vs.
AC (95% CrI)
ICER (£ per
QALY gained)
Base-case
analysis
(cross-walk)
732.73 38.14 694.59
(636.46 to 760.09)
4.2164 4.1991 0.0173
(–0.05 to 0.10)
40,164
1. Complete-case
analysis
733.08 38.18 694.90
(633.87 to 762.28)
4.2302 4.2040 0.0262
(–0.03 to 0.11)
26,555
2. Using English
EQ-5D-5L tariff
732.25 38.17 694.09
(634.95 to 759.75)
4.8537 4.8402 0.0135
(–0.04 to 0.09)
51,308
3. Using carer
proxy EQ-5D-5L
measure
733.06 38.18 694.88
(634.58 to 761.87)
3.5339 3.5085 0.0254
(–0.05 to 0.12)
27,397
4. Use EQ-5D-5L
mapping of
Hernandez-Alava
et al.63
732.96 38.18 694.78
(634.94 to 760.21)
4.1568 4.1356 0.0211
(–0.04 to 0.11)
32,835
5. Including carer
QALYs
732.17 38.14 694.03
(635.13 to 759.61)
7.9251 7.9271 –0.0020
(–0.10 to 0.10)
Dominated
6. Assume that all
CSLT participants
loaned computer
and use clinician
licence
690.85 38.20 652.65
(594.21 to 727.91)
4.2133 4.1938 0.0176
(–0.04 to 0.10)
37,091
7. Assume that all
CSLT participants
use own computer
and individual
licence
822.16 38.15 784.01
(732.89 to 838.53)
4.2165 4.1983 0.0182
(–0.04 to 0.10)
43,113
8. Assume that
75% of CSLT
participants use
own computer
789.12 38.18 750.95
(698.85 to 806.41)
4.2187 4.2013 0.0174
(–0.04 to 0.10)
43,051
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TABLE 39 Cost-effectiveness results from base-case and secondary analyses: CSLT vs. AC model-based analysis
(continued )
Analysis
CSLT
cost (£)
AC
cost (£)
Incremental cost
(£): CSLT vs. AC
(95% CrI)
CSLT
QALYs
AC
QALYs
Incremental
QALYs: CSLT vs.
AC (95% CrI)
ICER (£ per
QALY gained)
9. Pay £120 for a
6-month licence
instead of £250
for lifetime
licence
691.27 38.19 653.08
(597.08 to 715.97)
4.2135 4.1961 0.0175
(–0.04 to 0.11)
37,346
10. Zero cost of
software
619.35 38.19 581.21 (NC) 4.2164 4.1991 0.0173
(–0.05 to 0.10)
33,608
11. Zero SLT and
SLTA costs
165.11 38.19 126.97 (NC) 4.2164 4.1991 0.0173
(–0.05 to 0.10)
7342
12. SLT and SLTA
costs halved
448.92 38.19 410.78 (NC) 4.2164 4.1991 0.0173
(–0.05 to 0.10)
23,753
13. Assume same
outcomes with
28 hours of band
6 face-to-face SLT
time and travel
1342.78 38.19 1304.59 (NC) 4.2164 4.1991 0.0173
(–0.05 to 0.10)
75,049
14. Broader
perspective
789.39 38.18 751.21
(689.57 to 819.71)
4.2166 4.1987 0.0179
(–0.05 to 0.10)
41,974
NC, not calculated.
TABLE 40 Cost-effectiveness results from base-case and secondary analyses: AC vs. UC model-based analysis
Analysis
AC
cost (£)
UC
cost (£)
Incremental cost
(£): AC vs. UC
(95% CrI)
AC
QALYs
UC
QALYs
Incremental
QALYs: AC vs.
UC (95% CrI)
ICER (£ per
QALY gained)
Base-case
analysis
(cross-walk)
38.14 0.00 38.14
(34.94 to 41.50)
4.1991 4.1992 –0.0001
(–0.02 to 0.02)
Dominated
1. Complete-case
analysis
38.18 0.00 38.18
(34.89 to 41.66)
4.2040 4.2042 –0.0002
(–0.02 to 0.02)
Dominated
2. Using English
EQ-5D-5L tariff
38.17 0.00 38.17
(34.92 to 41.53)
4.8402 4.8406 –0.0004
(–0.02 to 0.02)
Dominated
3. Using carer
proxy EQ-5D-5L
measure
38.18 0.00 38.18
(34.95 to 41.62)
3.5085 3.5084 0.0001
(–0.02 to 0.02)
522,118
4. Use EQ-5D-5L
mapping of
Hernandez-Alava
et al.63
38.18 0.00 38.18
(34.90 to 41.57)
4.1356 4.1358 –0.0002
(–0.02 to 0.02)
Dominated
5. Including carer
QALYs
38.14 0.00 38.14
(34.87 to 41.52)
5.2343 5.2348 –0.0005
(–0.03 to 0.02)
Dominated
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Appendix 15 Model-based subgroup
analysis results
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TABLE 41 Results of subgroup analyses comparing CSLT with UC: model-based analysis
Analysis Subgroup CSLT cost (£) UC cost (£)
Incremental cost (£):
CSLT vs. UC (95% CrI) CSLT QALYs UC QALYs
Incremental QALYs:
CSLT vs. UC (95% CrI)
ICER (£ per
QALY gained)
Word-finding
difficulty (baseline)
Mild 653.49 0.00 653.49 (586.44 to 728.36) 4.2856 4.2564 0.0292 (–0.06 to 0.17) 22,371
Moderate 822.77 0.00 822.77 (715.54 to 942.22) 4.3290 4.3006 0.0284 (–0.10 to 0.22) 28,898
Severe 778.71 0.00 778.71 (674.77 to 890.79) 3.9971 4.0137 –0.0166 (–0.16 to 0.11) Dominated
Comprehension
ability (baseline)
Normal 695.77 0.00 695.77 (613.47 to 785.33) 4.0083 4.0108 –0.0024 (–0.28 to 0.32) Dominated
Mild 677.12 0.00 677.12 (599.44 to 763.04) 4.3544 4.3595 –0.0051 (–0.10 to 0.08) Dominated
Moderate 804.44 0.00 804.44 (699.07 to 922.11) 4.1968 4.1360 0.0608 (–0.05 to 0.28) 13,235
Severe 940.81 0.00 940.81 (669.69 to 1292.58) 3.6722 3.7654 –0.0932 (–0.95 to 0.42) Dominated
Time post stroke
(quartiles)
1 (shortest) 721.32 0.00 721.32 (637.43 to 816.21) 4.3279 4.3211 0.0068 (–0.36 to 0.39) 105,532
2 763.36 0.00 763.36 (635.70 to 913.21) 4.6455 4.5172 0.1280 (–0.12 to 0.50) 5948
3 752.31 0.00 752.31 (655.33 to 861.75) 4.0446 3.9979 0.04668 (–0.17 to 0.40) 16,115
4 (longest) 687.08 0.00 687.08 (581.95 to 809.62) 3.9071 3.8632 0.0444 (–0.03 to 0.22) 15,663
A
P
P
E
N
D
IX
1
5
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
1
6
2
TABLE 42 Results of subgroup analyses comparing CSLT with AC: model-based analysis
Analysis Subgroup CSLT cost (£) AC cost (£)
Incremental cost (£):
CSLT vs. AC (95% CrI) CSLT QALYs AC QALYs
Incremental QALYs:
CSLT vs. AC (95% CrI)
ICER (£ per
QALY gained)
Word-finding
difficulty (baseline)
Mild 653.49 40.17 613.32 (545.64 to 689.09) 4.2856 4.2658 0.0198 (–0.07 to 0.16) 30,911
Moderate 822.77 37.99 784.78 (677.99 to 904.96) 4.3290 4.2874 0.0416 (–0.12 to 0.26) 18,855
Severe 778.71 35.08 743.63 (640.27 to 856.15) 3.9971 4.0056 –0.0084 (–0.14 to 0.12) Dominated
Comprehension
ability (baseline)
Normal 695.77 39.99 655.78 (572.95 to 746.36) 4.0083 4.0031 0.0053 (–0.29 to 0.36) 124,456
Mild 677.12 37.10 640.02 (562.53 to 725.97) 4.3544 4.3597 –0.0053 (–0.10 to 0.07) Dominated
Moderate 804.44 39.68 764.76 (659.50 to 882.54) 4.1968 4.1342 0.0626 (–0.04 to 0.28) 12,207
Severe 940.81 34.26 906.55 (635.42 to 1259.27) 3.6722 3.8511 –0.1789 (–1.06 to 0.32) Dominated
Time post stroke
(quartiles)
1 (shortest) 721.32 34.43 686.88 (603.04 to 781.92) 4.3279 4.3159 0.0120 (–0.32 to 0.36) 57,220
2 763.36 44.19 719.17 (591.14 to 869.35) 4.6455 4.4419 0.2037 (–0.07 to 0.62) 3531
3 752.31 36.27 716.04 (618.51 to 826.13) 4.0446 3.9685 0.0760 (–0.17 to 0.45) 9418
4 (longest) 687.08 37.39 649.70 (544.46 to 772.47) 3.9071 3.8880 0.0191 (–0.12 to 0.18) 34,008
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TABLE 43 Results of subgroup analyses comparing AC with UC: model-based analysis
Analysis Subgroup AC cost (£) UC cost (£)
Incremental cost (£):
AC vs. UC (95% CrI) AC QALYs UC QALYs
Incremental QALYs:
AC vs. UC (95% CrI)
ICER (£ per
QALY gained)
Word-finding difficulty
(baseline)
Mild 40.17 0.00 40.17 (35.37 to 45.37) 4.2658 4.2564 0.0094 (–0.04 to 0.09) 4273
Moderate 37.99 0.00 37.99 (31.95 to 44.72) 4.2874 4.3006 –0.0132 (–0.07 to 0.03) Dominated
Severe 35.08 0.00 35.08 (29.78 to 40.81) 4.0056 4.0137 –0.0081 (–0.14 to 0.10) Dominated
Comprehension ability
(baseline)
Normal 39.99 0.00 39.99 (33.87 to 46.81) 4.0031 4.0108 –0.0077 (–0.31 to 0.26) Dominated
Mild 37.10 0.00 37.10 (31.93 to 42.73) 4.3597 4.3595 0.0002 (–0.03 to 0.03) 185,500
Moderate 39.68 0.00 39.68 (33.86 to 45.91) 4.1342 4.1360 –0.0018 (–0.08 to 0.08) Dominated
Severe 34.26 0.00 34.26 (23.83 to 46.67) 3.8511 3.7654 0.0857 (–0.19 to 0.45) 400
Time post stroke (quartiles) 1 (shortest) 34.43 0.00 34.43 (27.37 to 42.61) 4.3159 4.3211 –0.0052 (–0.08 to 0.07) Dominated
2 44.19 0.00 44.19 (37.28 to 51.70) 4.4419 4.5172 –0.0753 (–0.30 to 0.03) Dominated
3 36.27 0.00 36.27 (29.62 to 43.76) 3.9685 3.9979 –0.0294 (–0.41 to 0.33) Dominated
4 (longest) 37.39 0.00 37.39 (32.73 to 42.59) 3.8880 3.8632 0.0248 (–0.04 to 0.17) 1508
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Appendix 16 Within-trial analysis:
utility scores
TABLE 45 Mean, SD and sample size of accessible EQ-5D-5L scores by treatment group at each time point for
complete cases
Time point
EQ-5D-5L score, mean (SD); n
UC AC CSLT
0 months 0.63 (0.23); 101 0.59 (0.26); 80 0.61 (0.24); 96
6 months 0.61 (0.25); 89 0.59 (0.27); 71 0.60 (0.29); 84
9 months 0.63 (0.24); 86 0.63 (0.25); 64 0.62 (0.27); 80
12 months 0.66 (0.24); 87 0.60 (0.26); 62 0.59 (0.28); 77
TABLE 46 Mean and SD of accessible EQ-5D-5L scores by treatment group at each time point for participants who
provided a complete response at every data collection point
Time point
EQ-5D-5L score, mean (SD)
UC (n= 81) AC (n= 61) CSLT (n= 73)
0 months 0.67 (0.19) 0.61 (0.25) 0.62 (0.25)
6 months 0.63 (0.25) 0.60 (0.27) 0.63 (0.27)
9 months 0.63 (0.25) 0.63 (0.25) 0.63 (0.27)
12 months 0.66 (0.24) 0.60 (0.26) 0.60 (0.28)
TABLE 44 Mean and SD of accessible EQ-5D-5L scores by treatment group at each time point after missing EQ-5D-5L
scores are imputed
Time point
EQ-5D-5L score, mean (SD)
UC (n= 101) AC (n= 80) CSLT (n= 97)
0 months 0.63 (0.23) 0.59 (0.26) 0.61 (0.24)
6 months 0.61 (0.24) 0.59 (0.26) 0.60 (0.28)
9 months 0.63 (0.23) 0.62 (0.23) 0.62 (0.25)
12 months 0.65 (0.23) 0.59 (0.24) 0.59 (0.25)
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FIGURE 28 Means and 95% CIs of accessible EQ-5D-5L scores by treatment group at each time point for complete cases.
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FIGURE 29 Means and 95% CIs of accessible EQ-5D-5L scores by treatment group at each time point for participants
who provided a complete response at every data collection point.
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FIGURE 30 Means and 95% CIs of proxy EQ-5D-5L scores by treatment group at each time point (complete cases).
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FIGURE 31 Means and 95% CIs of carer EQ-5D-5L scores by treatment group at each time point (complete cases).
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Appendix 17 Within-trial analysis:
histograms of cost distributions
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FIGURE 32 Histogram of CSLT costs.
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FIGURE 33 Histogram of AC costs.
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Appendix 18 Within-trial analysis:
base-case cost-effectiveness planes and
cost-effectiveness acceptability curve
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FIGURE 34 Cost-effectiveness plane: within-trial analysis, base case (CSLT vs. UC).
–0.2
–100
0
100
200
300
400
500
600
700
800
900
1000
–0.1 0.1 0.2 0.30
Differential QALYs
D
if
fe
re
n
ti
al
 c
o
st
 (£
)
FIGURE 35 Cost-effectiveness plane: within-trial analysis, base case (CSLT vs. AC).
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FIGURE 36 Cost-effectiveness plane: within-trial analysis, base case (AC vs. UC).
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FIGURE 37 Cost-effectiveness acceptability curve: within-trial analysis, base case.
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Appendix 19 Within-trial analysis:
secondary analysis results
TABLE 47 Cost-effectiveness results from base-case and secondary within-trial analyses: CSLT vs. UC
Analysis
Incremental cost (£):
CSLT vs. UC (95% CI)
Incremental QALYs:
CSLT vs. UC (95% CI)
ICER (£ per
QALY gained)
Base-case analysis (cross-walk) 732.37 (665.59 to 799.15) –0.007 (–0.05 to 0.03) Dominated
1. Complete-case analysis 732.37 (665.59 to 799.15) 0.014 (–0.03 to 0.06) 52,312
2. Using English EQ-5D-5L tariff 732.37 (665.59 to 799.15) –0.007 (–0.05 to 0.03) Dominated
3. Using carer proxy EQ-5D-5L measure 732.37 (665.59 to 799.15) 0.007 (–0.03 to 0.04) 104,624
4. Use EQ-5D-5L mapping of
Hernandez-Alava et al.63
732.37 (665.59 to 799.15) –0.011 (–0.05 to 0.03) Dominated
5. Including carer QALYs 732.37 (665.59 to 799.15) 0.006a 126,708
11. Broader perspective 789.60 (725.90 to 853.30) –0.007 (–0.05 to 0.03) Dominated
a Carer QALYs were weighted by a factor of 0.71, reflecting that 71% of patients had a carer at baseline, and carer
QALYs were added to patient QALYs to calculate a total QALY gain (or loss). No CI can be derived from this method.
TABLE 48 Cost-effectiveness results from base-case and secondary within-trial analyses: CSLT vs. AC
Analysis
Incremental cost (£):
CSLT vs. AC (95% CI)
Incremental QALYs:
CSLT vs. AC (95% CI)
ICER (£ per
QALY gained)
Base-case analysis (cross-walk) 694.65 (619.54 to 769.75) –0.007 (–0.05 to 0.03) Dominated
1. Complete-case analysis 694.65 (619.54 to 769.75) 0.006 (–0.04 to 0.05) 115,775
2. Using English EQ-5D-5L tariff 694.65 (619.54 to 769.75) –0.013 (–0.05 to 0.02) Dominated
3. Using carer proxy EQ-5D-5L measure 694.65 (619.54 to 769.75) –0.003 (–0.04 to 0.03) Dominated
4. Use EQ-5D-5L mapping of
Hernandez-Alava et al.63
694.65 (619.54 to 769.75) –0.019 (–0.06 to 0.02) Dominated
5. Including carer QALYs 694.65 (619.54 to 769.75) 0.009a 80,586
11. Broader perspective 751.80 (680.20 to 823.50) –0.007 (–0.05 to 0.03) Dominated
a Carer QALYs were weighted by a factor of 0.71, reflecting that 71% of patients had a carer at baseline, and carer
QALYs were added to patient QALYs to calculate a total QALY gain (or loss). No CI can be derived from this method.
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TABLE 49 Cost-effectiveness results from base-case and secondary within-trial analyses: AC vs. UC
Analysis
Incremental cost (£):
AC vs. UC (95% CI)
Incremental QALYs:
AC vs. UC (95% CI)
ICER (£ per
QALY gained)
Base-case analysis (cross-walk) 37.72 (34.61 to 40.82) –0.004 (–0.04 to 0.04) Dominated
1. Complete-case analysis 37.72 (34.61 to 40.82) 0.004 (–0.04 to 0.05) 10,117
2. Using English EQ-5D-5L tariff 37.72 (34.61 to 40.82) 0.005 (–0.03 to 0.04) 7544
3. Using carer proxy EQ-5D-5L measure 37.72 (34.61 to 40.82) 0.012 (–0.02 to 0.05) 3143
4. Use EQ-5D-5L mapping of
Hernandez-Alava et al.63
37.72 (34.61 to 40.82) 0.004 (–0.03 to 0.04) 9430
5. Including carer QALYs 37.72 (34.61 to 40.82) –0.006a Dominated
a Carer QALYs were weighted by a factor of 0.71, reflecting that 71% of patients had a carer at baseline, and carer
QALYs were added to patient QALYs to calculate a total QALY gain (or loss). No CI can be derived from this method.
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Appendix 20 Within-trial analysis:
subgroup analysis results
TABLE 50 Results of subgroup analyses comparing CSLT with UC: within-trial analysis
Analysis Subgroup
Incremental cost (£):
CSLT vs. UC (95% CI)
Incremental QALYs:
CSLT vs. UC (95% CI)
ICER (£ per
QALY gained)
Word-finding difficulty
(baseline)
Mild 639.0 (555.9 to 722.1) –0.014 (–0.07 to 0.04) Dominated
Moderate 832.3 (691.1 to 973.5) –0.021 (–0.09 to 0.04) Dominated
Severe 776.9 (656.9 to 896.9) 0.027 (–0.05 to 0.11) 28,774
Comprehension ability
(baseline)
Normal 685.5 (603.6 to 767.3) –0.104 (–0.18 to –0.02) Dominated
Mild 671.9 (575.2 to 768.5) 0.021 (–0.03 to 0.07) 31,995
Moderate 803.8 (662.9 to 944.7) 0.028 (–0.06 to 0.11) 28,707
Severe 949.2 (601.2 to 1297.2) –0.012 (–0.22 to 0.19) Dominated
Time post stroke (quartiles) 1 (shortest) 716.5 (605.3 to 827.7) –0.006 (–0.09 to 0.08) Dominated
2 760.2 (596.5 to 923.9) –0.039 (–0.10 to 0.03) Dominated
3 759.2 (632.8 to 885.6) 0.026 (–0.06 to 0.11) 29,200
4 (longest) 687.7 (559.9 to 815.5) –0.013 (–0.07 to 0.04) Dominated
TABLE 51 Results of subgroup analyses comparing CSLT with AC: within-trial analysis
Analysis Subgroup
Incremental cost (£):
CSLT vs. AC (95% CI)
Incremental QALYs:
CSLT vs. AC (95% CI)
ICER (£ per
QALY gained)
Word-finding difficulty
(baseline)
Mild 599.2 (518.2 to 680.1) –0.012 (–0.07 to 0.05) Dominated
Moderate 794.9 (608.7 to 980.9) 0.032 (–0.03 to 0.09) 24,715
Severe 742.7 (608.7 to 875.7) –0.015 (–0.08 to 0.05) Dominated
Comprehension ability
(baseline)
Normal 643.7 (542.0 to 745.5) –0.036 (–0.14 to 0.06) Dominated
Mild 635.7 (522.2 to 749.3) 0.021 (–0.02 to 0.07) 30,080
Moderate 764.5 (617.8 to 911.2) 0.006 (–0.07 to 0.08) 126,750
Severe 916.9 (632.5 to 1201.4) –0.164 (–0.31 to –0.02) Dominated
Time post stroke (quartiles) 1 (shortest) 682.8 (560.2 to 805.3) –0.001 (–0.09 to 0.09) Dominated
2 716.4 (526.0 to 906.8) –0.076 (–0.14 to –0.01) Dominated
3 723.3 (559.0 to 887.6) –0.018 (–0.10 to 0.07) Dominated
4 (longest) 650.6 (525.2 to 775.9) 0.052 (–0.02 to 0.12) 12,434
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TABLE 52 Results of subgroup analyses comparing AC with UC: within-trial analysis
Analysis Subgroup
Incremental cost (£):
AC vs. UC (95% CI)
Incremental QALYs:
AC vs. UC (95% CI)
ICER (£ per
QALY gained)
Word-finding difficulty
(baseline)
Mild 39.8 (34.4 to 45.2) –0.008 (–0.06 to 0.05) Dominated
Moderate 37.5 (32.8 to 42.1) –0.042 (–0.09 to 0.01) Dominated
Severe 34.2 (29.0 to 39.5) 0.041 (–0.05 to 0.13) 836
Comprehension ability
(baseline)
Normal 41.7 (36.5 to 46.9) –0.077 (–0.15 to 0.00) Dominated
Mild 36.2 (31.2 to 41.1) 0.001 (–0.05 to 0.05) 361,000
Moderate 39.3 (34.0 to 44.6) 0.028 (–0.06 to 0.11) 1403
Severe 32.2 (17.0 to 47.5) 0.106 (–0.10 to 0.32) 301
Time post stroke (quartiles) 1 (shortest) 33.7 (26.1 to 41.2) 0.013 (–0.08 to 0.11) 2592
2 43.8 (37.3 to 50.3) 0.031 (–0.03 to 0.10) 1412
3 35.9 (30.5 to 41.3) 0.021 (–0.08 to 0.12) 1709
4 (longest) 37.1 (32.4 to 41.8) –0.062 (–0.13 to 0.00) Dominated
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